[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Tosoh Bioscience Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":319},{"warningLetters":4,"total":318},[5,31,56,77,97,120,144,164,185,204,223,244,263,281,299],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1534,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-21T04:00:00Z\">03\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagena-bioscience-inc-665159-03212024\">Agena Bioscience, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roman Haehn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and General Manager of Clinical Genomics\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Agena Bioscience, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4755 Eastgate Mall\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Roman.Haehn@agenabio.com\"> Roman.Haehn@agenabio.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd> Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 665159\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 21, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Haehn,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 4755 Eastgate Mall, San Diego, CA on June 7, 2023, through June 13, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the MassARRAY4 System (MA4) and the iPLEX HS chemistry panels including the iPLEX HS Colon Panel in vitro diagnostic (IVD) products. Based on the inspection and our review of your firm’s website, it appears the iPLEX HS Colon Panel intended for use with the MA4 is intended for clinical diagnostic use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>The evidence reveals that the iPLEX HS Colon Panel intended for use with the MA4 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>You currently have clearance for the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) under 21 CFR 864.7280 for the following indications:\u003C\u002Fp>\n\n\u003Cp>The IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test is a qualitative in vitro diagnostic device intended for use in the detection and genotyping of a single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA isolated from EDTA anti-coagulated human whole blood samples. The test is to be performed on the IMPACT Dx™ System and is indicated for use as an aid in diagnosis of patients with suspected thrombophilia.\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm’s Director of Regulatory and Quality made verbal statements to the FDA investigator that your firm no longer sells the cleared Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System and has since only marketed and distributed the MA4.\u003C\u002Fp>\n\n\u003Cp>Based on evidence obtained during the inspection and a review of your firm’s website the iPLEX HS Colon Panel intended for use with the MA4 appears intended for clinical diagnostic use. Such evidence includes:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Verbal statements made to the FDA investigator during the inspection on behalf of your firm by your firm’s Director of Regulatory and Quality indicating that your firm no longer sells the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) and has instead replaced it with a new system, the MA4, and admitting that your firm sells the MA4 and reagent panels to companies who analyze patient samples that are used for clinical diagnosis.\u003C\u002Fli>\n\t\u003Cli>Distribution records and a customer list obtained during inspection that indicates your firm shipped MA4 Systems and iPLEX HS Colon Panels to clinical testing laboratories.\u003C\u002Fli>\n\t\u003Cli>A customer notification your firm sent to customers dated June 1, 2021, regarding distributed iPLEX HS Colon Panels that alerted customers of an increase in false negative results of certain reagent lots and stated that Agena was taking steps “to not impact your laboratory workflow.” This customer notification was sent to a clinical hospital in Texas and there is no evidence that these reagents were intended for research use only.\u003C\u002Fli>\n\t\u003Cli>A copy of the iPLEX HS Panels User Guide obtained during inspection that included instructions for preparing and testing samples as well as instructions for interpreting iPLEX HS Reports including the iPLEX HS Colon Panel intended for use with the MA4.\u003C\u002Fli>\n\t\u003Cli>Your firm’s website (last accessed on March 20, 2024) includes product descriptions and statements that the iPLEX HS Colon Panel “enables tumor profiling studies of colorectal cancer specimens”, and that, with the iPLEX HS Colon Panel, users can “Detect more than 80 clinically relevant variants across BRAF, EGFR, KRAS, NRAS, and PIK3CA” and “Identify variants at as low as 1% variant allele frequency.” [https:\u002F\u002Fwww.agenabio.com\u002Fproducts\u002Fpanel\u002Fiplex-hs-colon-panel\u002F]\u003C\u002Fli>\n\t\u003Cli>Your firm’s website (last accessed on March 20, 2024) includes customer stories from clients of Agena that indicate your MA4 System is intended for clinical diagnostic use. For instance, on the “FEATURED CUSTOMER STORIES” page, a portion of a testimonial reads, “Accurate, Cost-effective Newborn Screening for the Illinois Department of Health on the MassARRAY [MA4]…” And a statement from your CEO reads, “We are proud to have the MassARRAY System [MA4] chosen to be an integral part of one of the top newborn screening programs in the country…” [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fhgt\u002Faccurate-cost-effective-cftr-variant-detection-newborn-screening\u002F]. Another customer story comes from a client that is identified as a hospital system that uses your MA4 and iPLEX HS chemistry panels in tumor profiling and can deliver a quick and cost-effective test for clinically informative variants with a statement that other labs should explore the MassARRAY (MA4) for rapid, low-cost tumor profiling panels with a link to a product page for the iPLEX HS Colon Panel. [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fonc\u002Fmassarray-enables-sensitivity-quick-turnaround-tumor-profiling-bsw\u002F].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s Director of Regulatory and Quality indicated that your firm markets the MA4 as a research use only (RUO) product and that your firm sells and distributes the MA4 to both research and clinical diagnostic companies. Your firm’s Director of Regulatory and Quality also indicated that labeling distributed with your MA4 products, and the labeling obtained during the inspection for your iPLEX HS Colon Panel, included the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” Your firm’s website also includes the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” But, as discussed in this letter, on numerous occasions your iPLEX HS Colon Panel and your MA4 were not being shipped or delivered for an investigation (21 CFR 809.10(c)). And these devices were not for use in the laboratory research phase of development but rather were represented as effective IVDs (21 CFR 809.10(c)(2)(i)). Your disclaimers that the MA4 and your iPLEX HS Colon Panel are intended for research use only (RUO) are inconsistent with the evidence obtained during the inspection and statements identified on your firm’s website as identified above and FDA has determined that your MA4 and iPLEX HS Colon Panel are intended for clinical diagnostic use.\u003C\u002Fp>\n\n\u003Cp>Your iPLEX HS Colon Panel intended for use with the MA4 appears to be a tumor profiling test intended for the diagnosis of colorectal cancer. You were required to submit to FDA a 510(k) for this device, because it either is a new device (21 CFR 807.81(a)(1)) or, if your iPLEX HS Colon Panel intended for use with the MA4 represents a change or modification from the device cleared in K132978 (which is indicated for use as an aid in diagnosis of patients with suspected thrombophilia), has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s iPLEX HS Colon Panel is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, failure to submit a written report to FDA of any correction or removal of a device initiated to reduce a risk to health posed by the device, as required by 21 CFR Part 806.10. For example:\u003C\u002Fp>\n\n\u003Cp>On June 1, 2021, your firm issued a Customer Notification alerting customers that certain lots of your iPLEX HS Colon v1.0 Panel did not include the A nucleotide termination in Well #8 which your firm determined could result in false negative results for three target variant alleles. Your firm instructed customers to not use the results for the impacted variants and that your firm would reformulate and verify the termination mix and provide further updates on availability. Your firm did not submit a written report of this removal to the agency, as required by 21 CFR 806.10.\u003C\u002Fp>\n\n\u003Cp>We request that your firm immediately cease any activities that result in the misbranding or adulteration of your devices. Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to both: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov and to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS # 665159 when replying. If you have any questions about the contents of this letter, please contact: Jeff R. Wooley, Compliance Officer, at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney Lias, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT 7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director, Division 3\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Glen Wise\u003Cbr>\nDirector, Quality and Regulatory\u003Cbr>\nGlenn.wise@agenabio.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRoman Haehn\n\nRecipient Title\n\nVice President and General Manager of Clinical Genomics\n\nAgena Bioscience, Inc.\n\n4755 Eastgate Mall\n\nSan Diego, CA 92121\n\nUnited States\n\nRoman.Haehn@agenabio.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS # 665159\n\nMarch 21, 2024\n\nDear Mr. Haehn,\n\nDuring an inspection of your firm located at 4755 Eastgate Mall, San Diego, CA on June 7, 2023, through June 13, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the MassARRAY4 System (MA4) and the iPLEX HS chemistry panels including the iPLEX HS Colon Panel in vitro diagnostic (IVD) products. Based on the inspection and our review of your firm’s website, it appears the iPLEX HS Colon Panel intended for use with the MA4 is intended for clinical diagnostic use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThe evidence reveals that the iPLEX HS Colon Panel intended for use with the MA4 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nYou currently have clearance for the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) under 21 CFR 864.7280 for the following indications:\n\nThe IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test is a qualitative in vitro diagnostic device intended for use in the detection and genotyping of a single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA isolated from EDTA anti-coagulated human whole blood samples. The test is to be performed on the IMPACT Dx™ System and is indicated for use as an aid in diagnosis of patients with suspected thrombophilia.\n\nDuring the inspection, your firm’s Director of Regulatory and Quality made verbal statements to the FDA investigator that your firm no longer sells the cleared Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System and has since only marketed and distributed the MA4.\n\nBased on evidence obtained during the inspection and a review of your firm’s website the iPLEX HS Colon Panel intended for use with the MA4 appears intended for clinical diagnostic use. Such evidence includes:\n\nVerbal statements made to the FDA investigator during the inspection on behalf of your firm by your firm’s Director of Regulatory and Quality indicating that your firm no longer sells the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) and has instead replaced it with a new system, the MA4, and admitting that your firm sells the MA4 and reagent panels to companies who analyze patient samples that are used for clinical diagnosis.\n\nDistribution records and a customer list obtained during inspection that indicates your firm shipped MA4 Systems and iPLEX HS Colon Panels to clinical testing laboratories.\n\nA customer notification your firm sent to customers dated June 1, 2021, regarding distributed iPLEX HS Colon Panels that alerted customers of an increase in false negative results of certain reagent lots and stated that Agena was taking steps “to not impact your laboratory workflow.” This customer notification was sent to a clinical hospital in Texas and there is no evidence that these reagents were intended for research use only.\n\nA copy of the iPLEX HS Panels User Guide obtained during inspection that included instructions for preparing and testing samples as well as instructions for interpreting iPLEX HS Reports including the iPLEX HS Colon Panel intended for use with the MA4.\n\nYour firm’s website (last accessed on March 20, 2024) includes product descriptions and statements that the iPLEX HS Colon Panel “enables tumor profiling studies of colorectal cancer specimens”, and that, with the iPLEX HS Colon Panel, users can “Detect more than 80 clinically relevant variants across BRAF, EGFR, KRAS, NRAS, and PIK3CA” and “Identify variants at as low as 1% variant allele frequency.” [https:\u002F\u002Fwww.agenabio.com\u002Fproducts\u002Fpanel\u002Fiplex-hs-colon-panel\u002F]\n\nYour firm’s website (last accessed on March 20, 2024) includes customer stories from clients of Agena that indicate your MA4 System is intended for clinical diagnostic use. For instance, on the “FEATURED CUSTOMER STORIES” page, a portion of a testimonial reads, “Accurate, Cost-effective Newborn Screening for the Illinois Department of Health on the MassARRAY [MA4]…” And a statement from your CEO reads, “We are proud to have the MassARRAY System [MA4] chosen to be an integral part of one of the top newborn screening programs in the country…” [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fhgt\u002Faccurate-cost-effective-cftr-variant-detection-newborn-screening\u002F]. Another customer story comes from a client that is identified as a hospital system that uses your MA4 and iPLEX HS chemistry panels in tumor profiling and can deliver a quick and cost-effective test for clinically informative variants with a statement that other labs should explore the MassARRAY (MA4) for rapid, low-cost tumor profiling panels with a link to a product page for the iPLEX HS Colon Panel. [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fonc\u002Fmassarray-enables-sensitivity-quick-turnaround-tumor-profiling-bsw\u002F].\n\nYour firm’s Director of Regulatory and Quality indicated that your firm markets the MA4 as a research use only (RUO) product and that your firm sells and distributes the MA4 to both research and clinical diagnostic companies. Your firm’s Director of Regulatory and Quality also indicated that labeling distributed with your MA4 products, and the labeling obtained during the inspection for your iPLEX HS Colon Panel, included the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” Your firm’s website also includes the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” But, as discussed in this letter, on numerous occasions your iPLEX HS Colon Panel and your MA4 were not being shipped or delivered for an investigation (21 CFR 809.10(c)). And these devices were not for use in the laboratory research phase of development but rather were represented as effective IVDs (21 CFR 809.10(c)(2)(i)). Your disclaimers that the MA4 and your iPLEX HS Colon Panel are intended for research use only (RUO) are inconsistent with the evidence obtained during the inspection and statements identified on your firm’s website as identified above and FDA has determined that your MA4 and iPLEX HS Colon Panel are intended for clinical diagnostic use.\n\nYour iPLEX HS Colon Panel intended for use with the MA4 appears to be a tumor profiling test intended for the diagnosis of colorectal cancer. You were required to submit to FDA a 510(k) for this device, because it either is a new device (21 CFR 807.81(a)(1)) or, if your iPLEX HS Colon Panel intended for use with the MA4 represents a change or modification from the device cleared in K132978 (which is indicated for use as an aid in diagnosis of patients with suspected thrombophilia), has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\n\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur inspection also revealed that your firm’s iPLEX HS Colon Panel is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, failure to submit a written report to FDA of any correction or removal of a device initiated to reduce a risk to health posed by the device, as required by 21 CFR Part 806.10. For example:\n\nOn June 1, 2021, your firm issued a Customer Notification alerting customers that certain lots of your iPLEX HS Colon v1.0 Panel did not include the A nucleotide termination in Well #8 which your firm determined could result in false negative results for three target variant alleles. Your firm instructed customers to not use the results for the impacted variants and that your firm would reformulate and verify the termination mix and provide further updates on availability. Your firm did not submit a written report of this removal to the agency, as required by 21 CFR 806.10.\n\nWe request that your firm immediately cease any activities that result in the misbranding or adulteration of your devices. Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to both: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov and to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS # 665159 when replying. If you have any questions about the contents of this letter, please contact: Jeff R. Wooley, Compliance Officer, at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney Lias, Ph.D.\n\nActing Director\n\nOHT 7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director, Division 3\n\nOffice of Medical Device and Radiological Health\n\nOffice of Regulatory Affairs\n\nCC: Glen Wise\n\nDirector, Quality and Regulatory\n\nGlenn.wise@agenabio.com","Agena Bioscience, Inc.","agena-bioscience-inc-665159-03212024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagena-bioscience-inc-665159-03212024","2026-10-26T08:07:51.129425+00:00","Warning Letter","Issued","2024-04-02","665159","Medical Devices","Roman Haehn","2026-08-20T00:12:02.998+00:00","VIA UNITED PARCEL SERVICE","2024-03-21",{"id":32,"raw":33,"subject":38,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":47,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":51,"issuing_office":37,"recipient_name":52,"body_fetched_at":53,"delivery_method":54,"recipient_title":19,"reference_number":19,"action_taken_date":55,"medical_device_id":19,"response_letter_date":19},2357,[34,35,36,37,38,13,39,13],"\u003Ctime datetime=\"2022-11-08T14:20:00Z\">11\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-31T04:00:00Z\">10\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabraxis-bioscience-llc-633713-10312022\">Abraxis Bioscience LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabraxis-bioscience-llc-633713-01182024\">\u003Ctime datetime=\"2024-03-25T04:00:00Z\">03\u002F25\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Giovanni Caforio\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Abraxis Bioscience LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>620 N 51st Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85043\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Giovanni.Caforio@bms.com\"> Giovanni.Caforio@bms.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 31, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Caforio:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Abraxis Bioscience, LLC, FEI 3006441852, at 620 N 51st Ave., Phoenix, AZ from March 28 to April 6, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 27, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to effectively implement corrective actions and preventive actions (CAPA) and return your aseptic processing line and manufacturing operations to a state of control. Multiple media fill failures occurred between April and October 2021, when simulating aseptic processing operations on the filling line used for your drug product Abraxane (a sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug).\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform a sufficiently comprehensive evaluation and remediation upon this loss of state of control in your aseptic operations. In December 2021, you released batches potentially impacted by these failures following \u003Cstrong>(b)(4)\u003C\u002Fstrong> successful media fill run (conducted in November 2021).\u003C\u002Fp>\n\n\u003Cp>Your investigations into the following media fill failures were inadequate in that they lacked sufficient rigor in determining root causes and scope of impact after the media fills revealed serious non-sterility risks in your aseptic process operations.\u003C\u002Fp>\n\n\u003Cp>Specifically,\u003C\u002Fp>\n\n\u003Cp>1) On April 20, 2021, you conducted a media fill using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of incubation, you observed a very high number (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of contaminated units. Ten different microbes were identified from samples of contaminated units including sporeforming, vegetative, gram-negative, and gram-positive microbes. Your investigation attributed the root cause to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the filling manifold that included a damaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was contaminated during \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>equipment cleaning step. The investigation indicated that the valve harbored such excessive bioburden that it apparently enabled numerous bacteria to survive the subsequent filling equipment sterilization cycle, and the contaminated valve then caused the extensive contamination of units during the media fill. The investigation failed to adequately address how not only sporeforming microbes, but also vegetative microbes with far \u003Cstrong>(b)(4)\u003C\u002Fstrong>, presumably survived your validated sterilization cycle. Also, you did not explain whether the sterilization cycle design allows for robust \u003Cstrong>(b)(4)\u003C\u002Fstrong> and reproducible exposure of all equipment parts in your sterilizer loads.\u003C\u002Fp>\n\n\u003Cp>2) On July 12, 2021, you conducted a repeat media fill using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which revealed multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminated units. You attributed the root cause of the media fill failure to personnel gowning, poor disinfection of the inner Restricted Access Barrier System(RABS), and contaminated forceps used during the stopper bowl interventions in your RABS. However, the CAPA did not sufficiently expand to more holistic remediation of the root causes, including but not limited to, ensuring a comprehensive evaluation of the frequency, specificity, sufficiency, and robustness of your disinfection and decontamination program for the RABS and the surrounding cleanroom(s).\u003C\u002Fp>\n\n\u003Cp>3) On October 5, 2021, you conducted a media fill using \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>as part of your process improvement. Although you aborted the run due to “unloading equipment failure,” you again observed a high number (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of contaminated units. Your firm observed this contamination, which was present in \u003Cstrong>(b)(4)\u003C\u002Fstrong> shelves, while unloading the units from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You attributed the root cause to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and stated that the bacterial contamination was introduced via the \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed with \u003Cstrong>(b)(4)\u003C\u002Fstrong> apparatus that consists of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for purposes of sample collection. Notably, your process has incorporated multiple pieces of \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment on your sterile processing line rather than traditional reusable equipment. As with traditional equipment, high standards for robustness and integrity are essential for each of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> elements of your sterile operation.\u003C\u002Fp>\n\n\u003Cp>The investigation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> failure was insufficient. For example, it lacked sufficient evaluation of the ruggedness of these disposable systems, which your firm states are intended to be “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” while adding that they can be contaminated by the operator manipulations in the ISO 7 (Grade B) environment. While the investigation acknowledges “vulnerability of the syringe sampling system” and inadequate instructions for use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as factors contributing to the contamination of the sterile product process stream, the CAPA did not include a broader review of suitability for their intended use of other \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;equipment, adequacy of their instructions, and potential hazards posed when sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> are exposed to lower area classifications than ISO 5 (Grade A).\u003C\u002Fp>\n\n\u003Cp>4) On November 15, 2021, you conducted a media fill using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as part of qualification of this new system. You observed one turbid vial on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of incubation. You attributed the contamination to inadequate disinfection of the area below the work surface that contaminated the pump apparatus after equipment changeover, which in turn may have contaminated RABS gloves used for unplanned mechanical interventions. However, you did not address the extent of other equipment underneath the filling line worksurface that can pose a contamination risk due to insufficient disinfection.\u003C\u002Fp>\n\n\u003Cp>These \u003Cstrong>(b)(4)\u003C\u002Fstrong> media fill contaminations indicate your aseptic manufacturing operations were not in control. Without a comprehensive assessment of contamination hazards, and a CAPA that builds more holistic risk mitigation into your operational design, there is no assurance that you can prevent recurrence of sterility problems due to various latent or active failure modes in your operation.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that your firm took significant steps in response to the media fill failures, including a Field Alert Report, batch rejections, and suspension of operations.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate. You state that “... the media fill investigations determined root cause of each media fill event, supported the establishment of CAPA to prevent future recurrence as well as the decisions made in relation to the product under scope of the events.” However, you continued to observe contaminated units in subsequent media fills. The recurring incidents of contaminated units in media fills are an indicator of an adverse trend in your aseptic filling line. You did not provide a comprehensive assessment of contamination risk factors in your aseptic processing operations that support robust and holistic remediations to your aseptic processing operation design. Systemic remediations are essential to address a pattern of recurring contamination events and ensure sustainable control of your aseptic processing operations.\u003C\u002Fp>\n\n\u003Cp>The response also lacks adequate justification to support the sufficiency of your CAPA activities. For example, regarding the October 5, 2021, media fill, your response fails to adequately explain how your CAPA will ensure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringe in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> will no longer cause contamination of the sterile product pathway. This type of fragility questions the basic functionality and selection of a system that is explicitly designed to maintain sterility. You also did not adequately address whether you intend to revisit the area classification, the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>equipment choice or supplier of this system considering the media fill finding.\u003C\u002Fp>\n\n\u003Cp>In response to the letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o&nbsp; All human interactions within the ISO 5 area.\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Equipment placement and ergonomics.\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Air quality in the ISO 5 area and surrounding room.\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Facility layout.\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations).\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Other variables that have potential to cause contamination in your operations (e.g., insufficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization frequency).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations and management oversight of facilities and equipment. This plan should include, among other things, improved management of operations that assures prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fli>\n\t\u003Cli>A thorough evaluation of the suitability of each \u003Cstrong>(b)(4)\u003C\u002Fstrong> apparatus for its intended use. Your evaluation of all of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment should include a determination of whether they are appropriate, durable, and maintain integrity. Also, regarding the media fill failure that involved \u003Cstrong>(b)(4)\u003C\u002Fstrong> difficulties, include an assessment of sampling robustness based upon its purpose and associated hazards, and discuss the feasibility of a lower risk sampling location.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A detailed description of the degree of involvement of quality assurance (QA) staff in evaluation, oversight, performance, and guiding of the content and depth of your investigations. Among other things, explain whether quality assurance plays a lead role throughout each investigation or only at certain specified intervals. Also explain the role and authority of the QA function in assuring appropriate root cause determinations and identification of an effective CAPA plan.\u003C\u002Fli>\n\t\u003Cli>A retrospective evaluation by a qualified third party of investigations and failure modes related to the capability of your aseptic processing operation to robustly produce sterile drugs, including, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; All media fill contamination events, and all sterility positives, since January 1, 2019,regardless of whether the batch was shipped to the United States.\u003Cbr>\n&nbsp; o&nbsp; Identification of all potential failure modes associated with these media fill and sterility positives.\u003Cbr>\n&nbsp; o&nbsp; A detailed evaluation and description of each aseptic connection and operation made down stream of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including, but not limited to, the manipulations at sampling ports in the product flow pathway \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n&nbsp; o&nbsp; A comparison of your aseptic manufacturing process to the process simulation protocol to identify areas in which media fills may be improved to simulate actual operations more accurately.\u003Cbr>\n&nbsp; o&nbsp; Media fill criteria used by your firm, and adequacy of provisions to ensure thorough investigation of any contamination.\u003Cbr>\n&nbsp; o&nbsp; All changes implemented to your aseptic operations in response to any aseptic process simulation incidents and sterility failures since 2019, including an evaluation of their adequacy and sufficiency, and a risk assessment of any distributed product affected by deficient aseptic processing operations that occurred during this period.\u003Cbr>\n&nbsp; o&nbsp; Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\n\t\u003Cli>An independent review of the validity and robustness of your equipment parts sterilizationcycles. This review should include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; A comprehensive assessment, including load configurations, pre-assembled parts, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, biological indicator placement in worst-case locations, correlation of heat and biological kill, and other factors.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o&nbsp; A thorough evaluation of the ability of the vegetative microbes, named in your April 2021, media fill investigation to survive the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization cycle used for equipment parts. The review should also re-evaluate whether vegetative microbes may have been introduced to that media fill through other routes of contamination.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete list of complaints received for Abraxane drug products since January 2019.Include the lot number, date of manufacture, sufficient narrative regarding the nature of the complaint, any CAPA steps taken, and conclusions.\u003C\u002Fli>\n\t\u003Cli>An updated risk assessment that addresses any product quality or patient safety risks related to batches of Abraxane (manufactured between October 2020 and April 2021) in U.S. distribution, including potential customer notification and recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with the unique identifier: \u003Cstrong>CMS# 633713\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to ORAPHARM4_RESPONSES@fda.hhs.gov with ATTN: CDR Steven E. Porter, Jr. or mail your written response to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612-2506\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact Jamie Dion, compliance officer, at 303-236-3133, or by email at Jamie.Dion@fda.hhs.gov. www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Nathan Trembath (via email Nathan.Trembath@bms.com)\u003Cbr>\nExecutive Director, Site Head\u003Cbr>\nAbraxis Bioscience LLC\u003Cbr>\n620 N 51st Ave.\u003Cbr>\nPhoenix, AZ 85043\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Giovanni Caforio\n\nRecipient Title\n\nChief Executive Officer\n\nAbraxis Bioscience LLC\n\n620 N 51st Ave.\n\nPhoenix, AZ 85043\n\nUnited States\n\nGiovanni.Caforio@bms.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nOctober 31, 2022\n\nDear Mr. Caforio:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Abraxis Bioscience, LLC, FEI 3006441852, at 620 N 51st Ave., Phoenix, AZ from March 28 to April 6, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 27, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following:\n\nYour firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to effectively implement corrective actions and preventive actions (CAPA) and return your aseptic processing line and manufacturing operations to a state of control. Multiple media fill failures occurred between April and October 2021, when simulating aseptic processing operations on the filling line used for your drug product Abraxane (a sterile (b)(4) drug).\n\nYour firm failed to perform a sufficiently comprehensive evaluation and remediation upon this loss of state of control in your aseptic operations. In December 2021, you released batches potentially impacted by these failures following (b)(4) successful media fill run (conducted in November 2021).\n\nYour investigations into the following media fill failures were inadequate in that they lacked sufficient rigor in determining root causes and scope of impact after the media fills revealed serious non-sterility risks in your aseptic process operations.\n\nSpecifically,\n\n1) On April 20, 2021, you conducted a media fill using the (b)(4). On the (b)(4) of incubation, you observed a very high number ((b)(4)) of contaminated units. Ten different microbes were identified from samples of contaminated units including sporeforming, vegetative, gram-negative, and gram-positive microbes. Your investigation attributed the root cause to (b)(4) in the filling manifold that included a damaged (b)(4) that was contaminated during (b)(4) equipment cleaning step. The investigation indicated that the valve harbored such excessive bioburden that it apparently enabled numerous bacteria to survive the subsequent filling equipment sterilization cycle, and the contaminated valve then caused the extensive contamination of units during the media fill. The investigation failed to adequately address how not only sporeforming microbes, but also vegetative microbes with far (b)(4), presumably survived your validated sterilization cycle. Also, you did not explain whether the sterilization cycle design allows for robust (b)(4) and reproducible exposure of all equipment parts in your sterilizer loads.\n\n2) On July 12, 2021, you conducted a repeat media fill using the (b)(4), which revealed multiple (b)(4) contaminated units. You attributed the root cause of the media fill failure to personnel gowning, poor disinfection of the inner Restricted Access Barrier System(RABS), and contaminated forceps used during the stopper bowl interventions in your RABS. However, the CAPA did not sufficiently expand to more holistic remediation of the root causes, including but not limited to, ensuring a comprehensive evaluation of the frequency, specificity, sufficiency, and robustness of your disinfection and decontamination program for the RABS and the surrounding cleanroom(s).\n\n3) On October 5, 2021, you conducted a media fill using (b)(4) as part of your process improvement. Although you aborted the run due to “unloading equipment failure,” you again observed a high number ((b)(4)) of contaminated units. Your firm observed this contamination, which was present in (b)(4) shelves, while unloading the units from the (b)(4). You attributed the root cause to (b)(4) and stated that the bacterial contamination was introduced via the (b)(4) performed with (b)(4) apparatus that consists of a (b)(4) for purposes of sample collection. Notably, your process has incorporated multiple pieces of (b)(4) equipment on your sterile processing line rather than traditional reusable equipment. As with traditional equipment, high standards for robustness and integrity are essential for each of the (b)(4) elements of your sterile operation.\n\nThe investigation of the (b)(4) failure was insufficient. For example, it lacked sufficient evaluation of the ruggedness of these disposable systems, which your firm states are intended to be “(b)(4)” while adding that they can be contaminated by the operator manipulations in the ISO 7 (Grade B) environment. While the investigation acknowledges “vulnerability of the syringe sampling system” and inadequate instructions for use of the (b)(4) as factors contributing to the contamination of the sterile product process stream, the CAPA did not include a broader review of suitability for their intended use of other (b)(4) equipment, adequacy of their instructions, and potential hazards posed when sterile (b)(4) are exposed to lower area classifications than ISO 5 (Grade A).\n\n4) On November 15, 2021, you conducted a media fill using the (b)(4), as part of qualification of this new system. You observed one turbid vial on the (b)(4) of incubation. You attributed the contamination to inadequate disinfection of the area below the work surface that contaminated the pump apparatus after equipment changeover, which in turn may have contaminated RABS gloves used for unplanned mechanical interventions. However, you did not address the extent of other equipment underneath the filling line worksurface that can pose a contamination risk due to insufficient disinfection.\n\nThese (b)(4) media fill contaminations indicate your aseptic manufacturing operations were not in control. Without a comprehensive assessment of contamination hazards, and a CAPA that builds more holistic risk mitigation into your operational design, there is no assurance that you can prevent recurrence of sterility problems due to various latent or active failure modes in your operation.\n\nWe acknowledge that your firm took significant steps in response to the media fill failures, including a Field Alert Report, batch rejections, and suspension of operations.\n\nYour firm’s response is inadequate. You state that “... the media fill investigations determined root cause of each media fill event, supported the establishment of CAPA to prevent future recurrence as well as the decisions made in relation to the product under scope of the events.” However, you continued to observe contaminated units in subsequent media fills. The recurring incidents of contaminated units in media fills are an indicator of an adverse trend in your aseptic filling line. You did not provide a comprehensive assessment of contamination risk factors in your aseptic processing operations that support robust and holistic remediations to your aseptic processing operation design. Systemic remediations are essential to address a pattern of recurring contamination events and ensure sustainable control of your aseptic processing operations.\n\nThe response also lacks adequate justification to support the sufficiency of your CAPA activities. For example, regarding the October 5, 2021, media fill, your response fails to adequately explain how your CAPA will ensure the (b)(4) syringe in your (b)(4) will no longer cause contamination of the sterile product pathway. This type of fragility questions the basic functionality and selection of a system that is explicitly designed to maintain sterility. You also did not adequately address whether you intend to revisit the area classification, the (b)(4) equipment choice or supplier of this system considering the media fill finding.\n\nIn response to the letter, provide:\n\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area.\n\no Equipment placement and ergonomics.\n\no Air quality in the ISO 5 area and surrounding room.\n\no Facility layout.\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations).\n\no Other variables that have potential to cause contamination in your operations (e.g., insufficient (b)(4) sterilization frequency).\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nYour CAPA plan to implement routine, vigilant operations and management oversight of facilities and equipment. This plan should include, among other things, improved management of operations that assures prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\n\nA thorough evaluation of the suitability of each (b)(4) apparatus for its intended use. Your evaluation of all of your (b)(4) equipment should include a determination of whether they are appropriate, durable, and maintain integrity. Also, regarding the media fill failure that involved (b)(4) difficulties, include an assessment of sampling robustness based upon its purpose and associated hazards, and discuss the feasibility of a lower risk sampling location.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA detailed description of the degree of involvement of quality assurance (QA) staff in evaluation, oversight, performance, and guiding of the content and depth of your investigations. Among other things, explain whether quality assurance plays a lead role throughout each investigation or only at certain specified intervals. Also explain the role and authority of the QA function in assuring appropriate root cause determinations and identification of an effective CAPA plan.\n\nA retrospective evaluation by a qualified third party of investigations and failure modes related to the capability of your aseptic processing operation to robustly produce sterile drugs, including, but not be limited to:\n\no All media fill contamination events, and all sterility positives, since January 1, 2019,regardless of whether the batch was shipped to the United States.\n\no Identification of all potential failure modes associated with these media fill and sterility positives.\n\no A detailed evaluation and description of each aseptic connection and operation made down stream of the (b)(4), including, but not limited to, the manipulations at sampling ports in the product flow pathway (b)(4).\n\no A comparison of your aseptic manufacturing process to the process simulation protocol to identify areas in which media fills may be improved to simulate actual operations more accurately.\n\no Media fill criteria used by your firm, and adequacy of provisions to ensure thorough investigation of any contamination.\n\no All changes implemented to your aseptic operations in response to any aseptic process simulation incidents and sterility failures since 2019, including an evaluation of their adequacy and sufficiency, and a risk assessment of any distributed product affected by deficient aseptic processing operations that occurred during this period.\n\no Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and its support operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\nAn independent review of the validity and robustness of your equipment parts sterilizationcycles. This review should include:\n\no A comprehensive assessment, including load configurations, pre-assembled parts, (b)(4), biological indicator placement in worst-case locations, correlation of heat and biological kill, and other factors.\n\no A thorough evaluation of the ability of the vegetative microbes, named in your April 2021, media fill investigation to survive the (b)(4) sterilization cycle used for equipment parts. The review should also re-evaluate whether vegetative microbes may have been introduced to that media fill through other routes of contamination.\n\nA complete list of complaints received for Abraxane drug products since January 2019.Include the lot number, date of manufacture, sufficient narrative regarding the nature of the complaint, any CAPA steps taken, and conclusions.\n\nAn updated risk assessment that addresses any product quality or patient safety risks related to batches of Abraxane (manufactured between October 2020 and April 2021) in U.S. distribution, including potential customer notification and recalls.\n\nAdditional Guidance on Aseptic Processing\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease identify your response with the unique identifier: CMS# 633713.\n\nSend your electronic response to ORAPHARM4_RESPONSES@fda.hhs.gov with ATTN: CDR Steven E. Porter, Jr. or mail your written response to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612-2506\n\nIf you have questions regarding the content of this letter, please contact Jamie Dion, compliance officer, at 303-236-3133, or by email at Jamie.Dion@fda.hhs.gov. www.fda.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nCC: Nathan Trembath (via email Nathan.Trembath@bms.com)\n\nExecutive Director, Site Head\n\nAbraxis Bioscience LLC\n\n620 N 51st Ave.\n\nPhoenix, AZ 85043","Abraxis Bioscience LLC","abraxis-bioscience-llc-633713-10312022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabraxis-bioscience-llc-633713-10312022","2026-10-26T08:07:49.018355+00:00","Closed Out","2022-11-08","633713","Drugs","2024-03-25","Mr. Giovanni Caforio","2026-08-20T01:27:18.294+00:00","VIA EMAIL CONFIRMED DELIVERY","2022-10-31",{"id":57,"raw":58,"subject":63,"body_html":64,"body_text":65,"firm_name":66,"letter_id":67,"created_at":68,"fei_number":19,"letter_url":69,"updated_at":70,"action_type":22,"case_status":23,"posted_date":71,"marcs_cms_no":72,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":19,"reference_number":19,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},357,[59,60,61,11,62,13,13,13],"\u003Ctime datetime=\"2026-01-27T05:00:00Z\">01\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-22T05:00:00Z\">12\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmeridian-bioscience-inc-720826-12222025\">Meridian Bioscience, Inc \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tony Serafini-Lamanna\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President of Diagnostics \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Meridian Bioscience, Inc \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3471 Riverhills Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cincinnati\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45244\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Tony.Serafini-Lamanna@meridianbioscience.com\"> Tony.Serafini-Lamanna@meridianbioscience.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 720826\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 22, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Serafini-Lamanna:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Magellan Diagnostics, Inc. located in North Billerica, MA from August 5, 2025, through August 26, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures in-vitro diagnostics (IVD) kits that measure blood lead levels, including the LeadCare II Blood Lead Analyzer and Test Kit. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Vernon Brown Director – Quality Assurance and Regulatory Affairs, Meridian Biosciences, Inc. dated September 17, 2025, October 3, 2025, October 17, 2025, November 14, 2025, November 26, 2025, and December 12, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address your responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to follow its CAPA procedure, SOP 128, Rev 15, Effective March 27, 2025, including opening CAPAs as required by your procedure. Section 2 of this SOP indicates CAPA’s can arise from “A systemic issue identified through trend monitoring.” For example:\u003C\u002Fp>\u003Cp>A) Your firm failed to open a CAPA in October 2024, when you began trending an increase in patient false positive complaints (PATFP) associated with the use of certain third-party (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) collection tubes used with your LeadCare II Blood Lead Test Kit. From October 7, 2024, to August 14, 2025, you identified approximately 179 of these PATFP complaints. We are also aware that you did not take these complaints into account with a previous CAPA 1288 which was initiated on May 3, 2023, to address increased patient false positive complaints (PATFP) for the LeadCare II Blood Lead Test Kit. This CAPA 1288 was closed out on May 22, 2025, noting that “current complaint trending reports confirm that the PATFP complaint rate has reached a steady state.” However, your firm received 31 complaints of false positives after this date and did not take any further action, such as the opening of a new CAPA, as required by your procedure.\u003C\u002Fp>\u003Cp>B) Your firm failed to open a CAPA to address at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> out-of-range control complaints (\"COORLO\") received for your LeadCare II Blood Lead Test Kit from June 22, 2021, to July 2025.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and concluded they are not adequate. We understand that you have revised product labeling to indicate that the customer must use only the capillary tubes included in the LeadCare II Blood Lead Test Kit for blood collection and that you plan to send customers a letter to inform them of this update. Please be aware that this action would require a report to be submitted to FDA as required by 21 CFR 806. However, your firm has not provided copies of the CAPAs opened in response to this observation to demonstrate your proposed corrective actions will be effective, nor did it indicate that it will be performing any retrospective review of previous complaints or trends to ensure CAPAs have been opened appropriately and as required by your procedure.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient. The procedures shall include a mechanism for addressing incomplete, ambiguous, or conflicting requirements. The design input requirements shall be documented and shall be reviewed and approved by a designated individual(s). The approval, including the date and signature of the individual(s) approving the requirements, shall be documented, as required by 21 CFR 820.30(c).\u003C\u002Fp>\u003Cp>For example, your firm failed to establish design inputs for the Level 1 and Level 2 Controls used in LeadCare II Blood Lead Testing Systems as required by your Design Control Procedure, SOP 131, Revision 13, Effective Date June 6, 2021. The Instructions for Use for LeadCare II Blood Lead Testing System states that Level 1 and Level 2 controls are intended \"to verify system performance and accuracy before testing patient results.\" Yet, the Design Requirement Matrix, Rev G, dated July 1, 2020, which was provided as the latest specification for LeadCare II testing system, fails to establish specific and separate design requirements for the Level 1 or Level 2 Controls that are part of the LeadCare II testing system.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and concluded they are not adequate. Your firm indicated that a CAPA will be opened to evaluate the level 1 and 2 controls and will also include a retrospective review of complaints to further evaluate the issue. However, your firm did not provide a copy of the CAPA to demonstrate your proposed corrective actions will be effective. Also, your response did not include a timeline for revising your design documents nor any plans for assessing your design control program to mitigate the above observation.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for validating the device design. Design validation shall be performed under \u003Cstrong>(b)(4)\u003C\u002Fstrong> operating conditions on \u003Cstrong>(b)(4)\u003C\u002Fstrong> production units, lots, or batches, or their equivalents. Design validation shall ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions. Design validation shall include software validation and risk analysis, where appropriate. The results of the design validation, including identification of the design, method(s), the date, and the individual(s) performing the validation, shall be documented in the DHF, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>A) Your firm did not validate the cleaning and decontamination instructions written in the Instructions for Use (IFU) for Blood Lead Testing Systems - LeadCare II, LeadCare Ultra, and LeadCare Plus Analyzers.\u003C\u002Fp>\u003Cp>B) Your firm failed to adequately establish your Risk Management Procedure SOP 159, Rev 08, dated March 12, 2025, which requires the Risk Management File to be updated periodically or when previously unrecognized hazards are present. For example:\u003C\u002Fp>\u003Cp>o Your firm failed to update your risk files for your LeadCare II test system, after becoming aware of an increase in false positive complaints associated with the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tubes from October 7, 2024, to August 14, 2025. Specifically, your DFMEA dated December 1, 2022, PFMEA dated November 5, 2020, and UFMEA dated June 18, 2020, were not updated to include this previously unrecognized hazard.\u003C\u002Fp>\u003Cp>o Your firm failed to update your risk files for their LeadCare II test system, after becoming aware of two separate labeling control failures during manufacturing in March of 2023 and again in May of 2024 that resulted in mislabeled products being distributed. Specifically, the PFMEA dated November 5, 2020, was not updated to identify any risks associated with the mislabeling of products being released.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and concluded they are not adequate. Your firm indicated it will validate the cleaning process and expect this to be completed by January 9, 2026. Your firm’s response noted a CAPA will be opened for review and revision of the risk management files, but did not provide any details, including a copy of the CAPA to demonstrate your proposed corrective actions will be effective. Also, the responses did not include a plan to perform any retrospective review of ECO’s to ensure risk management files will be updated appropriately.\u003C\u002Fp>\u003Cp>4. Failure to validate a process with a high degree of assurance and approved according to established procedures, when the results of a process cannot be fully verified by subsequent inspection and test. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented, as required by 21 CFR 820.75(a). For example:\u003C\u002Fp>\u003Cp>A) Your firm failed to have validation data to demonstrate how calibration verification with only \u003Cstrong>(b)(4)\u003C\u002Fstrong> of data can ensure reliable device performance across the reportable range for a diagnostic device. Your calibration verification procedure 65055, allows exclusion of up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> of test results when they exceed the reportable range. This procedure includes instructions for operators to \"leave blank\" any \"High\" results and exclude \"obvious outliers or contaminated samples,\" and if remaining data fails bias specification, it allows \u003Cstrong>(b)(4)\u003C\u002Fstrong> calibration adjustments.\u003C\u002Fp>\u003Cp>B) Your firm failed to validate the revised manufacturing process which included new acceptance criteria to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to demonstrate consistent manufacturing capability. Engineering Change Order (ECO) 7378 was initiated on June 30, 2023, to “Update Procedures for \"LC II Sensor Calibration Verification\" (Document Reference 650055) and \"LeadCare Ultra Sensor Calibration Verification Procedure\" (Document Reference 65064) to include release requirements for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> based on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing data obtained.” The ECO noted this process change was considered a low risk, and no additional validation was performed, even though this is critical acceptance criteria.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses, and concluded they are not adequate. Your responses indicated CAPAs were opened to address the above items; however, they did not provide a copy of the CAPAs to demonstrate your proposed corrective actions will be effective or a plan to ensure re-validation is performed, as necessary, when manufacturing operations are revised, including anytime acceptance criteria is modified.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements. Acceptance or rejection shall be documented, as required by 21 CFR 820.80(b).\u003C\u002Fp>\u003Cp>For example, your firm failed to establish adequate incoming inspection procedures for capillary collection tubes used with your blood lead testing kits. The current procedure requires a sample of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tubes from lot sizes of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units per \u003Cstrong>(b)(4)\u003C\u002Fstrong> for packaging verification only. Your Incoming Inspection Procedure, SOP 105, Rev 10, Effective Date April 18, 2025, does not specify inspection of any critical quality attributes for these capillary tubes.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined at this time. We understand that you plan to revise specifications for LCII Blood Collection Capillary – Plungers Kit, and plan to initiate incoming inspection on these components, including testing the tubes for lead, however, these revisions are still in progress. We will need to verify that your firm is performing sufficient inspections to ensure these components meet their required specifications.\u003C\u002Fp>\u003Cp>6. Failure to have written sampling plans that are based on a valid statistical rationale. Each manufacturer shall establish and maintain procedures to ensure that sampling methods are adequate for their intended use and to ensure that when changes occur the sampling plans are reviewed. These activities shall be documented, as required by 21 CFR 820.250(b).\u003C\u002Fp>\u003Cp>For example, your firm failed to follow your Statistical Methods &amp; Analysis of Data Procedure, SOP 139, Rev 04, Effective Date November 16, 2020, Section 6.5, which requires adequate sample size justification for process\u002Fproduct verification\u002Fvalidation\u002Ftest method validation studies. Validation testing performed on August 30, 2023, to validate mold modification of caps through \u003Cstrong>(b)(4)\u003C\u002Fstrong> Caps (P\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>), inspected only 10 caps from Cavity \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Cavity \u003Cstrong>(b)(4)\u003C\u002Fstrong> (5 each) without describing lot size or providing valid statistical rationale for the sample size chosen.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined at this time. You indicated a CAPA was opened to review your procedures related to statistical evaluation, but you did not provide any additional documentation, including a copy of the CAPA to demonstrate your proposed corrective actions will be effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s LeadCare Plus Blood Lead Testing Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 ‐ Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to report to us the information required by § 803.52 in accordance with the\u003Cbr>requirements of § 803.12(a), no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example:\u003C\u002Fp>\u003Cul>\u003Cli>The information included for Complaint #MAG-CC-05942 describes an event where the pediatric patient experienced a false negative result while using your firm’s LeadCare Plus blood lead testing system, as a result of a device malfunction (e.g., corroded sensor pin). We believe this malfunction resulted in the device’s failure to perform its essential function and compromise the device’s diagnostic effectiveness and would be likely to cause or contribute to a death or serious injury. There’s no information included for the complaint indicating that the malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Accordingly, the complaint represents an MDR-reportable malfunction, as defined in 21 CFR 803.3. Your firm became aware of the event on October 30, 2023, and firm failed to submit the MDR within the required 30-calendar-day timeframe.\u003C\u002Fli>\u003Cli>The information included for Complaint # MAG-CC-06971, describes a malfunction (i.e., analyzer emitting a burning smell) involving your firm’s LeadCare Plus Blood Lead Testing System. Your firm became aware of MAG-CC-06971 on July 17, 2024, and submitted a malfunction MDR for the event. FDA received the corresponding MDR# 1218996-2025-00006 on January 29, 2025, which is beyond the 30-calendar day timeframe after becoming aware.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your firm has not yet submitted an MDR for complaint #MAG-CC-05942. In addition, the response states that your firm plans to initiate a CAPA to evaluate and optimize the MDR reporting process and conduct a retrospective review to address the issue in accordance with the revised process. However, your firm has not provided documentation or evidence demonstrating that the systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s LeadCare II Blood Lead Test Kits devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10. For example: Magellan Diagnostics, Inc. became aware of labelling error during assembly of LeadCare II Blood Lead Test Kits, halted assembly and conducted a “Stop Shipment.” Your firm sent a customer communication titled “MEDICAL DEVICE FIELD CORRECTION” dated 5\u002F8\u002F2024, to notify customers that \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the LeadCare II Testing Kit calibration button was incorrectly labeled as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which could result in inaccurate results and patient testing could be delayed. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA within 10 working days of initiation. As of the date of the close of the inspection, August 26, 2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>Your firm’s responses adequately satisfy this citation. Magellan Diagnostics, Inc. notified customers of the problem, initiated a medical device removal, and submitted a Report of Correction or Removal to FDA as of October 27, 2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>We are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality System regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\u003Cul>\u003Cli>Initial certifications by consultant and establishment – July 31, 2026\u003C\u002Fli>\u003Cli>Subsequent certifications – July 31, 2027, and July 31, 2028.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 720826” when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon, Compliance Officer at karen.archdeacon@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Vernon Brown, Director – Quality Assurance and Regulatory Affairs, vernon.brown@meridianbioscience.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTony Serafini-Lamanna\n\nRecipient Title\n\nPresident of Diagnostics\n\nMeridian Bioscience, Inc\n\n3471 Riverhills Dr.\n\nCincinnati, OH 45244\n\nUnited States\n\nTony.Serafini-Lamanna@meridianbioscience.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 720826\nDecember 22, 2025\nDear Mr. Serafini-Lamanna:\nDuring an inspection of your firm, Magellan Diagnostics, Inc. located in North Billerica, MA from August 5, 2025, through August 26, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures in-vitro diagnostics (IVD) kits that measure blood lead levels, including the LeadCare II Blood Lead Analyzer and Test Kit. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Vernon Brown Director – Quality Assurance and Regulatory Affairs, Meridian Biosciences, Inc. dated September 17, 2025, October 3, 2025, October 17, 2025, November 14, 2025, November 26, 2025, and December 12, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address your responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a).\nSpecifically, your firm failed to follow its CAPA procedure, SOP 128, Rev 15, Effective March 27, 2025, including opening CAPAs as required by your procedure. Section 2 of this SOP indicates CAPA’s can arise from “A systemic issue identified through trend monitoring.” For example:\nA) Your firm failed to open a CAPA in October 2024, when you began trending an increase in patient false positive complaints (PATFP) associated with the use of certain third-party ((b)(4)) collection tubes used with your LeadCare II Blood Lead Test Kit. From October 7, 2024, to August 14, 2025, you identified approximately 179 of these PATFP complaints. We are also aware that you did not take these complaints into account with a previous CAPA 1288 which was initiated on May 3, 2023, to address increased patient false positive complaints (PATFP) for the LeadCare II Blood Lead Test Kit. This CAPA 1288 was closed out on May 22, 2025, noting that “current complaint trending reports confirm that the PATFP complaint rate has reached a steady state.” However, your firm received 31 complaints of false positives after this date and did not take any further action, such as the opening of a new CAPA, as required by your procedure.\nB) Your firm failed to open a CAPA to address at least (b)(4) out-of-range control complaints (\"COORLO\") received for your LeadCare II Blood Lead Test Kit from June 22, 2021, to July 2025.\nWe reviewed your firm’s responses and concluded they are not adequate. We understand that you have revised product labeling to indicate that the customer must use only the capillary tubes included in the LeadCare II Blood Lead Test Kit for blood collection and that you plan to send customers a letter to inform them of this update. Please be aware that this action would require a report to be submitted to FDA as required by 21 CFR 806. However, your firm has not provided copies of the CAPAs opened in response to this observation to demonstrate your proposed corrective actions will be effective, nor did it indicate that it will be performing any retrospective review of previous complaints or trends to ensure CAPAs have been opened appropriately and as required by your procedure.\n2. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient. The procedures shall include a mechanism for addressing incomplete, ambiguous, or conflicting requirements. The design input requirements shall be documented and shall be reviewed and approved by a designated individual(s). The approval, including the date and signature of the individual(s) approving the requirements, shall be documented, as required by 21 CFR 820.30(c).\nFor example, your firm failed to establish design inputs for the Level 1 and Level 2 Controls used in LeadCare II Blood Lead Testing Systems as required by your Design Control Procedure, SOP 131, Revision 13, Effective Date June 6, 2021. The Instructions for Use for LeadCare II Blood Lead Testing System states that Level 1 and Level 2 controls are intended \"to verify system performance and accuracy before testing patient results.\" Yet, the Design Requirement Matrix, Rev G, dated July 1, 2020, which was provided as the latest specification for LeadCare II testing system, fails to establish specific and separate design requirements for the Level 1 or Level 2 Controls that are part of the LeadCare II testing system.\nWe reviewed your firm’s responses and concluded they are not adequate. Your firm indicated that a CAPA will be opened to evaluate the level 1 and 2 controls and will also include a retrospective review of complaints to further evaluate the issue. However, your firm did not provide a copy of the CAPA to demonstrate your proposed corrective actions will be effective. Also, your response did not include a timeline for revising your design documents nor any plans for assessing your design control program to mitigate the above observation.\n3. Failure to establish and maintain procedures for validating the device design. Design validation shall be performed under (b)(4) operating conditions on (b)(4) production units, lots, or batches, or their equivalents. Design validation shall ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions. Design validation shall include software validation and risk analysis, where appropriate. The results of the design validation, including identification of the design, method(s), the date, and the individual(s) performing the validation, shall be documented in the DHF, as required by 21 CFR 820.30(g). For example:\nA) Your firm did not validate the cleaning and decontamination instructions written in the Instructions for Use (IFU) for Blood Lead Testing Systems - LeadCare II, LeadCare Ultra, and LeadCare Plus Analyzers.\nB) Your firm failed to adequately establish your Risk Management Procedure SOP 159, Rev 08, dated March 12, 2025, which requires the Risk Management File to be updated periodically or when previously unrecognized hazards are present. For example:\no Your firm failed to update your risk files for your LeadCare II test system, after becoming aware of an increase in false positive complaints associated with the use of (b)(4) Tubes from October 7, 2024, to August 14, 2025. Specifically, your DFMEA dated December 1, 2022, PFMEA dated November 5, 2020, and UFMEA dated June 18, 2020, were not updated to include this previously unrecognized hazard.\no Your firm failed to update your risk files for their LeadCare II test system, after becoming aware of two separate labeling control failures during manufacturing in March of 2023 and again in May of 2024 that resulted in mislabeled products being distributed. Specifically, the PFMEA dated November 5, 2020, was not updated to identify any risks associated with the mislabeling of products being released.\nWe reviewed your firm’s responses and concluded they are not adequate. Your firm indicated it will validate the cleaning process and expect this to be completed by January 9, 2026. Your firm’s response noted a CAPA will be opened for review and revision of the risk management files, but did not provide any details, including a copy of the CAPA to demonstrate your proposed corrective actions will be effective. Also, the responses did not include a plan to perform any retrospective review of ECO’s to ensure risk management files will be updated appropriately.\n4. Failure to validate a process with a high degree of assurance and approved according to established procedures, when the results of a process cannot be fully verified by subsequent inspection and test. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented, as required by 21 CFR 820.75(a). For example:\nA) Your firm failed to have validation data to demonstrate how calibration verification with only (b)(4) of data can ensure reliable device performance across the reportable range for a diagnostic device. Your calibration verification procedure 65055, allows exclusion of up to (b)(4) of test results when they exceed the reportable range. This procedure includes instructions for operators to \"leave blank\" any \"High\" results and exclude \"obvious outliers or contaminated samples,\" and if remaining data fails bias specification, it allows (b)(4) calibration adjustments.\nB) Your firm failed to validate the revised manufacturing process which included new acceptance criteria to include (b)(4), to demonstrate consistent manufacturing capability. Engineering Change Order (ECO) 7378 was initiated on June 30, 2023, to “Update Procedures for \"LC II Sensor Calibration Verification\" (Document Reference 650055) and \"LeadCare Ultra Sensor Calibration Verification Procedure\" (Document Reference 65064) to include release requirements for (b)(4) and (b)(4) based on the (b)(4) testing data obtained.” The ECO noted this process change was considered a low risk, and no additional validation was performed, even though this is critical acceptance criteria.\nWe reviewed your firm’s responses, and concluded they are not adequate. Your responses indicated CAPAs were opened to address the above items; however, they did not provide a copy of the CAPAs to demonstrate your proposed corrective actions will be effective or a plan to ensure re-validation is performed, as necessary, when manufacturing operations are revised, including anytime acceptance criteria is modified.\n5. Failure to establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements. Acceptance or rejection shall be documented, as required by 21 CFR 820.80(b).\nFor example, your firm failed to establish adequate incoming inspection procedures for capillary collection tubes used with your blood lead testing kits. The current procedure requires a sample of (b)(4) tubes from lot sizes of (b)(4) units per (b)(4) for packaging verification only. Your Incoming Inspection Procedure, SOP 105, Rev 10, Effective Date April 18, 2025, does not specify inspection of any critical quality attributes for these capillary tubes.\nWe reviewed your firm’s responses and the adequacy cannot be determined at this time. We understand that you plan to revise specifications for LCII Blood Collection Capillary – Plungers Kit, and plan to initiate incoming inspection on these components, including testing the tubes for lead, however, these revisions are still in progress. We will need to verify that your firm is performing sufficient inspections to ensure these components meet their required specifications.\n6. Failure to have written sampling plans that are based on a valid statistical rationale. Each manufacturer shall establish and maintain procedures to ensure that sampling methods are adequate for their intended use and to ensure that when changes occur the sampling plans are reviewed. These activities shall be documented, as required by 21 CFR 820.250(b).\nFor example, your firm failed to follow your Statistical Methods & Analysis of Data Procedure, SOP 139, Rev 04, Effective Date November 16, 2020, Section 6.5, which requires adequate sample size justification for process\u002Fproduct verification\u002Fvalidation\u002Ftest method validation studies. Validation testing performed on August 30, 2023, to validate mold modification of caps through (b)(4) Caps (P\u002FN (b)(4)), inspected only 10 caps from Cavity (b)(4) and Cavity (b)(4) (5 each) without describing lot size or providing valid statistical rationale for the sample size chosen.\nWe reviewed your firm’s responses and the adequacy cannot be determined at this time. You indicated a CAPA was opened to review your procedures related to statistical evaluation, but you did not provide any additional documentation, including a copy of the CAPA to demonstrate your proposed corrective actions will be effective.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s LeadCare Plus Blood Lead Testing Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 ‐ Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to report to us the information required by § 803.52 in accordance with the\nrequirements of § 803.12(a), no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example:\nThe information included for Complaint #MAG-CC-05942 describes an event where the pediatric patient experienced a false negative result while using your firm’s LeadCare Plus blood lead testing system, as a result of a device malfunction (e.g., corroded sensor pin). We believe this malfunction resulted in the device’s failure to perform its essential function and compromise the device’s diagnostic effectiveness and would be likely to cause or contribute to a death or serious injury. There’s no information included for the complaint indicating that the malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Accordingly, the complaint represents an MDR-reportable malfunction, as defined in 21 CFR 803.3. Your firm became aware of the event on October 30, 2023, and firm failed to submit the MDR within the required 30-calendar-day timeframe.\nThe information included for Complaint # MAG-CC-06971, describes a malfunction (i.e., analyzer emitting a burning smell) involving your firm’s LeadCare Plus Blood Lead Testing System. Your firm became aware of MAG-CC-06971 on July 17, 2024, and submitted a malfunction MDR for the event. FDA received the corresponding MDR# 1218996-2025-00006 on January 29, 2025, which is beyond the 30-calendar day timeframe after becoming aware.\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm has not yet submitted an MDR for complaint #MAG-CC-05942. In addition, the response states that your firm plans to initiate a CAPA to evaluate and optimize the MDR reporting process and conduct a retrospective review to address the issue in accordance with the revised process. However, your firm has not provided documentation or evidence demonstrating that the systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\nCorrections and Removals Violations\nOur inspection also revealed that your firm’s LeadCare II Blood Lead Test Kits devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10. For example: Magellan Diagnostics, Inc. became aware of labelling error during assembly of LeadCare II Blood Lead Test Kits, halted assembly and conducted a “Stop Shipment.” Your firm sent a customer communication titled “MEDICAL DEVICE FIELD CORRECTION” dated 5\u002F8\u002F2024, to notify customers that (b)(4) of the LeadCare II Testing Kit calibration button was incorrectly labeled as (b)(4), which could result in inaccurate results and patient testing could be delayed. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA within 10 working days of initiation. As of the date of the close of the inspection, August 26, 2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm’s responses adequately satisfy this citation. Magellan Diagnostics, Inc. notified customers of the problem, initiated a medical device removal, and submitted a Report of Correction or Removal to FDA as of October 27, 2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nWe are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality System regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\nInitial certifications by consultant and establishment – July 31, 2026\nSubsequent certifications – July 31, 2027, and July 31, 2028.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 720826” when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon, Compliance Officer at karen.archdeacon@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Vernon Brown, Director – Quality Assurance and Regulatory Affairs, vernon.brown@meridianbioscience.com","Meridian Bioscience, Inc","meridian-bioscience-inc-720826-12222025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmeridian-bioscience-inc-720826-12222025","2026-10-26T08:09:24.106242+00:00","2026-01-27","720826","Tony Serafini-Lamanna","2026-08-19T07:16:48.363+00:00","VIA Electronic Mail","2025-12-22",{"id":78,"raw":79,"subject":38,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":68,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":19,"issuing_office":83,"recipient_name":93,"body_fetched_at":94,"delivery_method":75,"recipient_title":19,"reference_number":95,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},452,[80,81,82,83,38,13,13,13],"\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-30T04:00:00Z\">10\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowen-biosciences-inc-710275-10302025\">Owen Biosciences, Inc. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-11\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Donald R. Owen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Owen Biosciences, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7053 Revenue Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baton Rouge\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70809-4918\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-11\u003C\u002Fp>\u003Cp>October 30, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Owen:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Owen Biosciences, Inc., FEI 1000132299, at 7053 Revenue Drive, Baton Rouge, from March 25 to 27, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 10, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications for drug products prior to release (21 CFR 211.160(b) and 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures various topical over-the-counter (OTC) drug products, including those containing the active ingredient benzoyl peroxide. There is a known degradation mechanism of benzoyl peroxide, under certain conditions, to form benzene, a known carcinogen. Your firm failed to establish scientifically sound and appropriate finished product specifications and failed to conduct benzene testing on your OTC topical drug products prior to release. For example, you manufactured and released at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion without testing for benzene. FDA laboratory analysis of one lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion your firm manufactured and distributed yielded excessive benzene levels of more than 20 parts per million (ppm). You failed to ensure that your drug products do not contain unacceptable benzene impurity levels.\u003C\u002Fp>\u003Cp>During the inspection, you informed our investigator that a retain sample of the FDA-tested lot as well as other lots manufactured of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion were sent to a contract testing laboratory (CTL) to conduct impurity and assay testing.\u003C\u002Fp>\u003Cp>In your response, you mention that you will use a CTL to conduct benzene testing on the above-mentioned drug product. However, it is not clear if benzene testing will be performed on all lots prior to release. Your response also states that you are not aware of any FDA guideline on benzene testing, but FDA has alerted drug manufacturers of products at risk for presence of benzene that they should be testing those drug products for benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not detail any retrospective risk assessments (e.g., the actions that you will take) should any of the lots sent to your CTL for testing yield unacceptable benzene impurity levels. Further, your response lacks information that your CTL is qualified to test your drug products for benzene.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug product before a lot disposition decision.\u003C\u002Fli>\u003Cli>A detailed description of the method you establish to test for benzene in finished products prior to release.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all lots of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each lot of benzoyl peroxide products that are currently on the U.S. market within expiry. If the testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your stability program was not adequate to ensure that the OTC drug products you manufacture maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, full shelf-life studies were not conducted for the entire stated expiry period. Additionally, the studies performed lacked adequate identity, microbiological, and impurities testing.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate ongoing stability testing with scientific justification. Additionally, it does not include a retrospective risk assessment or information on how you will ensure marketed drug products meet stability specifications throughout shelf life.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to:\u003Cbr>o Validated stability-indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint). Given that benzene is a known degradant of benzoyl peroxide and FDA analysis yielded excessive levels of benzene in your drug product, include benzene testing at each stability timepoint.\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) is inadequate. Your QU did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Review of production and control records to ensure completeness and accuracy (21 CFR 211.192).\u003C\u002Fli>\u003Cli>Adequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.22(d); 21 CFR 211.192).\u003C\u002Fli>\u003Cli>Appropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Performance of periodic (i.e., at least annual) product review (21 CFR 211.180(e)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you will address nonconforming products by quarantining the products and taking action to eliminate detected nonconformity. You also state that you will “follow the annual review of products,” identify nonconforming products, and make any necessary adjustments with supporting documentation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not adequately detail how your quality function plans to improve its oversight of manufacturing quality. You also fail to assess the effects that your insufficient QU oversight had on product quality.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help with implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations in 21 CFR 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failed Commitment to Recall Contaminated Drug Lot\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA sampled and tested one lot of Benzoyl Peroxide Acne Lotion that is used as part of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Acne System Kit. On March 4, 2025, FDA held a teleconference with the drug product distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to recommend removal of this product lot from the U.S. market because it contained excessive benzene impurity levels of more than 20 ppm. During that call and again on March 5, 2025, \u003Cstrong>(b)(4)\u003C\u002Fstrong> communicated that it would voluntarily recall the product containing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Benzoyl Peroxide Acne Lotion that FDA tested. However, neither Owen Biosciences, Inc. nor \u003Cstrong>(b)(4)\u003C\u002Fstrong> recalled the product before it expired.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to adequately address this matter may lead to regulatory or legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when considering the award of contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may be cause for FDA to withhold issuance of Export Certificates. Any violations of CGMP requirements may also be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000132299 and ATTN: Daniel W. Brisker.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-11\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nDr. Donald R. Owen\n\nRecipient Title\n\nChief Executive Officer\n\nOwen Biosciences, Inc.\n\n7053 Revenue Drive\n\nBaton Rouge, LA 70809-4918\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-11\nOctober 30, 2025\nDear Dr. Owen:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Owen Biosciences, Inc., FEI 1000132299, at 7053 Revenue Drive, Baton Rouge, from March 25 to 27, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 10, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nCGMP Violations\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications for drug products prior to release (21 CFR 211.160(b) and 211.165(a)).\nYour firm manufactures various topical over-the-counter (OTC) drug products, including those containing the active ingredient benzoyl peroxide. There is a known degradation mechanism of benzoyl peroxide, under certain conditions, to form benzene, a known carcinogen. Your firm failed to establish scientifically sound and appropriate finished product specifications and failed to conduct benzene testing on your OTC topical drug products prior to release. For example, you manufactured and released at least (b)(4) lots of the (b)(4) 2.5% benzoyl peroxide acne lotion without testing for benzene. FDA laboratory analysis of one lot of (b)(4) 2.5% benzoyl peroxide acne lotion your firm manufactured and distributed yielded excessive benzene levels of more than 20 parts per million (ppm). You failed to ensure that your drug products do not contain unacceptable benzene impurity levels.\nDuring the inspection, you informed our investigator that a retain sample of the FDA-tested lot as well as other lots manufactured of the (b)(4) 2.5% benzoyl peroxide acne lotion were sent to a contract testing laboratory (CTL) to conduct impurity and assay testing.\nIn your response, you mention that you will use a CTL to conduct benzene testing on the above-mentioned drug product. However, it is not clear if benzene testing will be performed on all lots prior to release. Your response also states that you are not aware of any FDA guideline on benzene testing, but FDA has alerted drug manufacturers of products at risk for presence of benzene that they should be testing those drug products for benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\nYour response is inadequate because it does not detail any retrospective risk assessments (e.g., the actions that you will take) should any of the lots sent to your CTL for testing yield unacceptable benzene impurity levels. Further, your response lacks information that your CTL is qualified to test your drug products for benzene.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug product before a lot disposition decision.\nA detailed description of the method you establish to test for benzene in finished products prior to release.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all lots of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each lot of benzoyl peroxide products that are currently on the U.S. market within expiry. If the testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n2. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nYour stability program was not adequate to ensure that the OTC drug products you manufacture maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, full shelf-life studies were not conducted for the entire stated expiry period. Additionally, the studies performed lacked adequate identity, microbiological, and impurities testing.\nYour response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate ongoing stability testing with scientific justification. Additionally, it does not include a retrospective risk assessment or information on how you will ensure marketed drug products meet stability specifications throughout shelf life.\nIn your response to this letter, provide:\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to:\no Validated stability-indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint). Given that benzene is a known degradant of benzoyl peroxide and FDA analysis yielded excessive levels of benzene in your drug product, include benzene testing at each stability timepoint.\nAll procedures that describe these and other elements of your remediated stability program.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) is inadequate. Your QU did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure:\nReview of production and control records to ensure completeness and accuracy (21 CFR 211.192).\nAdequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.22(d); 21 CFR 211.192).\nAppropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\nPerformance of periodic (i.e., at least annual) product review (21 CFR 211.180(e)).\nIn your response, you state that you will address nonconforming products by quarantining the products and taking action to eliminate detected nonconformity. You also state that you will “follow the annual review of products,” identify nonconforming products, and make any necessary adjustments with supporting documentation.\nYour response is inadequate. You do not adequately detail how your quality function plans to improve its oversight of manufacturing quality. You also fail to assess the effects that your insufficient QU oversight had on product quality.\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help with implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations in 21 CFR 210 and 211.\nFailed Commitment to Recall Contaminated Drug Lot\nFDA sampled and tested one lot of Benzoyl Peroxide Acne Lotion that is used as part of the (b)(4) Acne System Kit. On March 4, 2025, FDA held a teleconference with the drug product distributor, (b)(4), to recommend removal of this product lot from the U.S. market because it contained excessive benzene impurity levels of more than 20 ppm. During that call and again on March 5, 2025, (b)(4) communicated that it would voluntarily recall the product containing the (b)(4) Benzoyl Peroxide Acne Lotion that FDA tested. However, neither Owen Biosciences, Inc. nor (b)(4) recalled the product before it expired.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to adequately address this matter may lead to regulatory or legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when considering the award of contracts.\nFailure to address violations may be cause for FDA to withhold issuance of Export Certificates. Any violations of CGMP requirements may also be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000132299 and ATTN: Daniel W. Brisker.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Owen Biosciences, Inc.","owen-biosciences-inc-710275-10302025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowen-biosciences-inc-710275-10302025","2026-10-26T08:09:39.713108+00:00","2025-11-25","710275","Drugs Over-the-Counter Drugs","Dr. Donald R. Owen","2026-08-19T13:26:35.546+00:00","320-26-11","2025-10-30",{"id":98,"raw":99,"subject":105,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":110,"fei_number":19,"letter_url":111,"updated_at":112,"action_type":22,"case_status":23,"posted_date":113,"marcs_cms_no":114,"product_type":115,"closeout_date":19,"issuing_office":103,"recipient_name":116,"body_fetched_at":117,"delivery_method":118,"recipient_title":19,"reference_number":19,"action_taken_date":119,"medical_device_id":19,"response_letter_date":19},1450,[100,101,102,103,104,13,13,13],"\u003Ctime datetime=\"2024-05-21T13:20:00Z\">05\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-30T04:00:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fakan-biosciences-inc-654674-04302024\">Akan Biosciences, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division I","CGMP\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","CGMP\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mukesh NMI Kumar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Akan Biosciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>610 Professional Drive, Ste 103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gaithersburg\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20879-3460\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 30, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>24-654674\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kumar,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Akan Biosciences, Inc., located at 610 Professional Drive, Ste 103; Gaithersburg, MD 20879-3460 from September 20-30, 2022. During the inspection, an FDA investigator documented your manufacture of an adipose derived, stromal vascular fraction (SVF) cellular product for allogenic use with the brand name Ayama™ (hereinafter, also referred to as “your product”). The product’s labeling indicates it is sterile. You and your distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have distributed this product to practitioners and medical facilities throughout the United States.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and after the inspection, including information on your website, https:\u002F\u002Fakanbio.com\u002Fayama\u002F, reflect that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or a condition in humans. For example, according to your website at https:\u002F\u002Fakanbio.com\u002Fayama\u002F (last visited April 2024), your product is an injectable product intended to “repair, reconstruct and replace your skin tissue”. Because these intended uses indicate that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, your product is a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. Your product is also a drug under section 201(g)(1)(C) of the FD&amp;C Act because it is intended to affect the structure or any function of the body. Your product is also a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003C\u002Fp>\n\n\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all the criteria in 21 CFR 1271.10(a). Specifically, your product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the adipose tissue related to its utility for reconstruction, repair, or replacement.\u003C\u002Fp>\n\n\u003Cp>In addition, your product fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” Your product is not intended to perform the same basic function or functions of adipose tissue in the recipient as in the donor, such as cushioning and support for other tissues, including the skin and internal organs, storing energy in the form of lipids, and insulating the body, among other functions. Using your product for the repair, reconstruction, and replacement of skin tissue, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because your product does not meet all the criteria in 21 CFR 1271.10(a), and Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, your product is regulated as a drug as defined in section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)(B)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\u003C\u002Fp>\n\n\u003Cp>Be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, an FDA investigator documented significant violations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) from 21 CFR 1271 and issued under the authority of Section 361 of the PHS Act [42 U.S.C. § 264]. Further, FDA investigators documented evidence of significant violations from current good manufacturing practice (CGMP) requirements, including violation of section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR 210 and 211.\u003C\u002Fp>\n\n\u003Cp>The violations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. Additional violations were noted upon further review of the records collected during the inspection. The violations, involving 585 vials of product manufactured between May 2021 and April 2022 from three donors, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>Failure to test a specimen from a donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]\u003C\u002Fstrong>. For example, FDA has identified human immunodeficiency virus, type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) as relevant communicable disease agents [21 CFR 1271.3(r)], and donors of HCT\u002FPs must be tested for such agents to adequately and appropriately reduce the risk of transmission of relevant communicable disease. The donor specimens collected from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> were not tested for the antibody to hepatitis B core antigen (anti-HBc) and HIV-1, HCV, and HBV by the nucleic acid test (NAT) method. Such donors were not tested to adequately and appropriately reduce the risk of transmission of these diseases because NAT testing can detect evidence of infection at a significantly earlier stage than is possible under other tests. These donors were determined eligible on 3\u002F30\u002F2022 and 3\u002F31\u002F2022, respectively.\u003C\u002Fp>\n\n\u003Cp>2. \u003Cstrong>Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery of cells or tissue from the donor or up to seven days before or after recovery [21 CFR 1271.80(b)]\u003C\u002Fstrong>. For example, HCT\u002FPs were recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, however a donor specimen for testing was collected from the donor on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, which is not within the required timeframe for collection of a specimen for testing.\u003C\u002Fp>\n\n\u003Cp>3. \u003Cstrong>Failure to test using appropriate FDA-licensed, approved or cleared donor screening tests, in accordance with the manufacturer’s instructions, to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents or diseases [21 CFR 1271.80(c)]\u003C\u002Fstrong>. For example, the specimens for communicable disease testing, collected from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, were tested for the antibody to human immunodeficiency virus, types 1 and 2 (anti-HIV-1\u002F2), hepatitis B surface antigen (HBsAg), the antibody to hepatitis C virus (anti-HCV), and \u003Cem>Treponema pallidum\u003C\u002Fem> using test kits that were not FDA-licensed, approved, or cleared for donor screening. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 3\u002F30\u002F2022. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 3\u002F31\u002F2022.\u003C\u002Fp>\n\n\u003Cp>4. \u003Cstrong>Failure to screen a donor of cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)(1)]\u003C\u002Fstrong>. For example:\u003Cbr>\na) Your Form, DS-01-02 (Version 1.0) \"Donor Screening Questionnaire,” is used as a relevant medical record to determine donor eligibility and was used to screen donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. However, the form does not address certain risk factors for relevant communicable disease agents and diseases, including, for example, a donor’s risk of having West Nile Virus (WNV), among other risk factors.\u003C\u002Fp>\n\n\u003Cp>The following provides examples of conditions and behaviors that increase a donor’s relevant communicable disease risk. You should determine to be ineligible any potential donor who exhibits one or more of the following conditions or behaviors:\u003C\u002Fp>\n\n\u003Cp>i. Men who have had sex with another man in the preceding 5 years.\u003Cbr>\nii. Persons who have engaged in sex in exchange for money or drugs in the preceding 5 years. Your questionnaire only asks whether the donor has had “sexual contact with a prostitute or anyone else who takes money or drug or other payment for sex” in the past 12 months.\u003Cbr>\niii. Persons who have been in juvenile detention, lock up, jail or prison for more than 72 consecutive hours in the preceding 12 months.\u003Cbr>\niv. Persons who have had a past diagnosis of clinical, symptomatic viral hepatitis after their 11th birthday.\u003Cbr>\nv. Persons who have had a medical diagnosis or suspicion of WNV infection.\u003Cbr>\nvi. Persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\u003Cbr>\nvii. Persons who have been treated for or had syphilis within the preceding 12 months.\u003Cbr>\nviii. Persons who are at increased risk for Creutzfeldt-Jakob Disease (CJD) due to receiving a non-synthetic dura mater transplant, human pituitary-derived growth hormone, or having one or more blood relatives diagnosed with CJD.\u003Cbr>\nix. Persons with a medical diagnosis of Zika Virus (ZIKV) in the past 6 months.\u003Cbr>\nx. Persons who have engaged in sex within the past 6 months with a person who has residence in, or travel to, an area with an increased risk for ZIKV transmission.\u003Cbr>\nxi. Persons who have had a diagnosis with dementia or any degenerative or demyelinating disease of the central nervous system or other neurological disease of unknown etiology.\u003Cbr>\nxii. Persons who have had intimate contact with a xenotransplantation product recipient.\u003C\u002Fp>\n\n\u003Cp>b) A review of records for donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> found that the donor did not complete a “Donor Screening Questionnaire” and was not screened for almost all risks of relevant communicable disease agents or diseases. From 4\u002F2022 to 7\u002F2022, you distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;vials of Ayama™ that had been manufactured from 5\u002F27\u002F2021 to 4\u002F4\u002F2022 from adipose tissue recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>5. \u003Cstrong>Failure to clearly identify an HCT\u002FP that is in quarantine pending completion of a donor-eligibility determination and failure to ship HCT\u002FPs with the required accompanying records for which the donor eligibility determination has not been completed [21 CFR 1271.60(b) and (c)]\u003C\u002Fstrong>. For example, your firm distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;vials&nbsp;of Ayama™ to \u003Cstrong>(b)(4)\u003C\u002Fstrong> physician\u002Fclinic locations in \u003Cstrong>(b)(4)\u003C\u002Fstrong> shipments between 4\u002F6\u002F2022 and 7\u002F5\u002F2022. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials were part of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials of Ayama™ manufactured from 5\u002F27-28\u002F2021 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> batches, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials total) from adipose tissue recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. Donor screening and donor testing had not been completed for donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>; therefore, a donor-eligibility determination had not been documented. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of Ayama were not clearly identified as quarantined and were not accompanied by records stating that the product must not be implanted, transplanted, infused, or transferred until completion of donor eligibility determination.\u003C\u002Fp>\n\n\u003Cp>6. \u003Cstrong>Failure to ship in quarantine a pre-distribution shipment of HCT\u002FPs between establishments for which the pre-established criteria designed to prevent communicable disease transmission have not been documented as being met [21 CFR 1271.265(b)]\u003C\u002Fstrong>. For example, your firm delivered \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of Ayama™ (part of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials manufactured between 3\u002F31\u002F2022 and 4\u002F4\u002F2022 from adipose tissue recovered from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>) to your distributor on 5\u002F11\u002F2022 that were not shipped in quarantine to prevent improper release. The products had not been determined to be available for distribution, as described in 21 CFR 1271.265(c), as there was no documentation that the pre-established criteria designed to prevent communicable disease transmission had been met.\u003C\u002Fp>\n\n\u003Cp>7. \u003Cstrong>Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]\u003C\u002Fstrong>. For example, your firm has not validated the manufacturing process for the adipose tissue product, Ayama™, with respect to identity, strength, quality and purity.\u003C\u002Fp>\n\n\u003Cp>8. \u003Cstrong>Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]\u003C\u002Fstrong>. For example,\u003Cbr>\na) You have not performed environmental monitoring of the aseptic processing area in association with each production run. You process batches on \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. However, SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Version 3, Effective date: August 8, 2020) indicates that “\u003Cstrong>(b)(4)\u003C\u002Fstrong> plates” sampling (i.e., contact plates and settle plates) for evaluation of viable microbial contamination of the biosafety cabinet will be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Infrequent monitoring during production of the subject drug product may preclude identification of potential microbial contaminants that could adulterate your product.\u003C\u002Fp>\n\n\u003Cp>b) Your incubation conditions of \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates used as contact plates and settle plates for environmental monitoring is not appropriate for the detection of viable microbial contamination. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Version 3, Effective date: August 8, 2020) indicates that settle and contact plates should be incubated at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours. Incubation at \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature for \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours may exclude detection of certain microbial contaminants.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter dated 10\u002F25\u002F2022, which provides a response and corrective actions to FDA’s inspectional observations (FDA-483). We have reviewed the corrective actions outlined in the response. We also acknowledge your voluntary product recall of Ayama™, initiated on 09\u002F29\u002F2022, as well as your commitment to correct firm operations and\u002For procedures involving donor eligibility (including donor screening\u002Ftesting); product quarantine; equipment calibration\u002Finspection; and labeling controls. However, we have determined that the response is inadequate to address our concerns regarding the above-noted violations as indicated below.\u003C\u002Fp>\n\n\u003Cp>21 CFR 211.100(a) requires written procedures for the production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Process validation studies determine whether \u003Cstrong>(b)(4)\u003C\u002Fstrong> state of control has been established while routine monitoring of process performance attributes determines whether control is maintained. Establishment of appropriate attributes and validation of processing method(s) of your sterile, allogeneic\u002Fnon-autologous, non-family related, HCT\u002FP product, Ayama,™ to be completed, approved, and documented prior to implementation of manufacturing operations, is essential for assuring product quality over the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>According to your voluntary product recall documentation, you initiated a voluntary recall based upon available information regarding your product (i.e., associated deficiencies in donor screening processes affecting three batches sourced from two donors), although you “believe that no specific concerns existed for the safety of the product”. Your response to the FDA-483 states that you believe “the corrective and preventive actions taken by [you] adequately address the inspectional observations.” Regarding your responses to observations 4 and 5 (shipping under quarantine) and observation 7 (procedures appropriate to meet core CGTP requirements), we acknowledge that you have updated your donor eligibility determination criteria and procedures. These updated documents will be reviewed and verified during the next inspection of your establishment. However, your response does not provide sufficient information as well as corrective\u002Fpreventative actions such as:\u003C\u002Fp>\n\n\u003Cp>a) Your response lacks detail about remaining product on hand outside the recalled product and its disposition. Please identify all finished product produced, on-hand, and shipped as well as your intended disposition of this product.\u003C\u002Fp>\n\n\u003Cp>b) Your revised process validation report for Ayama lacks significant documentation to assure that the product has the identity, strength, purity, and quality it purports or is represented to possess. For example, it lacks donor eligibility information as well as full, proper validation (with approved protocol[s]) and approval of your processing methods (including test method suitability) for your sterile, HCT\u002FP product - Ayama™ in order to ensure your processing method:\u003Cbr>\n• reduces the risk of transmission of communicable disease by an HCT\u002FP (i.e., sterility); and\u003Cbr>\n• does not cause contamination or cross-contamination during processing; and prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of violations that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations. This letter notifies you of our findings and provides you an opportunity to address them. You should take prompt action to correct any violations and prevent their recurrence. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent via email to: Jason D. Abel, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 1, email address: orabioinspectionalcorrespondence@fda.hhs.gov (Cc: Jason.Abel@fda.hhs.gov, please include firm name and FEI # within email subject line). If you have any questions, please contact Jason D. Abel via email.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMichael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMukesh NMI Kumar\n\nRecipient Title\n\nPresident\n\nAkan Biosciences, Inc.\n\n610 Professional Drive, Ste 103\n\nGaithersburg, MD 20879-3460\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division I\n\nUnited States\n\nApril 30, 2024\n\nWARNING LETTER\n\n24-654674\n\nDear Mr. Kumar,\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Akan Biosciences, Inc., located at 610 Professional Drive, Ste 103; Gaithersburg, MD 20879-3460 from September 20-30, 2022. During the inspection, an FDA investigator documented your manufacture of an adipose derived, stromal vascular fraction (SVF) cellular product for allogenic use with the brand name Ayama™ (hereinafter, also referred to as “your product”). The product’s labeling indicates it is sterile. You and your distributor, (b)(4), have distributed this product to practitioners and medical facilities throughout the United States.\n\nInformation and records gathered prior to, during, and after the inspection, including information on your website, https:\u002F\u002Fakanbio.com\u002Fayama\u002F, reflect that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or a condition in humans. For example, according to your website at https:\u002F\u002Fakanbio.com\u002Fayama\u002F (last visited April 2024), your product is an injectable product intended to “repair, reconstruct and replace your skin tissue”. Because these intended uses indicate that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, your product is a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. Your product is also a drug under section 201(g)(1)(C) of the FD&C Act because it is intended to affect the structure or any function of the body. Your product is also a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\n\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nAkan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all the criteria in 21 CFR 1271.10(a). Specifically, your product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the adipose tissue related to its utility for reconstruction, repair, or replacement.\n\nIn addition, your product fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” Your product is not intended to perform the same basic function or functions of adipose tissue in the recipient as in the donor, such as cushioning and support for other tissues, including the skin and internal organs, storing energy in the form of lipids, and insulating the body, among other functions. Using your product for the repair, reconstruction, and replacement of skin tissue, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nTherefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because your product does not meet all the criteria in 21 CFR 1271.10(a), and Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, your product is regulated as a drug as defined in section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\n\nBe advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product.\n\nAdditionally, during the inspection, an FDA investigator documented significant violations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) from 21 CFR 1271 and issued under the authority of Section 361 of the PHS Act [42 U.S.C. § 264]. Further, FDA investigators documented evidence of significant violations from current good manufacturing practice (CGMP) requirements, including violation of section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR 210 and 211.\n\nThe violations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. Additional violations were noted upon further review of the records collected during the inspection. The violations, involving 585 vials of product manufactured between May 2021 and April 2022 from three donors, include, but are not limited to, the following:\n\n1. Failure to test a specimen from a donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]. For example, FDA has identified human immunodeficiency virus, type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) as relevant communicable disease agents [21 CFR 1271.3(r)], and donors of HCT\u002FPs must be tested for such agents to adequately and appropriately reduce the risk of transmission of relevant communicable disease. The donor specimens collected from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C) were not tested for the antibody to hepatitis B core antigen (anti-HBc) and HIV-1, HCV, and HBV by the nucleic acid test (NAT) method. Such donors were not tested to adequately and appropriately reduce the risk of transmission of these diseases because NAT testing can detect evidence of infection at a significantly earlier stage than is possible under other tests. These donors were determined eligible on 3\u002F30\u002F2022 and 3\u002F31\u002F2022, respectively.\n\n2. Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery of cells or tissue from the donor or up to seven days before or after recovery [21 CFR 1271.80(b)]. For example, HCT\u002FPs were recovered from donor (b)(6), (b)(7)(C) on (b)(6), (b)(7)(C), however a donor specimen for testing was collected from the donor on (b)(6), (b)(7)(C), which is not within the required timeframe for collection of a specimen for testing.\n\n3. Failure to test using appropriate FDA-licensed, approved or cleared donor screening tests, in accordance with the manufacturer’s instructions, to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents or diseases [21 CFR 1271.80(c)]. For example, the specimens for communicable disease testing, collected from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C), were tested for the antibody to human immunodeficiency virus, types 1 and 2 (anti-HIV-1\u002F2), hepatitis B surface antigen (HBsAg), the antibody to hepatitis C virus (anti-HCV), and Treponema pallidum using test kits that were not FDA-licensed, approved, or cleared for donor screening. Donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F30\u002F2022. Donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F31\u002F2022.\n\n4. Failure to screen a donor of cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)(1)]. For example:\n\na) Your Form, DS-01-02 (Version 1.0) \"Donor Screening Questionnaire,” is used as a relevant medical record to determine donor eligibility and was used to screen donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C). However, the form does not address certain risk factors for relevant communicable disease agents and diseases, including, for example, a donor’s risk of having West Nile Virus (WNV), among other risk factors.\n\nThe following provides examples of conditions and behaviors that increase a donor’s relevant communicable disease risk. You should determine to be ineligible any potential donor who exhibits one or more of the following conditions or behaviors:\n\ni. Men who have had sex with another man in the preceding 5 years.\n\nii. Persons who have engaged in sex in exchange for money or drugs in the preceding 5 years. Your questionnaire only asks whether the donor has had “sexual contact with a prostitute or anyone else who takes money or drug or other payment for sex” in the past 12 months.\n\niii. Persons who have been in juvenile detention, lock up, jail or prison for more than 72 consecutive hours in the preceding 12 months.\n\niv. Persons who have had a past diagnosis of clinical, symptomatic viral hepatitis after their 11th birthday.\n\nv. Persons who have had a medical diagnosis or suspicion of WNV infection.\n\nvi. Persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\n\nvii. Persons who have been treated for or had syphilis within the preceding 12 months.\n\nviii. Persons who are at increased risk for Creutzfeldt-Jakob Disease (CJD) due to receiving a non-synthetic dura mater transplant, human pituitary-derived growth hormone, or having one or more blood relatives diagnosed with CJD.\n\nix. Persons with a medical diagnosis of Zika Virus (ZIKV) in the past 6 months.\n\nx. Persons who have engaged in sex within the past 6 months with a person who has residence in, or travel to, an area with an increased risk for ZIKV transmission.\n\nxi. Persons who have had a diagnosis with dementia or any degenerative or demyelinating disease of the central nervous system or other neurological disease of unknown etiology.\n\nxii. Persons who have had intimate contact with a xenotransplantation product recipient.\n\nb) A review of records for donor (b)(6), (b)(7)(C) found that the donor did not complete a “Donor Screening Questionnaire” and was not screened for almost all risks of relevant communicable disease agents or diseases. From 4\u002F2022 to 7\u002F2022, you distributed (b)(4) vials of Ayama™ that had been manufactured from 5\u002F27\u002F2021 to 4\u002F4\u002F2022 from adipose tissue recovered from donor (b)(6), (b)(7)(C).\n\n5. Failure to clearly identify an HCT\u002FP that is in quarantine pending completion of a donor-eligibility determination and failure to ship HCT\u002FPs with the required accompanying records for which the donor eligibility determination has not been completed [21 CFR 1271.60(b) and (c)]. For example, your firm distributed (b)(4) vials of Ayama™ to (b)(4) physician\u002Fclinic locations in (b)(4) shipments between 4\u002F6\u002F2022 and 7\u002F5\u002F2022. The (b)(4) vials were part of (b)(4) batch vials of Ayama™ manufactured from 5\u002F27-28\u002F2021 ((b)(4) batches, (b)(4) batch vials total) from adipose tissue recovered from donor (b)(6), (b)(7)(C). Donor screening and donor testing had not been completed for donor (b)(6), (b)(7)(C); therefore, a donor-eligibility determination had not been documented. The (b)(4) vials of Ayama were not clearly identified as quarantined and were not accompanied by records stating that the product must not be implanted, transplanted, infused, or transferred until completion of donor eligibility determination.\n\n6. Failure to ship in quarantine a pre-distribution shipment of HCT\u002FPs between establishments for which the pre-established criteria designed to prevent communicable disease transmission have not been documented as being met [21 CFR 1271.265(b)]. For example, your firm delivered (b)(4) vials of Ayama™ (part of (b)(4) batch vials manufactured between 3\u002F31\u002F2022 and 4\u002F4\u002F2022 from adipose tissue recovered from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C)) to your distributor on 5\u002F11\u002F2022 that were not shipped in quarantine to prevent improper release. The products had not been determined to be available for distribution, as described in 21 CFR 1271.265(c), as there was no documentation that the pre-established criteria designed to prevent communicable disease transmission had been met.\n\n7. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, your firm has not validated the manufacturing process for the adipose tissue product, Ayama™, with respect to identity, strength, quality and purity.\n\n8. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]. For example,\n\na) You have not performed environmental monitoring of the aseptic processing area in association with each production run. You process batches on (b)(4) basis. However, SOP (b)(4) (Version 3, Effective date: August 8, 2020) indicates that “(b)(4) plates” sampling (i.e., contact plates and settle plates) for evaluation of viable microbial contamination of the biosafety cabinet will be performed (b)(4). Infrequent monitoring during production of the subject drug product may preclude identification of potential microbial contaminants that could adulterate your product.\n\nb) Your incubation conditions of (b)(4) plates used as contact plates and settle plates for environmental monitoring is not appropriate for the detection of viable microbial contamination. SOP (b)(4) (Version 3, Effective date: August 8, 2020) indicates that settle and contact plates should be incubated at (b)(4) for (b)(4) hours. Incubation at (b)(4) temperature for (b)(4) hours may exclude detection of certain microbial contaminants.\n\nWe acknowledge receipt of your letter dated 10\u002F25\u002F2022, which provides a response and corrective actions to FDA’s inspectional observations (FDA-483). We have reviewed the corrective actions outlined in the response. We also acknowledge your voluntary product recall of Ayama™, initiated on 09\u002F29\u002F2022, as well as your commitment to correct firm operations and\u002For procedures involving donor eligibility (including donor screening\u002Ftesting); product quarantine; equipment calibration\u002Finspection; and labeling controls. However, we have determined that the response is inadequate to address our concerns regarding the above-noted violations as indicated below.\n\n21 CFR 211.100(a) requires written procedures for the production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Process validation studies determine whether (b)(4) state of control has been established while routine monitoring of process performance attributes determines whether control is maintained. Establishment of appropriate attributes and validation of processing method(s) of your sterile, allogeneic\u002Fnon-autologous, non-family related, HCT\u002FP product, Ayama,™ to be completed, approved, and documented prior to implementation of manufacturing operations, is essential for assuring product quality over the product lifecycle.\n\nAccording to your voluntary product recall documentation, you initiated a voluntary recall based upon available information regarding your product (i.e., associated deficiencies in donor screening processes affecting three batches sourced from two donors), although you “believe that no specific concerns existed for the safety of the product”. Your response to the FDA-483 states that you believe “the corrective and preventive actions taken by [you] adequately address the inspectional observations.” Regarding your responses to observations 4 and 5 (shipping under quarantine) and observation 7 (procedures appropriate to meet core CGTP requirements), we acknowledge that you have updated your donor eligibility determination criteria and procedures. These updated documents will be reviewed and verified during the next inspection of your establishment. However, your response does not provide sufficient information as well as corrective\u002Fpreventative actions such as:\n\na) Your response lacks detail about remaining product on hand outside the recalled product and its disposition. Please identify all finished product produced, on-hand, and shipped as well as your intended disposition of this product.\n\nb) Your revised process validation report for Ayama lacks significant documentation to assure that the product has the identity, strength, purity, and quality it purports or is represented to possess. For example, it lacks donor eligibility information as well as full, proper validation (with approved protocol[s]) and approval of your processing methods (including test method suitability) for your sterile, HCT\u002FP product - Ayama™ in order to ensure your processing method:\n\n• reduces the risk of transmission of communicable disease by an HCT\u002FP (i.e., sterility); and\n\n• does not cause contamination or cross-contamination during processing; and prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of violations that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations. This letter notifies you of our findings and provides you an opportunity to address them. You should take prompt action to correct any violations and prevent their recurrence. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent via email to: Jason D. Abel, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 1, email address: orabioinspectionalcorrespondence@fda.hhs.gov (Cc: Jason.Abel@fda.hhs.gov, please include firm name and FEI # within email subject line). If you have any questions, please contact Jason D. Abel via email.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division I","Akan Biosciences, Inc.","akan-biosciences-inc-654674-04302024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fakan-biosciences-inc-654674-04302024","2026-10-26T08:07:51.818264+00:00","2024-05-21","654674","Biologics","Mukesh NMI Kumar","2026-08-20T00:04:21.225+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-04-30",{"id":121,"raw":122,"subject":127,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":133,"fei_number":19,"letter_url":134,"updated_at":135,"action_type":22,"case_status":47,"posted_date":136,"marcs_cms_no":137,"product_type":138,"closeout_date":139,"issuing_office":126,"recipient_name":140,"body_fetched_at":141,"delivery_method":142,"recipient_title":19,"reference_number":19,"action_taken_date":143,"medical_device_id":19,"response_letter_date":19},3560,[123,124,125,126,127,13,128,13],"\u003Ctime datetime=\"2021-02-02T14:20:00Z\">02\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-06T05:00:00Z\">01\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-01062021\">Entia Biosciences, Inc\u003C\u002Fa>","Division of Human and Animal Food Operations West VI","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-04292021\">\u003Ctime datetime=\"2021-05-12T04:00:00Z\">05\u002F12\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Timothy A. Timmins\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Entia Biosciences, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13565 SW Tualatin Sherwood Road, Suite 800\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sherwood\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 6, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 610493\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Timmins:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the US. Food and Drug Administration (FDA) reviewed your website at the Internet address www.totalnutraceutical.com in September 2020 and December 2020, and has determined that you take orders there for the products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement. The claims on these websites establish that these products are drugs under section 201(g)(1)(8) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321 (g)(1 )(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Lion's Mane - All Natural Supplement\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product page at www.totalnutraceutical.com\u002Flions-mane-supplement contains the following claims:\u003C\u002Fp>\n\n\u003Cp>• \"Helps to lower cholesterol\"\u003Cbr>\n• \"Anti-inflammatory\"\u003Cbr>\n• \"It has been linked to having positive implications towards reducing cholesterol levels and inflammation\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Antrodia Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Antrodia Mushroom Powder at www.totalnutraceutical.com\u002Fantrodia, you claim that your product has:\u003C\u002Fp>\n\n\u003Cp>• \"Anti-inflammatory properties,\" and\u003Cbr>\n• \" ... [t]he Antrodia mushroom has long been used as a potent anti-inflammatory for a variety of conditions including liver disease, hypertension ... It is also used to help increase the body's defenses and prevent illness\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Maitake Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product page for Maitake Mushroom Powder at www.totalnutraceutical.com\u002Fmaitake states that the product:\u003C\u002Fp>\n\n\u003Cp>• \"Promotes balanced blood sugar,\" and that the mushroom has been\u003Cbr>\n• \"Found to also have cancer fighting properties\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Reishi Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Reishi Mushroom at www.totalnutraceutical.com\u002Fmushroomsreishi, you state the following:\u003C\u002Fp>\n\n\u003Cp>\"There are many reported health benefits of the Reishi mushroom. Some of these include:\u003C\u002Fp>\n\n\u003Cp>• Relief of viral infections ...\u003Cbr>\n• Prevention of heart disease\u003Cbr>\n• Reduce high blood pressure\u003Cbr>\n• Lower high cholesterol\u003Cbr>\n• Prevention of prostate cancer\u003Cbr>\n• Strong anti-inflammatory properties\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cordyceps Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Cordyceps Mushroom at www.totalnutraceutical.com\u002Fmushrooms-cordyceps, you state the following:\u003C\u002Fp>\n\n\u003Cp>\"There are many reported health benefits of the cordyceps mushroom. Some of these include:\u003C\u002Fp>\n\n\u003Cp>• Cholesterol reduction\u003Cbr>\n• Promotes balanced blood sugar ...\u003Cbr>\n• Faster recovery from bronchitis and respiratory diseases ...\u003Cbr>\n• Anti-tumor ...\u003Cbr>\n• ... enhanced recovery from chemotherapy\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cordyceps - All Natural Mushroom Dietary Supplement\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page at www.totalnutraceutical.com\u002Fcordyceps-supplement, you claim:\u003C\u002Fp>\n\n\u003Cp>• \"Promotes balanced blood sugar\"\u003Cbr>\n• \" ... Cordyceps has long been used to treat a variety of health conditions. Its properties range from promoting lower cholesterol to balancing blood sugar levels.\"\u003C\u002Fp>\n\n\u003Cp>Your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps -All Natural Mushroom Dietary Supplement products are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are \"new drugs\" under section 201 (p) of the Act [21 U.S.C. § 321 (p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301 (d) and 505(a) of the Act [21 U.S.C. §§ 331 (d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003Cbr>\n\u003Cbr>\nYour products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301 (a) of the Act [21 U.S.C. § 331 (a)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen ( 15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be sent to the Food and Drug Administration, Attention: Mark Babbitt, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions, please contact Mark Babbitt at \u003Cspan>509-353-2136\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> ext. 107.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMiriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Mail\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTimothy A. Timmins\n\nRecipient Title\n\nPresident\n\nEntia Biosciences, Inc\n\n13565 SW Tualatin Sherwood Road, Suite 800\n\nSherwood, OR 97140\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West VI\n\nUnited States\n\nJanuary 6, 2021\n\nIn reply, refer to CMS 610493\n\nWARNING LETTER\n\nDear Mr. Timmins:\n\nThis is to advise you that the US. Food and Drug Administration (FDA) reviewed your website at the Internet address www.totalnutraceutical.com in September 2020 and December 2020, and has determined that you take orders there for the products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement. The claims on these websites establish that these products are drugs under section 201(g)(1)(8) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321 (g)(1 )(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nLion's Mane - All Natural Supplement\n\nYour product page at www.totalnutraceutical.com\u002Flions-mane-supplement contains the following claims:\n\n• \"Helps to lower cholesterol\"\n\n• \"Anti-inflammatory\"\n\n• \"It has been linked to having positive implications towards reducing cholesterol levels and inflammation\"\n\nAntrodia Mushroom Powder\n\nOn your product page for Antrodia Mushroom Powder at www.totalnutraceutical.com\u002Fantrodia, you claim that your product has:\n\n• \"Anti-inflammatory properties,\" and\n\n• \" ... [t]he Antrodia mushroom has long been used as a potent anti-inflammatory for a variety of conditions including liver disease, hypertension ... It is also used to help increase the body's defenses and prevent illness\"\n\nMaitake Mushroom Powder\n\nYour product page for Maitake Mushroom Powder at www.totalnutraceutical.com\u002Fmaitake states that the product:\n\n• \"Promotes balanced blood sugar,\" and that the mushroom has been\n\n• \"Found to also have cancer fighting properties\"\n\nReishi Mushroom Powder\n\nOn your product page for Reishi Mushroom at www.totalnutraceutical.com\u002Fmushroomsreishi, you state the following:\n\n\"There are many reported health benefits of the Reishi mushroom. Some of these include:\n\n• Relief of viral infections ...\n\n• Prevention of heart disease\n\n• Reduce high blood pressure\n\n• Lower high cholesterol\n\n• Prevention of prostate cancer\n\n• Strong anti-inflammatory properties\"\n\nCordyceps Mushroom Powder\n\nOn your product page for Cordyceps Mushroom at www.totalnutraceutical.com\u002Fmushrooms-cordyceps, you state the following:\n\n\"There are many reported health benefits of the cordyceps mushroom. Some of these include:\n\n• Cholesterol reduction\n\n• Promotes balanced blood sugar ...\n\n• Faster recovery from bronchitis and respiratory diseases ...\n\n• Anti-tumor ...\n\n• ... enhanced recovery from chemotherapy\"\n\nCordyceps - All Natural Mushroom Dietary Supplement\n\nOn your product page at www.totalnutraceutical.com\u002Fcordyceps-supplement, you claim:\n\n• \"Promotes balanced blood sugar\"\n\n• \" ... Cordyceps has long been used to treat a variety of health conditions. Its properties range from promoting lower cholesterol to balancing blood sugar levels.\"\n\nYour Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps -All Natural Mushroom Dietary Supplement products are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are \"new drugs\" under section 201 (p) of the Act [21 U.S.C. § 321 (p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301 (d) and 505(a) of the Act [21 U.S.C. §§ 331 (d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301 (a) of the Act [21 U.S.C. § 331 (a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and\u002For injunction.\n\nWithin fifteen ( 15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour written reply should be sent to the Food and Drug Administration, Attention: Mark Babbitt, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions, please contact Mark Babbitt at 509-353-2136 ext. 107.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director","Entia Biosciences, Inc","entia-biosciences-inc-610493-01062021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-01062021","2026-10-26T08:08:35.712624+00:00","2021-02-02","610493","Dietary SupplementsFood & Beverages","2021-05-12","Timothy A. Timmins","2026-08-20T03:25:06.576+00:00","Overnight Mail","2021-01-06",{"id":145,"raw":146,"subject":151,"body_html":152,"body_text":153,"firm_name":154,"letter_id":155,"created_at":68,"fei_number":19,"letter_url":156,"updated_at":157,"action_type":22,"case_status":23,"posted_date":158,"marcs_cms_no":159,"product_type":50,"closeout_date":19,"issuing_office":150,"recipient_name":160,"body_fetched_at":161,"delivery_method":162,"recipient_title":19,"reference_number":19,"action_taken_date":163,"medical_device_id":19,"response_letter_date":19},22,[147,148,149,150,151,13,13,13],"\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-05T04:00:00Z\">06\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmineral-biosciences-llc-724745-06052026\">Mineral BioSciences, LLC \u003C\u002Fa>","Human Foods Program","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Luke C. Blotsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mineral BioSciences, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4050 S Sarival Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Goodyear\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85338-3233\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 5, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #724745\u003C\u002Fp>\u003Cp>Dear Mr. Blotsky:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4050 S Sarival Ave, Goodyear, AZ, on November 12-24, 2025. Based on inspectional findings and subsequent review of your websites https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F, and your Facebook and Instagram social media pages at https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F and https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on November 24, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated December 18, 2025, April 13, 2026, April 30, 2026, and May 1, 2026, and we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA reviewed your websites at the Internet addresses https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F in May 2026 and determined that you take orders on the website https:\u002F\u002Fprotectcells.com\u002F for your products Totala Fulvic Ionic Mineral Complex and Ionicell. We also reviewed your social media pages on Facebook (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F) and Instagram (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F) in March 2026, where you direct consumers to your website, https:\u002F\u002Fprotectcells.com\u002F, to purchase your products. Claims on your social media webpages establish that your Totala Fulvic Ionic Mineral Complex and Ionicell products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\u003Cp>Examples of some of the claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex AND Ionicell\u003C\u002Fu>\u003Cbr>“Did you know Higher A1C levels are linked to diabetes complications? But did you also know that case reports have shown that Ioniplex can help control post-prandial blood sugar levels?” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated February 24, 2022)\u003C\u002Fli>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex AND Ionicell\u003C\u002Fu>\u003Cbr>“Ioniplex has been clinically shown to repair and stimulate the body at the cellular level, leading to better glucose management.” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated January 29, 2021)\u003C\u002Fli>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex\u003C\u002Fu>\u003Cbr>“[H]as been taking Totala … and has noticed not only a drop in his blood pressure, but less pain in his joints…” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 23, 2018)\u003C\u002Fli>\u003Cli>\u003Cu>Ionicell\u003C\u002Fu>\u003Cbr>“[H]as been taking IoniCell for several weeks and has already noticed a drop in her daily glucose levels and fasting glucose levels.” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 6, 2018)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your products Totala Fulvic Ionic Mineral Complex and Ionicell are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Totala Fulvic Ionic Mineral Complex and Ionicell fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility on November 12-24, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell products are also adulterated dietary supplements under section 402(g)(1) of the Act.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to meet sanitation requirements that apply to your physical plant and grounds under 21 CFR 111.15. Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>You failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). For example, from November 12-13, 2025, our investigator observed insulation hanging from the ceiling, one light casing which appeared to be taped with water leaking from it, two holes in your wall exposing outside elements, and multiple doors, including bay doors, with opening gaps allowing light to shine into your facility.\u003C\u002Fli>\u003Cli>You failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). For example, on November 13, 2025, our investigator reviewed your pest control records for April 2025 through November 2025 and observed several occasions in which a pest control technician documented interior stations with apparent rodent activity, including inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room, \u003Cstrong>(b)(4)\u003C\u002Fstrong> room where finished products are stored, and in the ambient warehouse. In addition, our investigator observed multiple exit doors propped open to the outside.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During the inspection, you stated that you would create a risk assessment based on your assessment of these observations and that you were already in the process of making certain changes, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will evaluate the adequacy of your corrective actions during our next inspection.\u003C\u002Fp>\u003Cp>2. Your quality control personnel failed to approve or reject all processes, specifications, written procedures, controls, tests, and examinations, and deviations from or modifications to them, that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>Your component specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong> had not been signed and approved by your quality control personnel.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that your raw material specifications will be signed, reviewed, and approved by quality control personnel. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your quality control personnel have approved your raw material specifications.\u003C\u002Fp>\u003Cp>3. Your written batch production records (BPRs) did not include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b), because they did not include all information required to be in a BPR under 21 CFR 111.260. Specifically, your firm’s BPRs for the dietary supplement products Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell did not include the following required information:\u003C\u002Fp>\u003Cul>\u003Cli>The time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained. [21 CFR 111.260(c)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for weighing or measuring each component used in the batch. [21 CFR 111.260(j)(2)(i)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for verifying the weight or measure of each component used in the batch. [21 CFR 111.260(j)(2)(ii)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for adding the component to the batch. [21 CFR 111.260(j)(2)(iii)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for verifying the addition of components to the batch. [21 CFR 111.260(j)(2)(iv)].\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that the batch production records will be updated. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your batch production records have been updated.\u003C\u002Fp>\u003Cp>4. Your firm failed to qualify certain suppliers by establishing the reliability of the suppliers’ certificates of analyses through confirmation of the results of the suppliers’ tests or examinations, in accordance with 21 CFR 111.75(a)(2)(ii)(A). Specifically, your firm relies on certificates of analyses to determine that component specifications for identity, purity, strength, composition, and limits on contamination are met, and you did not conduct testing on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary ingredients to establish the reliability of the suppliers’ certificates of analyses before use.\u003C\u002Fp>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated, “suppliers will be qualified establishing the reliability of the supplier’s certification of analysis through confirmation of the results of their tests or examinations.” On May 1, 2026, you provided component specification sheets that include instructions to confirm suppliers’ certificates of analyses with testing; however, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that the relevant suppliers have been qualified.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>We also have the following comment:\u003C\u002Fp>\u003Cp>21 CFR 111.75(a)(2) does not allow firms to rely on a certificate of analysis to confirm the identity of a dietary ingredient. Rather, under 21 CFR 111.75(a)(1)(i), you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, prior to using a component (or submit an exemption petition under 21 CFR 111.75(a)(2)(ii)). However, your component specification sheets submitted on May 1, 2026, for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary ingredients state that component identity testing will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> instead of every time the component is used.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #724745 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Luke C. Blotsky\n\nRecipient Title\n\nCEO\n\nMineral BioSciences, LLC\n\n4050 S Sarival Ave\n\nGoodyear, AZ 85338-3233\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJune 5, 2026\nWARNING LETTER\nCMS #724745\nDear Mr. Blotsky:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4050 S Sarival Ave, Goodyear, AZ, on November 12-24, 2025. Based on inspectional findings and subsequent review of your websites https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F, and your Facebook and Instagram social media pages at https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F and https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on November 24, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated December 18, 2025, April 13, 2026, April 30, 2026, and May 1, 2026, and we address your responses below.\nUnapproved New Drugs\nFDA reviewed your websites at the Internet addresses https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F in May 2026 and determined that you take orders on the website https:\u002F\u002Fprotectcells.com\u002F for your products Totala Fulvic Ionic Mineral Complex and Ionicell. We also reviewed your social media pages on Facebook (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F) and Instagram (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F) in March 2026, where you direct consumers to your website, https:\u002F\u002Fprotectcells.com\u002F, to purchase your products. Claims on your social media webpages establish that your Totala Fulvic Ionic Mineral Complex and Ionicell products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\nExamples of some of the claims that provide evidence that your products are intended for use as drugs include:\nTotala Fulvic Ionic Mineral Complex AND Ionicell\n“Did you know Higher A1C levels are linked to diabetes complications? But did you also know that case reports have shown that Ioniplex can help control post-prandial blood sugar levels?” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated February 24, 2022)\nTotala Fulvic Ionic Mineral Complex AND Ionicell\n“Ioniplex has been clinically shown to repair and stimulate the body at the cellular level, leading to better glucose management.” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated January 29, 2021)\nTotala Fulvic Ionic Mineral Complex\n“[H]as been taking Totala … and has noticed not only a drop in his blood pressure, but less pain in his joints…” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 23, 2018)\nIonicell\n“[H]as been taking IoniCell for several weeks and has already noticed a drop in her daily glucose levels and fasting glucose levels.” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 6, 2018)\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nMisbranded Drugs\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour products Totala Fulvic Ionic Mineral Complex and Ionicell are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Totala Fulvic Ionic Mineral Complex and Ionicell fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\nAdulterated Dietary Supplements\nThe inspection of your facility on November 12-24, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell products are also adulterated dietary supplements under section 402(g)(1) of the Act.\nYour significant violations of the CGMP requirements are as follows:\n1. You failed to meet sanitation requirements that apply to your physical plant and grounds under 21 CFR 111.15. Specifically:\nYou failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). For example, from November 12-13, 2025, our investigator observed insulation hanging from the ceiling, one light casing which appeared to be taped with water leaking from it, two holes in your wall exposing outside elements, and multiple doors, including bay doors, with opening gaps allowing light to shine into your facility.\nYou failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). For example, on November 13, 2025, our investigator reviewed your pest control records for April 2025 through November 2025 and observed several occasions in which a pest control technician documented interior stations with apparent rodent activity, including inside the (b)(4) room, (b)(4) room where finished products are stored, and in the ambient warehouse. In addition, our investigator observed multiple exit doors propped open to the outside.\nDuring the inspection, you stated that you would create a risk assessment based on your assessment of these observations and that you were already in the process of making certain changes, such as (b)(4). We will evaluate the adequacy of your corrective actions during our next inspection.\n2. Your quality control personnel failed to approve or reject all processes, specifications, written procedures, controls, tests, and examinations, and deviations from or modifications to them, that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically:\nYour component specifications for (b)(4) had not been signed and approved by your quality control personnel.\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that your raw material specifications will be signed, reviewed, and approved by quality control personnel. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your quality control personnel have approved your raw material specifications.\n3. Your written batch production records (BPRs) did not include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b), because they did not include all information required to be in a BPR under 21 CFR 111.260. Specifically, your firm’s BPRs for the dietary supplement products Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell did not include the following required information:\nThe time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained. [21 CFR 111.260(c)]\nThe initials of the person responsible for weighing or measuring each component used in the batch. [21 CFR 111.260(j)(2)(i)]\nThe initials of the person responsible for verifying the weight or measure of each component used in the batch. [21 CFR 111.260(j)(2)(ii)]\nThe initials of the person responsible for adding the component to the batch. [21 CFR 111.260(j)(2)(iii)]\nThe initials of the person responsible for verifying the addition of components to the batch. [21 CFR 111.260(j)(2)(iv)].\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that the batch production records will be updated. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your batch production records have been updated.\n4. Your firm failed to qualify certain suppliers by establishing the reliability of the suppliers’ certificates of analyses through confirmation of the results of the suppliers’ tests or examinations, in accordance with 21 CFR 111.75(a)(2)(ii)(A). Specifically, your firm relies on certificates of analyses to determine that component specifications for identity, purity, strength, composition, and limits on contamination are met, and you did not conduct testing on your (b)(4) dietary ingredients to establish the reliability of the suppliers’ certificates of analyses before use.\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated, “suppliers will be qualified establishing the reliability of the supplier’s certification of analysis through confirmation of the results of their tests or examinations.” On May 1, 2026, you provided component specification sheets that include instructions to confirm suppliers’ certificates of analyses with testing; however, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that the relevant suppliers have been qualified.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nWe also have the following comment:\n21 CFR 111.75(a)(2) does not allow firms to rely on a certificate of analysis to confirm the identity of a dietary ingredient. Rather, under 21 CFR 111.75(a)(1)(i), you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, prior to using a component (or submit an exemption petition under 21 CFR 111.75(a)(2)(ii)). However, your component specification sheets submitted on May 1, 2026, for your (b)(4) dietary ingredients state that component identity testing will be conducted (b)(4) instead of every time the component is used.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #724745 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nDirector, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Mineral BioSciences, LLC","mineral-biosciences-llc-724745-06052026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmineral-biosciences-llc-724745-06052026","2026-10-26T08:09:26.032125+00:00","2026-07-21","724745","Mr. Luke C. Blotsky","2026-08-19T04:29:08.005+00:00","Via Email","2026-06-05",{"id":165,"raw":166,"subject":170,"body_html":171,"body_text":172,"firm_name":173,"letter_id":174,"created_at":175,"fei_number":19,"letter_url":176,"updated_at":177,"action_type":22,"case_status":23,"posted_date":178,"marcs_cms_no":179,"product_type":50,"closeout_date":19,"issuing_office":37,"recipient_name":180,"body_fetched_at":181,"delivery_method":182,"recipient_title":19,"reference_number":183,"action_taken_date":184,"medical_device_id":19,"response_letter_date":19},3164,[167,168,169,37,170,13,13,13],"\u003Ctime datetime=\"2021-09-07T13:20:00Z\">09\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-26T04:00:00Z\">08\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkaleido-biosciences-inc-616026-08262021\">Kaleido Biosciences, Inc.\u003C\u002Fa>","Bioresearch Monitoring Program","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>21-HFD-45-08-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daniel Menichella\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kaleido Biosciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>65 Hayden Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lexington\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>02421-7994\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ref: 21-HFD-45-08-01\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Menichella:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted from February 24 to March 3, 2021. Investigator Kent A. Conforti, representing FDA, reviewed the role of Kaleido Biosciences, Inc. (Kaleido) as the sponsor of the following clinical investigations of the investigational drug KB109:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol K031-120: “A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients with Mild-to-Moderate COVID-19”\u003C\u002Fli>\n\t\u003Cli>Protocol K032-120: “An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients with Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Conforti presented and discussed with your staff the Form FDA 483, Inspectional Observations. We acknowledge our receipt of Kaleido’s March 23, 2021, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and Kaleido’s March 23, 2021, written response to the Form FDA 483, it appears that Kaleido did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to submit INDs for the conduct of clinical investigations with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA regulations require a sponsor to submit, and to have in effect, an investigational new drug application (IND) before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2 (see 21 CFR 312.20 and 312.40(a)). Kaleido failed to comply with these requirements. Specifically, Kaleido initiated and conducted the following clinical investigations of investigational drug products subject to section 505 of the FD&amp;C Act without submitting and having in effect an IND\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The clinical investigation of the investigational drug KB109 conducted under Protocol K031-120\u003C\u002Fli>\n\t\u003Cli>The clinical investigation of the investigational drug KB109 conducted under Protocol K032-120\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In Kaleido’s March 23, 2021, written response to the Form FDA 483, Kaleido argued that it was not obligated to submit an IND before initiating these clinical investigations because the article under study, KB109, was a food rather than a drug. Specifically, Kaleido argued that the investigations were conducted “to evaluate the effect of KB109 on the microbiome[,] as well as to determine the safety and tolerability of KB109 in the diseased population[,]” that is, human subjects with mild to moderate COVID-19, and thus it investigated KB109 for use as a food rather than a drug.\u003C\u002Fp>\n\n\u003Cp>To support this argument, Kaleido asserted that it did not intend for these “food studies” to evaluate whether KB109 would be an effective treatment or mitigation for COVID-19; rather, Kaleido argued that the secondary endpoints in these studies were determinative of safety and tolerability. For this reason, Kaleido stated that KB109 was a food intervention, and consistent with Agency guidance, it was appropriate to conduct these studies without an IND in a population with COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In further discussing the purported safety and tolerability endpoints of these two studies, Kaleido stated that because the medical community was still learning about risk factors for severe COVID-19, signs and symptoms of the disease were collected in both studies to support adequate safety monitoring, in order to capture signals of disease worsening that may warrant referral to emergency medical care. Kaleido argued that it collected information on symptoms related to worsening or improvement of disease conditions to determine if KB109 would have an impact on safety or tolerability in patients with COVID-19.\u003C\u002Fp>\n\n\u003Cp>Kaleido stated that the FD&amp;C Act specifically recognizes products used in the dietary management of a disease and subject to regulation as medical foods (when such products meet the definition of a medical food, comply with the requirements for medical foods, and are not subject to regulation as drugs). Although Kaleido did not explicitly argue that the clinical investigations were exempt from the IND requirement because they studied KB109 for use as a medical food, it did state that the findings from these studies could “enhance our understanding of the distinct nutritional requirements (DNR) that may exist in individuals with respiratory viral illnesses such as COVID-19 and would support the positioning of KB109 as a medical food.”\u003C\u002Fp>\n\n\u003Cp>In further arguing that its clinical investigations studied KB109’s use as a food, Kaleido stated that the Generally Recognized as Safe (GRAS) status of KB109 was determined by an outside firm that evaluated not only the composition of KB109, but also its consumption safety in patients with mild to moderate COVID-19. Kaleido asserted that this GRAS determination supported its conclusion that KB109 is a lawfully marketed food ingredient that could be evaluated in food studies such as Protocols K031-120 and K032-120.\u003C\u002Fp>\n\n\u003Cp>Finally, Kaleido stated that subjects were instructed to follow the Centers for Disease Control and Prevention (CDC) guidelines and supportive self-care (SSC) measures to manage COVID-19 symptoms, and argued that KB109 therefore was given for nutritional purposes and was not studied as a COVID-19 treatment.\u003C\u002Fp>\n\n\u003Cp>For the reasons described below, we conclude that the evidence collected during the inspection shows that KB109 was intended for use as a drug, not as a food, in the two clinical investigations named above.\u003C\u002Fp>\n\n\u003Cp>Section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)] defines \u003Cem>drug\u003C\u002Fem> as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals . . . .” Kaleido studied the efficacy and safety of KB109 to mitigate and treat COVID-19 in subjects who tested positive for COVID-19 as described below:\u003C\u002Fp>\n\n\u003Cp>As shown by the protocol, a published article supported by Kaleido, and Kaleido’s press releases, the objective of Protocol K031-120 was to compare the safety and efficacy of KB109 in combination with SSC under quarantine protocols set forth by the CDC, with SSC alone in human subjects with mild-to-moderate COVID-19. This study evaluated efficacy endpoints intended to assess KB109 for use in mitigating or treating COVID-19, including change from baseline in, and time to resolution of, overall composite and individual COVID-19-related symptom scores; time to resolution of fever; proportion of subjects with oxygen saturation &lt;95% and &lt;98%; and other endpoints, such as change from baseline in bedrest time, individual measures of quality of life (QOL), proportion of subjects with improvements in patient global impression on COVID-19 condition, proportion of subjects experiencing hospital admissions (all-cause and COVID-19-related), and number of healthcare utilizations.\u003C\u002Fp>\n\n\u003Cp>As shown by the protocol and a published article supported by Kaleido, the objective of Protocol K032-120 was to compare KB109, in combination with SSC under quarantine protocols set forth by the CDC or local ordinances and practices as advised by a healthcare provider, against SSC alone in human subjects with mild-to-moderate COVID-19. Physiologic effects were assessed by measuring biomarkers of inflammation and antibodies, physiologic responses of health in subjects, QOL, and hospital utilization. This study also assessed the effects of KB109 on the gut microbiome structure and function, and evaluated endpoints related to measures of health, as well as changes in laboratory measures, specific biomarkers, serology, and viral load in the presence and absence of KB109.\u003C\u002Fp>\n\n\u003Cp>For Protocol K031-120, the endpoints characterized in the protocol as secondary endpoints (for example, time to resolution of individual and composite COVID-19 symptoms, time to resolution of fever, and proportion of subjects hospitalized) clearly assessed the impact of KB109 on clinical manifestations of COVID-19 and were aligned with the recommended efficacy endpoints in published FDA guidances to aid sponsors in developing products to treat patients with COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4, 5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>For Protocol K032-120, while some endpoints could be considered safety outcomes that might be evaluated only to ensure that treatment with KB109 was not worsening the course of COVID-19, other endpoints (for example, proportion of subjects experiencing hospital admission during the follow-up period, measures of healthcare utilization, and proportion of subjects with oxygen saturation below normal) clearly assessed the use of KB109 in combination with SCC for the treatment or mitigation of COVID-19.\u003C\u002Fp>\n\n\u003Cp>We note that Kaleido itself described the purpose of KB109 in the clinical investigations conducted under Protocols K031-120 and K032-120 as “treatment of mild to moderate COVID-19” in a communication to FDA.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>To the extent that Kaleido intended to argue that KB109 was used as a medical food in these clinical investigations, this argument fails for the following reasons:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A product is a medical food if it is “a food . . . intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> No such distinctive nutritional requirements have been established for COVID-19. Dietary management of a disease is one way to treat or mitigate that disease; therefore, to the extent that a product that does not meet the medical food definition is intended for the dietary management of a disease, it is a drug under section 201(g)(1)(B) of the FD&amp;C Act.\u003C\u002Fli>\n\t\u003Cli>Even if there were distinctive nutritional requirements established for COVID-19, Protocols K031-120 and K032-120 went beyond “dietary management” of COVID-19 to evaluate KB109’s ability to treat COVID-19 by measuring the investigational product’s effects on fever, oxygen saturation, viral load, and other biomarkers of COVID-19 infection, among other things.\u003C\u002Fli>\n\t\u003Cli>Finally, the purported GRAS status of an article for one or more uses in food does not exempt the article from IND requirements when it is studied for use as a drug. In other words, an article may be a drug as used in a clinical trial, even if it is considered a food as used in other contexts. In addition, the instruction for subjects to adhere to CDC guidelines and SSC measures does not preclude investigating KB109 as an add-on therapy in the management of COVID-19 for subjects who are not at high risk for disease worsening or hospitalization.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>As Kaleido noted in its response to the Form FDA 483, whether an investigational article is a drug or a food depends on the intent of the investigation. Based on the study designs of Protocols K031-120 and K032-120, KB109 as used in these clinical investigations was a drug, per 201(g)(1) of the FD&amp;C Act, because KB109 was studied for use in the mitigation and treatment of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Thus, before initiating the clinical investigations of KB109 conducted under Protocol K031- 120 and Protocol K032-120, Kaleido was required to submit an IND to FDA and to have an IND in effect under 21 CFR 312.40. FDA’s records indicate that Kaleido failed to submit an IND before conducting these clinical investigations, in which 350 human subjects were randomized at 16 clinical sites for Protocol K031-120, and 49 human subjects were randomized at 7 clinical sites for Protocol K032-120.\u003C\u002Fp>\n\n\u003Cp>In its response to the Form FDA 483, Kaleido stated that it is developing a procedure for determining the need for an IND (in consultation with FDA) when developing protocols for clinical studies in a disease population where endpoints may be viewed as diagnosing, mitigating, treating, preventing, or curing a disease. Kaleido’s corrective action plan does not provide sufficient details about its new procedure for IND determination. Without these details, we are unable to determine whether Kaleido’s corrective action plan is adequate to prevent similar violations in the future.\u003Cbr>\n\u003Cbr>\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical studies of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please call Miah Jung, Pharm.D., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S., RAC (US)\u003Cbr>\nBranch Chief (Acting)\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5219\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Coronavirus Disease 2019 (COVID-19) is the respiratory disease caused by the novel coronavirus called \u003Cem>Severe Acute Respiratory Syndrome Coronavirus 2\u003C\u002Fem> (SARS-CoV-2).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Also, neither of these clinical investigations qualified for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>Guidance for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND, September 2013\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Guidance for industry \u003Cem>COVID-19: Developing Drugs and Biological Products for Treatment or Prevention\u003C\u002Fem> (May 2020; updated February 2021).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Guidance for industry \u003Cem>Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment \u003C\u002Fem>(September 2020).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Pre-IND 151218 Type B Meeting Package for KB109, Kaleido Biosciences, Inc. (July 2, 2020).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> 21 U.S.C. 360ee(b)(3).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\n21-HFD-45-08-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDaniel Menichella\n\nRecipient Title\n\nChief Executive Officer\n\nKaleido Biosciences, Inc.\n\n65 Hayden Avenue\n\nLexington, MA 02421-7994\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRef: 21-HFD-45-08-01\n\nDear Mr. Menichella:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted from February 24 to March 3, 2021. Investigator Kent A. Conforti, representing FDA, reviewed the role of Kaleido Biosciences, Inc. (Kaleido) as the sponsor of the following clinical investigations of the investigational drug KB109:\n\nProtocol K031-120: “A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-191 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients with Mild-to-Moderate COVID-19”\n\nProtocol K032-120: “An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients with Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting”\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Conforti presented and discussed with your staff the Form FDA 483, Inspectional Observations. We acknowledge our receipt of Kaleido’s March 23, 2021, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and Kaleido’s March 23, 2021, written response to the Form FDA 483, it appears that Kaleido did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\n\nFailure to submit INDs for the conduct of clinical investigations with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\n\nFDA regulations require a sponsor to submit, and to have in effect, an investigational new drug application (IND) before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2 (see 21 CFR 312.20 and 312.40(a)). Kaleido failed to comply with these requirements. Specifically, Kaleido initiated and conducted the following clinical investigations of investigational drug products subject to section 505 of the FD&C Act without submitting and having in effect an IND2:\n\nThe clinical investigation of the investigational drug KB109 conducted under Protocol K031-120\n\nThe clinical investigation of the investigational drug KB109 conducted under Protocol K032-120\n\nIn Kaleido’s March 23, 2021, written response to the Form FDA 483, Kaleido argued that it was not obligated to submit an IND before initiating these clinical investigations because the article under study, KB109, was a food rather than a drug. Specifically, Kaleido argued that the investigations were conducted “to evaluate the effect of KB109 on the microbiome[,] as well as to determine the safety and tolerability of KB109 in the diseased population[,]” that is, human subjects with mild to moderate COVID-19, and thus it investigated KB109 for use as a food rather than a drug.\n\nTo support this argument, Kaleido asserted that it did not intend for these “food studies” to evaluate whether KB109 would be an effective treatment or mitigation for COVID-19; rather, Kaleido argued that the secondary endpoints in these studies were determinative of safety and tolerability. For this reason, Kaleido stated that KB109 was a food intervention, and consistent with Agency guidance, it was appropriate to conduct these studies without an IND in a population with COVID-19.3\n\nIn further discussing the purported safety and tolerability endpoints of these two studies, Kaleido stated that because the medical community was still learning about risk factors for severe COVID-19, signs and symptoms of the disease were collected in both studies to support adequate safety monitoring, in order to capture signals of disease worsening that may warrant referral to emergency medical care. Kaleido argued that it collected information on symptoms related to worsening or improvement of disease conditions to determine if KB109 would have an impact on safety or tolerability in patients with COVID-19.\n\nKaleido stated that the FD&C Act specifically recognizes products used in the dietary management of a disease and subject to regulation as medical foods (when such products meet the definition of a medical food, comply with the requirements for medical foods, and are not subject to regulation as drugs). Although Kaleido did not explicitly argue that the clinical investigations were exempt from the IND requirement because they studied KB109 for use as a medical food, it did state that the findings from these studies could “enhance our understanding of the distinct nutritional requirements (DNR) that may exist in individuals with respiratory viral illnesses such as COVID-19 and would support the positioning of KB109 as a medical food.”\n\nIn further arguing that its clinical investigations studied KB109’s use as a food, Kaleido stated that the Generally Recognized as Safe (GRAS) status of KB109 was determined by an outside firm that evaluated not only the composition of KB109, but also its consumption safety in patients with mild to moderate COVID-19. Kaleido asserted that this GRAS determination supported its conclusion that KB109 is a lawfully marketed food ingredient that could be evaluated in food studies such as Protocols K031-120 and K032-120.\n\nFinally, Kaleido stated that subjects were instructed to follow the Centers for Disease Control and Prevention (CDC) guidelines and supportive self-care (SSC) measures to manage COVID-19 symptoms, and argued that KB109 therefore was given for nutritional purposes and was not studied as a COVID-19 treatment.\n\nFor the reasons described below, we conclude that the evidence collected during the inspection shows that KB109 was intended for use as a drug, not as a food, in the two clinical investigations named above.\n\nSection 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)] defines drug as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals . . . .” Kaleido studied the efficacy and safety of KB109 to mitigate and treat COVID-19 in subjects who tested positive for COVID-19 as described below:\n\nAs shown by the protocol, a published article supported by Kaleido, and Kaleido’s press releases, the objective of Protocol K031-120 was to compare the safety and efficacy of KB109 in combination with SSC under quarantine protocols set forth by the CDC, with SSC alone in human subjects with mild-to-moderate COVID-19. This study evaluated efficacy endpoints intended to assess KB109 for use in mitigating or treating COVID-19, including change from baseline in, and time to resolution of, overall composite and individual COVID-19-related symptom scores; time to resolution of fever; proportion of subjects with oxygen saturation \u003C95% and \u003C98%; and other endpoints, such as change from baseline in bedrest time, individual measures of quality of life (QOL), proportion of subjects with improvements in patient global impression on COVID-19 condition, proportion of subjects experiencing hospital admissions (all-cause and COVID-19-related), and number of healthcare utilizations.\n\nAs shown by the protocol and a published article supported by Kaleido, the objective of Protocol K032-120 was to compare KB109, in combination with SSC under quarantine protocols set forth by the CDC or local ordinances and practices as advised by a healthcare provider, against SSC alone in human subjects with mild-to-moderate COVID-19. Physiologic effects were assessed by measuring biomarkers of inflammation and antibodies, physiologic responses of health in subjects, QOL, and hospital utilization. This study also assessed the effects of KB109 on the gut microbiome structure and function, and evaluated endpoints related to measures of health, as well as changes in laboratory measures, specific biomarkers, serology, and viral load in the presence and absence of KB109.\n\nFor Protocol K031-120, the endpoints characterized in the protocol as secondary endpoints (for example, time to resolution of individual and composite COVID-19 symptoms, time to resolution of fever, and proportion of subjects hospitalized) clearly assessed the impact of KB109 on clinical manifestations of COVID-19 and were aligned with the recommended efficacy endpoints in published FDA guidances to aid sponsors in developing products to treat patients with COVID-19.4, 5\n\nFor Protocol K032-120, while some endpoints could be considered safety outcomes that might be evaluated only to ensure that treatment with KB109 was not worsening the course of COVID-19, other endpoints (for example, proportion of subjects experiencing hospital admission during the follow-up period, measures of healthcare utilization, and proportion of subjects with oxygen saturation below normal) clearly assessed the use of KB109 in combination with SCC for the treatment or mitigation of COVID-19.\n\nWe note that Kaleido itself described the purpose of KB109 in the clinical investigations conducted under Protocols K031-120 and K032-120 as “treatment of mild to moderate COVID-19” in a communication to FDA.6\n\nTo the extent that Kaleido intended to argue that KB109 was used as a medical food in these clinical investigations, this argument fails for the following reasons:\n\nA product is a medical food if it is “a food . . . intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”7 No such distinctive nutritional requirements have been established for COVID-19. Dietary management of a disease is one way to treat or mitigate that disease; therefore, to the extent that a product that does not meet the medical food definition is intended for the dietary management of a disease, it is a drug under section 201(g)(1)(B) of the FD&C Act.\n\nEven if there were distinctive nutritional requirements established for COVID-19, Protocols K031-120 and K032-120 went beyond “dietary management” of COVID-19 to evaluate KB109’s ability to treat COVID-19 by measuring the investigational product’s effects on fever, oxygen saturation, viral load, and other biomarkers of COVID-19 infection, among other things.\n\nFinally, the purported GRAS status of an article for one or more uses in food does not exempt the article from IND requirements when it is studied for use as a drug. In other words, an article may be a drug as used in a clinical trial, even if it is considered a food as used in other contexts. In addition, the instruction for subjects to adhere to CDC guidelines and SSC measures does not preclude investigating KB109 as an add-on therapy in the management of COVID-19 for subjects who are not at high risk for disease worsening or hospitalization.\n\nAs Kaleido noted in its response to the Form FDA 483, whether an investigational article is a drug or a food depends on the intent of the investigation. Based on the study designs of Protocols K031-120 and K032-120, KB109 as used in these clinical investigations was a drug, per 201(g)(1) of the FD&C Act, because KB109 was studied for use in the mitigation and treatment of COVID-19.\n\nThus, before initiating the clinical investigations of KB109 conducted under Protocol K031- 120 and Protocol K032-120, Kaleido was required to submit an IND to FDA and to have an IND in effect under 21 CFR 312.40. FDA’s records indicate that Kaleido failed to submit an IND before conducting these clinical investigations, in which 350 human subjects were randomized at 16 clinical sites for Protocol K031-120, and 49 human subjects were randomized at 7 clinical sites for Protocol K032-120.\n\nIn its response to the Form FDA 483, Kaleido stated that it is developing a procedure for determining the need for an IND (in consultation with FDA) when developing protocols for clinical studies in a disease population where endpoints may be viewed as diagnosing, mitigating, treating, preventing, or curing a disease. Kaleido’s corrective action plan does not provide sufficient details about its new procedure for IND determination. Without these details, we are unable to determine whether Kaleido’s corrective action plan is adequate to prevent similar violations in the future.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical studies of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nWithin 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant FDA regulations, please include your reasoning and any supporting information for our consideration.\n\nIf you have any questions, please call Miah Jung, Pharm.D., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S., RAC (US)\n\nBranch Chief (Acting)\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5219\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n\u002FS\u002F\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n_________________\n\n1 Coronavirus Disease 2019 (COVID-19) is the respiratory disease caused by the novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\n\n2 Also, neither of these clinical investigations qualified for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312.\n\n3 Guidance for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND, September 2013.\n\n4 Guidance for industry COVID-19: Developing Drugs and Biological Products for Treatment or Prevention (May 2020; updated February 2021).\n\n5 Guidance for industry Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment (September 2020).\n\n6 Pre-IND 151218 Type B Meeting Package for KB109, Kaleido Biosciences, Inc. (July 2, 2020).\n\n7 21 U.S.C. 360ee(b)(3).","Kaleido Biosciences, Inc.","kaleido-biosciences-inc-616026-08262021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkaleido-biosciences-inc-616026-08262021","2026-10-26T08:09:07.576596+00:00","2021-09-07","616026","Daniel Menichella","2026-08-20T02:37:45.127+00:00","VIA UPS and Electronic Mail","21-HFD-45-08-01","2021-08-26",{"id":186,"raw":187,"subject":191,"body_html":192,"body_text":193,"firm_name":194,"letter_id":195,"created_at":196,"fei_number":19,"letter_url":197,"updated_at":198,"action_type":22,"case_status":23,"posted_date":199,"marcs_cms_no":200,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":201,"body_fetched_at":202,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":203,"medical_device_id":19,"response_letter_date":19},2952,[188,189,190,11,191,13,13,13],"\u003Ctime datetime=\"2021-12-21T14:20:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-01T05:00:00Z\">12\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdermacare-biosciences-ltd-617910-12012021\">DermaCare Biosciences, LTD.\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rich Butler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DermaCare Biosciences, LTD.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 W. Atlantic Avenue Suite #05\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Delray Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33444\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rich@dermacarepkg.com\"> rich@dermacarepkg.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: December 1, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your websites at the Internet addresses https:\u002F\u002Fwww.easyrapidnow.com\u002F and https:\u002F\u002Fwww.dermacarepkg.com\u002F, on February 2, 2021, on September 20, 2021, and on October 22, 2021. We also reviewed your social media websites at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacare-packaging-private-label\u002F, https:\u002F\u002Fwww.facebook.com\u002Fdermacarepkg\u002F, and https:\u002F\u002FInstagram.com\u002Feasyrapidcovidtestkits where you direct consumers to your website, https:\u002F\u002Fwww.easyrapidnow.com, to purchase your products. The FDA has observed that your website offers for sale the Easy Rapid Now COVID-19 Nasal Swab Antigen Test (Colloidal Gold) (hereinafter referred to as “COVID-19 Test”) in the United States. Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The COVID-19 Test is offered for sale and distributed to consumers in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Your website, https:\u002F\u002Fwww.easyrapidnow.com\u002F, as well as social media websites, include statements that indicate that your firm’s COVID-19 Test is intended for screening or diagnosis\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of COVID-19, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Mass Surveillance. Protect Classrooms, Workplaces, and Other Populations.” [https:\u002F\u002Feasyrapidnow.com\u002F]\u003C\u002Fli>\n\t\u003Cli>“I was part of a surveillance screening at work. I was feeling symptoms and I took the EasyRapidNow™ test. It showed “positive”. I went for a PCR test and sure enough, it confirmed I had COVID. These really work!” [https:\u002F\u002Feasyrapidnow.com\u002Ftestimonials]\u003C\u002Fli>\n\t\u003Cli>“Routine Coronavirus surveillance gives you an early warning of infection, allowing targeted measures to be taken to stop the spread.” [https:\u002F\u002Feasyrapidnow.com\u002F]\u003C\u002Fli>\n\t\u003Cli>“These EasyRapidNow™ tests will be super easy for you to perform and I have firsthand experience. My wife came home Monday evening with a cough and not feeling well. In 15 minutes, we confirmed that she was positive, and we were able to take the appropriate precautions. She works in a doctor’s office and was able to get a PCR test the next day, which confirmed that she was positive. My son and I tested negative and have no symptoms so far. Two days later my son and I tested again, and I was positive, he was negative. We are grateful to have the early warning. This type of early warning will assist you in keeping your workplace and employees safer resulting in fewer business interruptions.” [https:\u002F\u002Feasyrapidnow.com\u002Ftestimonials]\u003C\u002Fli>\n\t\u003Cli>“Rapid detection of SARS-CoV-2 nucleocapsid antigen in less than 15 minute [sic]” [https:\u002F\u002Feasyrapidnow.com\u002Fwp-content\u002Fuploads\u002FEasyRapidNow-Brochure_Ja25_U.S.pdf]\u003C\u002Fli>\n\t\u003Cli>COVID-19 Nasal Swab Tests Available Now! Test results in as little as 5 minutes! Simple Easy Fast Affordable! Scan QR Code to buy now!” [https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacare-packaging-private-label\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s websites include a disclaimer that your tests “enable[] surveillance screening at a population level” are “not intended for diagnostic use or home use.”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, these disclaimers are inconsistent with the statements identified above on your firm’s websites that indicate these tests are intended to be used to identify individuals infected with COVID-19 so that individual decisions can be made based on the test results (e.g., quarantine or confirmatory testing). Furthermore, FDA has observed that your business offers for sale the COVID-19 Test directly to consumers in the United States. Based on the statements identified on your website above and your sale of these tests directly to consumers, the FDA has determined that your test is intended for diagnosis of COVID-19 including screening for COVID-19 in asymptomatic individuals without known exposure with the intent of making individual decisions based on the test results (e.g., who may return or what protective measures to take on an individual basis).\u003C\u002Fp>\n\n\u003Cp>We also note that your social media LinkedIn site, https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacarepackaging-private-label\u002F, displays a large FDA logo at the top right of the page alongside information about your COVID-19 test and other products. The FDA logo is for the official use of the FDA and not for use on private sector materials.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such use may send a misleading message that the FDA favors or endorses your products. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised) \u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>” provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send emails&nbsp;\u003C\u002Fstrong>\u003Cstrong>to\u003C\u002Fstrong> \u003Cstrong>COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and\u003Cbr>\n&nbsp; &nbsp; Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>______________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Screening for COVID-19 is looking for occurrence at the individual level even if there is no individual reason to suspect infection such as a known exposure. Examples of screening include testing plans developed by a workplace to test all employees returning to the workplace regardless of exposure or signs and systems and testing plans developed by a school to test all students and faculty returning to the school regardless of exposure or signs and symptoms, with the intent of using the results to determine who may return or what protective measures to take on an individual basis. Diagnostic testing for COVID-19 is also looking for occurrence at the individual level but is performed when there is a particular reason to suspect that an individual may be infected. Examples of diagnostic testing include testing symptomatic individuals presenting to their healthcare provider, testing individuals who indicate that they were exposed to an individual with a confirmed or suspected case of COVID-19, and testing all individuals present at an event where an attendee was later confirmed to have COVID-19. \u003Cem>See\u003C\u002Fem> COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2, \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Surveillance testing is primarily used to gain information at a population level, rather than an individual level. Surveillance testing may be a random sampling of a certain percentage of a specific population to monitor for increasing or decreasing prevalence and determining the population effect from community interventions such as social distancing. An example of surveillance testing is a testing plan developed by a State Public Health Department to randomly select and sample 1% of all individuals in a city on a rolling basis to determine local infection rates and trends. \u003Cem>See\u003C\u002Fem> COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2, \u003Cem>available at\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRich Butler\n\nRecipient Title\n\nManaging Director\n\nDermaCare Biosciences, LTD.\n\n301 W. Atlantic Avenue Suite #05\n\nDelray Beach, FL 33444\n\nUnited States\n\nrich@dermacarepkg.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: December 1, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your websites at the Internet addresses https:\u002F\u002Fwww.easyrapidnow.com\u002F and https:\u002F\u002Fwww.dermacarepkg.com\u002F, on February 2, 2021, on September 20, 2021, and on October 22, 2021. We also reviewed your social media websites at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacare-packaging-private-label\u002F, https:\u002F\u002Fwww.facebook.com\u002Fdermacarepkg\u002F, and https:\u002F\u002FInstagram.com\u002Feasyrapidcovidtestkits where you direct consumers to your website, https:\u002F\u002Fwww.easyrapidnow.com, to purchase your products. The FDA has observed that your website offers for sale the Easy Rapid Now COVID-19 Nasal Swab Antigen Test (Colloidal Gold) (hereinafter referred to as “COVID-19 Test”) in the United States. Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe COVID-19 Test is offered for sale and distributed to consumers in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nYour website, https:\u002F\u002Fwww.easyrapidnow.com\u002F, as well as social media websites, include statements that indicate that your firm’s COVID-19 Test is intended for screening or diagnosis4 of COVID-19, including:\n\n“Mass Surveillance. Protect Classrooms, Workplaces, and Other Populations.” [https:\u002F\u002Feasyrapidnow.com\u002F]\n\n“I was part of a surveillance screening at work. I was feeling symptoms and I took the EasyRapidNow™ test. It showed “positive”. I went for a PCR test and sure enough, it confirmed I had COVID. These really work!” [https:\u002F\u002Feasyrapidnow.com\u002Ftestimonials]\n\n“Routine Coronavirus surveillance gives you an early warning of infection, allowing targeted measures to be taken to stop the spread.” [https:\u002F\u002Feasyrapidnow.com\u002F]\n\n“These EasyRapidNow™ tests will be super easy for you to perform and I have firsthand experience. My wife came home Monday evening with a cough and not feeling well. In 15 minutes, we confirmed that she was positive, and we were able to take the appropriate precautions. She works in a doctor’s office and was able to get a PCR test the next day, which confirmed that she was positive. My son and I tested negative and have no symptoms so far. Two days later my son and I tested again, and I was positive, he was negative. We are grateful to have the early warning. This type of early warning will assist you in keeping your workplace and employees safer resulting in fewer business interruptions.” [https:\u002F\u002Feasyrapidnow.com\u002Ftestimonials]\n\n“Rapid detection of SARS-CoV-2 nucleocapsid antigen in less than 15 minute [sic]” [https:\u002F\u002Feasyrapidnow.com\u002Fwp-content\u002Fuploads\u002FEasyRapidNow-Brochure_Ja25_U.S.pdf]\n\nCOVID-19 Nasal Swab Tests Available Now! Test results in as little as 5 minutes! Simple Easy Fast Affordable! Scan QR Code to buy now!” [https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacare-packaging-private-label\u002F]\n\nYour firm’s websites include a disclaimer that your tests “enable[] surveillance screening at a population level” are “not intended for diagnostic use or home use.”5 However, these disclaimers are inconsistent with the statements identified above on your firm’s websites that indicate these tests are intended to be used to identify individuals infected with COVID-19 so that individual decisions can be made based on the test results (e.g., quarantine or confirmatory testing). Furthermore, FDA has observed that your business offers for sale the COVID-19 Test directly to consumers in the United States. Based on the statements identified on your website above and your sale of these tests directly to consumers, the FDA has determined that your test is intended for diagnosis of COVID-19 including screening for COVID-19 in asymptomatic individuals without known exposure with the intent of making individual decisions based on the test results (e.g., who may return or what protective measures to take on an individual basis).\n\nWe also note that your social media LinkedIn site, https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacarepackaging-private-label\u002F, displays a large FDA logo at the top right of the page alongside information about your COVID-19 test and other products. The FDA logo is for the official use of the FDA and not for use on private sector materials.6 Such use may send a misleading message that the FDA favors or endorses your products. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised) 7” provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send emails to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure, and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and\n\nRadiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n______________________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 Screening for COVID-19 is looking for occurrence at the individual level even if there is no individual reason to suspect infection such as a known exposure. Examples of screening include testing plans developed by a workplace to test all employees returning to the workplace regardless of exposure or signs and systems and testing plans developed by a school to test all students and faculty returning to the school regardless of exposure or signs and symptoms, with the intent of using the results to determine who may return or what protective measures to take on an individual basis. Diagnostic testing for COVID-19 is also looking for occurrence at the individual level but is performed when there is a particular reason to suspect that an individual may be infected. Examples of diagnostic testing include testing symptomatic individuals presenting to their healthcare provider, testing individuals who indicate that they were exposed to an individual with a confirmed or suspected case of COVID-19, and testing all individuals present at an event where an attendee was later confirmed to have COVID-19. See COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2, available at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2.\n\n5 Surveillance testing is primarily used to gain information at a population level, rather than an individual level. Surveillance testing may be a random sampling of a certain percentage of a specific population to monitor for increasing or decreasing prevalence and determining the population effect from community interventions such as social distancing. An example of surveillance testing is a testing plan developed by a State Public Health Department to randomly select and sample 1% of all individuals in a city on a rolling basis to determine local infection rates and trends. See COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2, available at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2.\n\n6 FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\n\n7 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","DermaCare Biosciences, LTD.","dermacare-biosciences-ltd-617910-12012021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdermacare-biosciences-ltd-617910-12012021","2026-10-26T08:08:23.165889+00:00","2021-12-21","617910","Rich Butler","2026-08-20T02:18:28.987+00:00","2021-12-01",{"id":205,"raw":206,"subject":38,"body_html":211,"body_text":212,"firm_name":213,"letter_id":214,"created_at":175,"fei_number":19,"letter_url":215,"updated_at":216,"action_type":22,"case_status":23,"posted_date":217,"marcs_cms_no":218,"product_type":50,"closeout_date":19,"issuing_office":210,"recipient_name":219,"body_fetched_at":220,"delivery_method":221,"recipient_title":19,"reference_number":19,"action_taken_date":222,"medical_device_id":19,"response_letter_date":19},3457,[207,208,209,210,38,13,13,13],"\u003Ctime datetime=\"2021-03-16T13:20:00Z\">03\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-10T05:00:00Z\">03\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffoshan-biours-biosciences-co-ltd-611319-03102021\">Foshan Biours Biosciences Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Paul Huang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Foshan Biours Biosciences Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13 East Xile Road, Tower B F1 Complex Bldg.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rooms 201, 202, 203 (2nd Floor) &amp; 302 (3rd Floor)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Foshan Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>528137\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-34\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 10, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Huang:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our April 3, 2020 request, and subsequent requests, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Foshan Biours Biosciences Co., Ltd., FEI 3011474550, at 13 East Xile Road, Tower B F1 Complex Bldg., Rooms 201, 202, 203 (2nd Floor) &amp; 302 (3rd Floor), Foshan, Guangdong.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See 21 CFR, parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures an over-the-counter (OTC) drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Patch containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response to our request for records and other information under section 704(a)(4) indicates that you distributed this drug product into the United States without adequate finished drug product testing.\u003C\u002Fp>\n\n\u003Cp>For example, in response to our request to provide release specifications of U.S. products and the test method used to evaluate them, you submitted a certificate of analysis for your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch that shows you did not conduct adequate testing for identity and strength of the active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as is required prior to release per 211.165(a). No other information provided was responsive to our request for information about release testing. Your response indicates that you do not perform assay testing for identity and strength of your active ingredient.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that your drug product batches conform to appropriate specifications prior to release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States:\u003C\u002Fp>\n\n\u003Cp>• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003Cbr>\n&nbsp; &nbsp;o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the U.S. that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp;o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003Cbr>\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the information you provided in response to our request for cleaning procedures for cleaning equipment for U.S. product lines, you have not conducted cleaning validation studies. For example, in response to our records request you indicated that there was no validated cleaning procedure for the equipment used in the manufacture and packaging of your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch. Additionally, you stated that the equipment used in the manufacture and packaging of your OTC&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch is not dedicated to that drug product.\u003C\u002Fp>\n\n\u003Cp>Without cleaning validation studies you cannot demonstrate that your cleaning procedures for non-dedicated production equipment are adequate to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States:\u003C\u002Fp>\n\n\u003Cp>• Steps your firm has taken to develop an adequate cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; o drugs with higher toxicities\u003Cbr>\n&nbsp; o drugs with higher drug potencies\u003Cbr>\n&nbsp; o drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; o drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; o swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; o maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In response to our request for a list all batches in stability and a list of all stability studies, you did not provide adequate stability data to demonstrate that the chemical properties of your drug products remain acceptable throughout the labeled expiry period. For example, your stability data for OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch does not include testing for the active ingredient. Therefore, the data does not demonstrate that the drug’s active ingredient is stable throughout its shelf life.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and corrective and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>\n&nbsp; o Stability indicating methods, including both analytical and microbiological test methods\u003Cbr>\n&nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; o detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>• All procedures that describe these and other elements of your remediated stability program,\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug product. You are responsible for investigating and determining the causes of any these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed the drug product manufactured by your firm on Import Alert 66-40 on October 22, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of this violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>Until all violations are addressed completely and we confirm your compliance with CGMP, they may be cause for FDA to withhold approval of any new drug applications or supplements listing your firm as a drug manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any deviations and violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011474550 and ATTN: CDR Frank Verni.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC (via email &amp; UPS):\u003Cbr>\nDavid Lennarz, U.S. Agent\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, Virginia 23666\u003Cbr>\ndrugs@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Paul Huang\n\nRecipient Title\n\nGeneral Manager\u002FCEO\n\nFoshan Biours Biosciences Co., Ltd.\n\n13 East Xile Road, Tower B F1 Complex Bldg.\n\nRooms 201, 202, 203 (2nd Floor) & 302 (3rd Floor)\n\nFoshan Shi\n\nGuangdong Sheng, 528137\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWarning Letter 320-21-34\n\nMarch 10, 2021\n\nDear Mr. Huang:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our April 3, 2020 request, and subsequent requests, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Foshan Biours Biosciences Co., Ltd., FEI 3011474550, at 13 East Xile Road, Tower B F1 Complex Bldg., Rooms 201, 202, 203 (2nd Floor) & 302 (3rd Floor), Foshan, Guangdong.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See 21 CFR, parts 210 and 211.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm manufactures an over-the-counter (OTC) drug product, (b)(4) Patch containing (b)(4). Your response to our request for records and other information under section 704(a)(4) indicates that you distributed this drug product into the United States without adequate finished drug product testing.\n\nFor example, in response to our request to provide release specifications of U.S. products and the test method used to evaluate them, you submitted a certificate of analysis for your OTC (b)(4) Patch that shows you did not conduct adequate testing for identity and strength of the active ingredient, (b)(4), as is required prior to release per 211.165(a). No other information provided was responsive to our request for information about release testing. Your response indicates that you do not perform assay testing for identity and strength of your active ingredient.\n\nWithout adequate testing, you do not have scientific evidence that your drug product batches conform to appropriate specifications prior to release.\n\nIn response to this letter, provide the following for all drug products imported to the United States:\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the U.S. that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nBased on the information you provided in response to our request for cleaning procedures for cleaning equipment for U.S. product lines, you have not conducted cleaning validation studies. For example, in response to our records request you indicated that there was no validated cleaning procedure for the equipment used in the manufacture and packaging of your OTC (b)(4) Patch. Additionally, you stated that the equipment used in the manufacture and packaging of your OTC (b)(4) Patch is not dedicated to that drug product.\n\nWithout cleaning validation studies you cannot demonstrate that your cleaning procedures for non-dedicated production equipment are adequate to prevent cross-contamination.\n\nIn response to this letter, provide the following for all drug products imported to the United States:\n\n• Steps your firm has taken to develop an adequate cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nIn response to our request for a list all batches in stability and a list of all stability studies, you did not provide adequate stability data to demonstrate that the chemical properties of your drug products remain acceptable throughout the labeled expiry period. For example, your stability data for OTC (b)(4) Patch does not include testing for the active ingredient. Therefore, the data does not demonstrate that the drug’s active ingredient is stable throughout its shelf life.\n\nIn response to this letter, provide the following for all drug products imported to the United States:\n\n• A comprehensive, independent assessment and corrective and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods, including both analytical and microbiological test methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no detailed definition of the specific attributes to be tested at each station (timepoint)\n\n• All procedures that describe these and other elements of your remediated stability program,\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug product. You are responsible for investigating and determining the causes of any these violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed the drug product manufactured by your firm on Import Alert 66-40 on October 22, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of this violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nUntil all violations are addressed completely and we confirm your compliance with CGMP, they may be cause for FDA to withhold approval of any new drug applications or supplements listing your firm as a drug manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any deviations and violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011474550 and ATTN: CDR Frank Verni.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC (via email & UPS):\n\nDavid Lennarz, U.S. Agent\n\n144 Research Drive\n\nHampton, Virginia 23666\n\ndrugs@registrarcorp.com","Foshan Biours Biosciences Co., Ltd.","foshan-biours-biosciences-co-ltd-611319-03102021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffoshan-biours-biosciences-co-ltd-611319-03102021","2026-10-26T08:08:42.810323+00:00","2021-03-16","611319","Mr. Paul Huang","2026-08-20T03:16:25.37+00:00","VIA UPS","2021-03-10",{"id":224,"raw":225,"subject":231,"body_html":232,"body_text":233,"firm_name":234,"letter_id":235,"created_at":44,"fei_number":19,"letter_url":236,"updated_at":237,"action_type":22,"case_status":23,"posted_date":238,"marcs_cms_no":239,"product_type":115,"closeout_date":19,"issuing_office":229,"recipient_name":240,"body_fetched_at":241,"delivery_method":29,"recipient_title":19,"reference_number":242,"action_taken_date":243,"medical_device_id":19,"response_letter_date":19},2429,[226,227,228,229,230,13,13,13],"\u003Ctime datetime=\"2022-09-20T13:20:00Z\">09\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-23T04:00:00Z\">08\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022\">BioLab Sciences, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 621465\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert D. Maguire\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioLab Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13825 N. Northsight Blvd., Suite 101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 23, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Maguire:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\u003C\u002Fp>\n\n\u003Cp>Because Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\u003C\u002Fp>\n\n\u003Cp>Your CGMP deficiencies, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You failed to validate the aseptic processes used to manufacture over&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> units of Fluid Flow™, Amnio Restore™,\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of these products since June 22, 2021.\u003C\u002Fp>\n\n\u003Cp>c. Your Fluid Flow™ \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation, entitled “\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You did not assess the impact of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\u003C\u002Fp>\n\n\u003Cp>d. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel monitoring is required only every \u003Cstrong>(b)(4)\u003C\u002Fstrong> for personnel who process your amniotic fluid products.\u003C\u002Fp>\n\n\u003Cp>e. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\u003C\u002Fp>\n\n\u003Cp>f. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\u003C\u002Fp>\n\n\u003Cp>g. Your written environmental monitoring procedure now describes that \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca>www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your BSCs.\u003Cbr>\n\u003Cbr>\nb. Your firm has not adequately established and followed written procedures for cleaning the \u003Cstrong>(b)(4)\u003C\u002Fstrong> BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used to clean the BSCs during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your cleanrooms.\u003C\u002Fp>\n\n\u003Cp>b. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. In accordance with your cleanroom cleaning procedure, a \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>cleaning of all contact surfaces in the cleanrooms is required at the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> processing operations. However, a review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You failed to ensure sufficient use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified \u003Cem>Bacillus\u003C\u002Fem>, species, a spore-forming organism, on your cleanroom floors. You noted that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iii. Your written procedure for cleanroom cleaning does not include the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)].\u003C\u002Fstrong> For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its&nbsp;\u003C\u002Fstrong>\u003Cstrong>specifications whether or not the batch has been already distributed [21 CFR 211.192].\u003C\u002Fstrong> For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include \u003Cem>Bacillus\u003C\u002Fem> species non-anthracis, \u003Cem>Fictibacillus\u003C\u002Fem> species, \u003Cem>Bacillus pumilus\u003C\u002Fem>, Gram Positive Cocci, fungi, and \u003Cem>Bacillus megaterium\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\u003C\u002Fp>\n\n\u003Cp>b. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\u003C\u002Fp>\n\n\u003Cp>c. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid Flow™, and Amnio Restore™.\u003C\u002Fp>\n\n\u003Cp>Your responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\u003C\u002Fp>\n\n\u003Cp>We note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\u003C\u002Fp>\n\n\u003Cp>Finally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>Cc: Robert D. Maguire\u003Cbr>\nPresident and Chief Executive Officer\u003Cbr>\nBioLab Sciences, Inc.\u003Cbr>\n7662 East Gray Road, Suite 107\u003Cbr>\nScottsdale, AZ 85260\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Some of your products are the same products marketed under different brand names. For example, you represented to FDA that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nReference #:\n\nOBPO 621465\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nRobert D. Maguire\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n13825 N. Northsight Blvd., Suite 101\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nAugust 23, 2022\n\nDear Mr. Maguire:\n\nDuring an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).1,2 You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\n\nMyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\n\nBased on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\n\nMyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\n\nAn HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are (b)(4) prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\n\nBecause Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].3\n\nPlease be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and (b)(4), are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&C Act.\n\nIn order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\n\nYour CGMP deficiencies, involving over (b)(4) units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\n\n1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. You failed to validate the aseptic processes used to manufacture over (b)(4) units of Fluid Flow™, Amnio Restore™,(b)(4), Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\n\nb. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over (b)(4) units of these products since June 22, 2021.\n\nc. Your Fluid Flow™ (b)(4) sterilization validation, entitled “(b)(4) Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\n\ni. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\n\nii. You did not assess the impact of the (b)(4) sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\n\nd. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\n\ni. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\n\nii. Personnel monitoring is required only every (b)(4) for personnel who process your amniotic fluid products.\n\ne. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\n\nf. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\n\ng. Your written environmental monitoring procedure now describes that (b)(4) colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\n\n3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your BSCs.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the (b)(4) BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the (b)(4) when (b)(4) is used to clean the BSCs during (b)(4) cleanings.\n\n4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your cleanrooms.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\n\ni. In accordance with your cleanroom cleaning procedure, a (b)(4) cleaning of all contact surfaces in the cleanrooms is required at the (b)(4) processing operations. However, a review of your (b)(4) cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\n\nii. You failed to ensure sufficient use of (b)(4), a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified Bacillus, species, a spore-forming organism, on your cleanroom floors. You noted that (b)(4) was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\n\niii. Your written procedure for cleanroom cleaning does not include the (b)(4) when (b)(4) is used during (b)(4) cleanings.\n\niv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\n\n5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)]. For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\n\n6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed [21 CFR 211.192]. For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include Bacillus species non-anthracis, Fictibacillus species, Bacillus pumilus, Gram Positive Cocci, fungi, and Bacillus megaterium.\n\n7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84]. For example:\n\na. Your firm used (b)(4) to manufacture approximately (b)(4) batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\n\nb. Your firm used (b)(4), to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\n\nc. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\n\n8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\n\n9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\n\nWe have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\n\nWe acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.4 You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing (b)(4), Stimuleyes™, Fluid Flow™, and Amnio Restore™.\n\nYour responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\n\nWe note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\n\nFinally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Robert D. Maguire\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n7662 East Gray Road, Suite 107\n\nScottsdale, AZ 85260\n\n_________________________\n\n1 This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\n\n2 Some of your products are the same products marketed under different brand names. For example, you represented to FDA that (b)(4) is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\n\n3 As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. (b)(4).\n\n4 We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.","BioLab Sciences, Inc.","biolab-sciences-inc-621465-08232022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022","2026-10-26T08:08:04.986053+00:00","2022-09-20","621465","Robert D. Maguire","2026-08-20T01:33:07.944+00:00","OBPO 621465","2022-08-23",{"id":245,"raw":246,"subject":231,"body_html":251,"body_text":252,"firm_name":253,"letter_id":254,"created_at":110,"fei_number":19,"letter_url":255,"updated_at":256,"action_type":22,"case_status":23,"posted_date":257,"marcs_cms_no":258,"product_type":115,"closeout_date":19,"issuing_office":250,"recipient_name":259,"body_fetched_at":260,"delivery_method":182,"recipient_title":19,"reference_number":261,"action_taken_date":262,"medical_device_id":19,"response_letter_date":19},1073,[247,248,249,250,230,13,13,13],"\u003Ctime datetime=\"2025-02-04T05:00:00Z\">02\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-17T05:00:00Z\">01\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiostem-life-sciences-673788-01172025\">BioStem Life Sciences\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-673788\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason V. Matuszewski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioStem Life Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2836 Center Port Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pompano Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33064\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:quality@biostemtech.com\"> quality@biostemtech.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cbr>January 17, 2025&nbsp;\u003C\u002Fp>\u003Cp>CBER 25-673788\u003C\u002Fp>\u003Cp>Dear Mr. Matuszewski:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between September 11, 2023, and September 15, 2023. During the inspection, FDA documented that your company manufactures cellular products derived from human umbilical cord, including those labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® (collectively, “your products”).&nbsp;\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your adulteration of your products while held for sale after shipment in interstate commerce, or the causing thereof, is a prohibited act under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).&nbsp;\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cp>NEOFYL®\u003Cbr>o &nbsp;“Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins. This array of components helps cushion and support damaged tissue and joints while providing structure and ideal microenvironment conditions for rebuilding.”&nbsp;\u003C\u002Fp>\u003Cp>o &nbsp;“The umbilical cord contains a collagenous matrix that is rich in hyaluronic acid, growth factors, and other cytokines. These elements are reported to have anti-inflammatory, anti-bacterial, and anti-scarring properties, making umbilical cord tissue an attractive biomaterial for use in an outpatient clinic or surgical procedures.”\u003C\u002Fp>\u003C\u002Fli>\u003Cli>OROPRO®\u003Cbr>o &nbsp;“Regenerative medicine harnesses your body’s own ability to heal and boosts it in a very powerful and effective way.”\u003Cbr>o &nbsp;“Umbilical cord and Wharton’s jelly allografts demonstrate anti-inflammatory, anti-bacterial and anti-fibrotic properties that support repair of damaged tissue.”\u003C\u002Fli>\u003Cli>PROVISCUS®\u003Cbr>o &nbsp;“Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins.”\u003C\u002Fli>\u003Cli>RHEO®\u003Cbr>o &nbsp;“RHEO® is a human perinatal tissue allograft derived from the extracellular matrix of the amniotic membrane. It is aseptically processed to preserve the endogenous cytokines, growth factors and scaffolding proteins present within the amniotic tissue matrix… By supplementing damaged tissue with these factors, you can stimulate the same scaffold creation naturally found in the body and allow the tissue to ‘self-heal’.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Biostem Life Sciences does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord (of products OROPRO®, PROVISCUS® and NEOFYL®) and amniotic membrane (of RHEO®) related to their utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form. The processing of the amniotic membrane from the form of a sheet into an injectable form drastically alters the physical state of the HCT\u002FP. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively altering or eliminating its physical integrity, tensile strength, and elasticity.\u003C\u002Fp>\u003Cp>In addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or serving as a barrier for amniotic membrane). Rather, your products are intended for use in treating damaged tissues and joints, which are not basic functions of the umbilical cord and amniotic membrane in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid biologics license application (BLA) must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> For example,\u003C\u002Fp>\u003Cp>a. Your firm has not performed routine (i.e., during every production batch) non-viable particulate monitoring and surface sampling of the critical area (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong> where your products are exposed to the environment). The environmental monitoring frequencies described in SOP QCD-034 titled, “Environmental Controls and Monitoring Procedure” (Effective date: December 12, 2022) are not sufficient to detect potential environmental contamination risks and demonstrate control inside the critical manufacturing area during manufacturing.\u003C\u002Fp>\u003Cp>b. Your firm does not require microbiological monitoring of operators’ arm coverings used in the critical aseptic processing area for manually processing your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example, your firm has failed to validate your procedure for cleaning and disinfecting the ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> and supporting ISO 7 cleanroom where your products are manufactured. Validation of a cleaning process is needed to verify suitable cleaning and disinfecting agents are used to remove potential microbial contaminants from the critical manufacturing areas where your products are exposed during manufacturing.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, your firm has not adequately validated your manufacturing processes for your products with respect to identity, strength, quality, and purity. Your testing is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These are not sufficient measures of identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>Process validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, strength, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> The review of batch records and procedure QAD-040 titled “Product Release” (Effective date: September 5, 2023) indicate final product testing is limited to sterility testing and endotoxin testing as measurements of product attributes and such testing does not demonstrate, for example, the identity and\u002For strength of your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> For example, your firm assigned expiration dates between \u003Cstrong>(b)(4)\u003C\u002Fstrong> months to your products without adequate supporting data that conform to appropriate standards of identity, strength, quality, and purity. For example, your expiration summary reports for RHEO® is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility testing only while Product 401 (OROPRO®) is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility and endotoxin testing. Product 403 (PROVISCUS®) and Product 404 (NEOFYL®) are limited to Hyaluronic Acid concentration only. Appropriate standards of identity, strength, quality, and purity during intervals through the expiry period are needed to ensure product attributes remain for the shelf life of the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responses to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge receipt of your correspondences dated September 29, 2023; October 13, 2023; October 27, 2023; November 10, 2023; November 28, 2023; December 8; 2023; December 22, 2023; January 5, 2024; January 9, 2024; February 29, 2024 and September 3, 2024 that provide a response to FDA’s inspectional observations and describe certain corrective actions. We have reviewed your responses and represented corrective actions and have found that they are inadequate. While you assert that your products were manufactured under section 361 of the PHS Act (and thus are not subject to cGMP regulations), the available evidence shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act. We acknowledge your commitment to submit a Pre-Request for Designation to FDA by February 29, 2024; however, this process remains incomplete, for you have not responded to the agency’s request for additional information. According to your correspondence, RHEO®, OROPRO®, and 403\u002F404 products have been removed from the market and shall no longer be manufactured by your firm. Your responses do not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a \u003Cstrong>(b)(4)\u003C\u002Fstrong>-month shelf life and remain within expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concern\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>We note that the Instructions for Use for each of your products state, “This allograft is processed aseptically, but is not sterile.” If your products are not sterile, FDA has serious safety concerns regarding their use on patients via injection.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> FDA expects injectable products to be sterile, consistent with basic quality standards and to ensure patient safety.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Be advised that, under 21 CFR 211.113(b), appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed, including validation of aseptic and sterilization processes. Please address this issue in your response.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not address whether this product meets other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The preparation instructions in the IFUs for your products state, “Apply the allograft using an 18g or larger needle. If applied topically, utilize aseptic technique and caution.” While intravenous or intrathecal application are contraindicated, injection is not contraindicated.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., USP&lt;1&gt; (“Parenteral articles are prepared scrupulously by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants, and, where appropriate, contain inhibitors of the growth of microorganisms.”).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-673788\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJason V. Matuszewski\n\nRecipient Title\n\nChief Executive Officer\n\nBioStem Life Sciences\n\n2836 Center Port Circle\n\nPompano Beach, FL 33064\n\nUnited States\n\nquality@biostemtech.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nJanuary 17, 2025\nCBER 25-673788\nDear Mr. Matuszewski:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between September 11, 2023, and September 15, 2023. During the inspection, FDA documented that your company manufactures cellular products derived from human umbilical cord, including those labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® (collectively, “your products”).\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your adulteration of your products while held for sale after shipment in interstate commerce, or the causing thereof, is a prohibited act under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nBased on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nNEOFYL®\no “Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins. This array of components helps cushion and support damaged tissue and joints while providing structure and ideal microenvironment conditions for rebuilding.”\no “The umbilical cord contains a collagenous matrix that is rich in hyaluronic acid, growth factors, and other cytokines. These elements are reported to have anti-inflammatory, anti-bacterial, and anti-scarring properties, making umbilical cord tissue an attractive biomaterial for use in an outpatient clinic or surgical procedures.”\n\nOROPRO®\no “Regenerative medicine harnesses your body’s own ability to heal and boosts it in a very powerful and effective way.”\no “Umbilical cord and Wharton’s jelly allografts demonstrate anti-inflammatory, anti-bacterial and anti-fibrotic properties that support repair of damaged tissue.”\nPROVISCUS®\no “Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins.”\nRHEO®\no “RHEO® is a human perinatal tissue allograft derived from the extracellular matrix of the amniotic membrane. It is aseptically processed to preserve the endogenous cytokines, growth factors and scaffolding proteins present within the amniotic tissue matrix… By supplementing damaged tissue with these factors, you can stimulate the same scaffold creation naturally found in the body and allow the tissue to ‘self-heal’.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Biostem Life Sciences does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord (of products OROPRO®, PROVISCUS® and NEOFYL®) and amniotic membrane (of RHEO®) related to their utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form. The processing of the amniotic membrane from the form of a sheet into an injectable form drastically alters the physical state of the HCT\u002FP. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively altering or eliminating its physical integrity, tensile strength, and elasticity.\nIn addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or serving as a barrier for amniotic membrane). Rather, your products are intended for use in treating damaged tissues and joints, which are not basic functions of the umbilical cord and amniotic membrane in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid biologics license application (BLA) must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe CGMP violations applicable to your products include, but are not limited to, the following:\n1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)]. For example,\na. Your firm has not performed routine (i.e., during every production batch) non-viable particulate monitoring and surface sampling of the critical area (i.e., (b)(4) where your products are exposed to the environment). The environmental monitoring frequencies described in SOP QCD-034 titled, “Environmental Controls and Monitoring Procedure” (Effective date: December 12, 2022) are not sufficient to detect potential environmental contamination risks and demonstrate control inside the critical manufacturing area during manufacturing.\nb. Your firm does not require microbiological monitoring of operators’ arm coverings used in the critical aseptic processing area for manually processing your products.\n2. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example, your firm has failed to validate your procedure for cleaning and disinfecting the ISO 5 (b)(4) and supporting ISO 7 cleanroom where your products are manufactured. Validation of a cleaning process is needed to verify suitable cleaning and disinfecting agents are used to remove potential microbial contaminants from the critical manufacturing areas where your products are exposed during manufacturing.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, your firm has not adequately validated your manufacturing processes for your products with respect to identity, strength, quality, and purity. Your testing is limited to (b)(4). These are not sufficient measures of identity, strength, quality, and purity.\nProcess validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, strength, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\n4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. The review of batch records and procedure QAD-040 titled “Product Release” (Effective date: September 5, 2023) indicate final product testing is limited to sterility testing and endotoxin testing as measurements of product attributes and such testing does not demonstrate, for example, the identity and\u002For strength of your products.\n5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. For example, your firm assigned expiration dates between (b)(4) months to your products without adequate supporting data that conform to appropriate standards of identity, strength, quality, and purity. For example, your expiration summary reports for RHEO® is limited to (b)(4) sterility testing only while Product 401 (OROPRO®) is limited to (b)(4) sterility and endotoxin testing. Product 403 (PROVISCUS®) and Product 404 (NEOFYL®) are limited to Hyaluronic Acid concentration only. Appropriate standards of identity, strength, quality, and purity during intervals through the expiry period are needed to ensure product attributes remain for the shelf life of the product.\nResponses to the Form FDA-483\nWe acknowledge receipt of your correspondences dated September 29, 2023; October 13, 2023; October 27, 2023; November 10, 2023; November 28, 2023; December 8; 2023; December 22, 2023; January 5, 2024; January 9, 2024; February 29, 2024 and September 3, 2024 that provide a response to FDA’s inspectional observations and describe certain corrective actions. We have reviewed your responses and represented corrective actions and have found that they are inadequate. While you assert that your products were manufactured under section 361 of the PHS Act (and thus are not subject to cGMP regulations), the available evidence shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act. We acknowledge your commitment to submit a Pre-Request for Designation to FDA by February 29, 2024; however, this process remains incomplete, for you have not responded to the agency’s request for additional information. According to your correspondence, RHEO®, OROPRO®, and 403\u002F404 products have been removed from the market and shall no longer be manufactured by your firm. Your responses do not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a (b)(4)-month shelf life and remain within expiry.\nAdditional Concern\nIn addition to the violations described above, we offer the following comment:\nWe note that the Instructions for Use for each of your products state, “This allograft is processed aseptically, but is not sterile.” If your products are not sterile, FDA has serious safety concerns regarding their use on patients via injection.2 FDA expects injectable products to be sterile, consistent with basic quality standards and to ensure patient safety.3 Be advised that, under 21 CFR 211.113(b), appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed, including validation of aseptic and sterilization processes. Please address this issue in your response.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n________________________\n1 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not address whether this product meets other criteria in 21 CFR 1271.10(a).\n2 The preparation instructions in the IFUs for your products state, “Apply the allograft using an 18g or larger needle. If applied topically, utilize aseptic technique and caution.” While intravenous or intrathecal application are contraindicated, injection is not contraindicated.\n3 See, e.g., USP\u003C1> (“Parenteral articles are prepared scrupulously by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants, and, where appropriate, contain inhibitors of the growth of microorganisms.”).","BioStem Life Sciences","biostem-life-sciences-673788-01172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiostem-life-sciences-673788-01172025","2026-10-26T08:08:05.524573+00:00","2025-02-04","673788","Jason V. Matuszewski","2026-08-19T17:02:42.585+00:00","CBER 25-673788","2025-01-17",{"id":264,"raw":265,"subject":269,"body_html":270,"body_text":271,"firm_name":272,"letter_id":273,"created_at":68,"fei_number":19,"letter_url":274,"updated_at":275,"action_type":22,"case_status":23,"posted_date":276,"marcs_cms_no":277,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":278,"body_fetched_at":279,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":280,"medical_device_id":19,"response_letter_date":19},382,[266,267,268,11,269,13,13,13],"\u003Ctime datetime=\"2025-12-30T05:00:00Z\">12\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-11T05:00:00Z\">12\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpalamur-biosciences-private-limited-708579-12112025\">Palamur Biosciences Private Limited\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>S. Ramamoorthy, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer (CEO)\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Palamur Biosciences Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Boothpur Mandal\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mahabubnagar\u003C\u002Fspan> \u003Cspan>509382\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Telangana\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ram.murthy@palamurbio.com\"> ram.murthy@palamurbio.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 11, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Ramamoorthy:\u003C\u002Fp>\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the United States Food and Drug Administration (FDA) inspection conducted at Palamur Biosciences Private Limited (PBS) from January 20, 2025, to January 27, 2025, by investigators from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI) Foreign Inspection Cadre. This inspection was conducted to determine whether activities and procedures related to your participation in Good Laboratory Practice (GLP) nonclinical studies complied with applicable federal regulations. Specifically, FDA investigators focused on the list of studies below including, but not limited to, implantation, acute systemic toxicity, material mediated pyrogenicity (MMP), and guinea pig maximization tests conducted at your facility.\u003C\u002Fp>\u003Cp>The list of studies below is not an all-inclusive list of studies impacted by the inspection or by the violations cited in this letter.\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cp>\u003Cstrong>Study number\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>\u003Cstrong>Test\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231918\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Implantation Study\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>24636\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Implantation Study\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231192\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Acute Systemic Toxicity\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231165\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Acute Systemic Toxicity\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231809\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Acute Systemic Toxicity\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231868\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Acute Systemic Toxicity\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>24085\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Acute Systemic Toxicity\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>24110\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Acute Systemic Toxicity\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>24005\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>MMP\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>24084\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>MMP\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>24378\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>MMP\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231866\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Guinea Pig Maximization Test\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231586\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Guinea Pig Maximization Test\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231191\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>Intracutaneous Reactivity\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp>231196\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp>In Vitro Cytotoxicity\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>These tests are used in nonclinical studies for the development of devices as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>The inspection was conducted under a program designed to ensure that data and information contained in requests for Investigational Device Exemption, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\u003Cp>Our review of the inspection report prepared by the OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies, which concerns, among other things, requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). Compliance with Part 58 is intended to assure the quality and integrity of the safety data filed in a premarket submission. At the close of the inspection, the FDA investigators presented an inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you.\u003C\u002Fp>\u003Cp>We received the initial response from your firm dated February 17, 2025, concerning our investigators’ observations noted on the Form FDA-483. We have since received follow-up responses to the initial response from your firm on the following dates:\u003C\u002Fp>\u003Cul>\u003Cli>April 13, 2025\u003C\u002Fli>\u003Cli>May 12, 2025\u003C\u002Fli>\u003Cli>July 8, 2025\u003C\u002Fli>\u003Cli>August 12, 2025\u003C\u002Fli>\u003Cli>September 16, 2025\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This letter discusses your written responses to the noted investigators’ observations and requests prompt corrective action to address violations of 21 CFR Part 58. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure of the study director to assure that all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified [21 CFR 58.33(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The study director has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation and reporting of results, and represents the single point of study control. The study director’s responsibilities include ensuring that all experimental data are accurately recorded and verified. Examples of the study director’s failures to adhere to this requirement include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. For study 231918, the Animal\u002FBird Requisition and Issuance Record shows that the rabbits were 7-8 months old, but the breeding records do not include birth dates. Additionally, the animals were only given identification (R1 through R12) when they were enrolled in and throughout the study, and this identification cannot be traced back to the Animal Issue Record maintained by the Animal Breeding and Husbandry (ABH) department. The Animal Issue Record lists species\u002Fstrain, sex, age range and body weight range for a group of rabbits issued for a particular study. However, there are no medical records associated with the individual rabbits and no way of verifying the accurate age of each animal. Because animal age can impact the analysis and interpretability of test results, it is important that the age of each animal in a study is accurately recorded and can be verified.\u003C\u002Fp>\u003Cp>b. The raw study data for the acute systemic toxicity studies (231192, 231165, 231809, 231868, 24085, and 24110) and MMP studies (24005, 24084, and 24378) did not have the rate of intravenous administration of the bolus in each animal recorded. Additionally, the start and end time of intravenous injection are not recorded. Study plans for all acute systemic toxicity and MMP studies require that intravenous injections be administered consistent with the guidelines outlined in the International Organization for Standardization (ISO) 10993, Biological Evaluation of Medical Devices, and\u002For the United States Pharmacopeia (USP) Chapter 151, Biological Tests – Pyrogen Test, as applicable. The rates of intravenous injections were not recorded; therefore, it cannot be verified whether these tests were conducted according to the testing guidelines.\u003C\u002Fp>\u003Cp>c. For study 24636, there were no records of physical examinations of Guinea Pigs 1 through 12 upon receipt of the animals from the vendor, upon release from quarantine, or before the surgical procedure. The health of the animals was not comprehensively examined and recorded at the start of the study and anesthesia status was not assessed before the surgical procedure. Therefore, it cannot be confirmed whether the animals were healthy or showing any abnormal clinical signs. Clinical observations are important to record for the reliability of the subsequent analysis of the responses of the animal to the test article, as well as for evaluating whether the animal needs any treatment or intervention.\u003C\u002Fp>\u003Cp>As the principal point of study control, the study director did not ensure that all experimental data were accurately recorded and verified, which in turn yields questionable study results. Based on this failure, the FDA has concerns about the quality and integrity of data generated from the nonclinical laboratory studies conducted at your testing facility. Complete and accurate study data are necessary to allow FDA to fully assess the overall safety and risk of a device with an associated premarket submission. The unreliable data raises concerns about the quality and integrity of associated premarket submissions, which may put public health and safety at risk.\u003C\u002Fp>\u003Cp>Your written responses are inadequate. The written responses provided revised standard operating procedures (SOPs), forms, and staff training records, but they do not include any planned preventive actions such as frequency (e.g., quarterly, annual) of audits to check for compliance or future training for new staff and\u002For new procedures. Additionally, while you provided a copy of the form, PRM\u002FPBS\u002FTOX\u002F014, “Animal\u002FBird Requisition and Issuance Record” as evidence of the health status of the animals, the form lacks detailed documentation of physical examinations conducted by qualified personnel (e.g. veterinarian). Furthermore, while your responses propose corrections for the specific observations noted, you have not indicated whether any systematic reviews of your procedures will be conducted to identify and correct any systemic issues. Your explanation, when taken into consideration with the violations described above, which occurred in multiple studies, suggests systemic failures in study director oversight of nonclinical laboratory studies and brings into question the quality and integrity of safety data collected at your testing facility. Thus, your responses do not provide assurance that similar violations would not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure of the testing facility to have standard operating procedures in writing setting forth nonclinical laboratory study methods that management is satisfied are adequate to ensure the quality and integrity of the data generated in the course of a study. [21 CFR 58.81(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>SOPs should be adequate to ensure the quality and integrity of data generated in a study. However, not all SOPs appear to be adequate. Examples of your failures to adhere to this requirement include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. SOP\u002FPBS\u002FTOX\u002F001, Recording of Body Weight and Procedure for Feed and Water Consumption, does not include procedures for calibration of the balance used for weighing animals. Section 5.1 of the SOP states that, “[t]he balance will be set and calibrated as specific to the balance in use.” However, there is no specific information as to who is responsible for calibration (e.g., study personnel assigned to each study) or when calibration should be performed (e.g., whether the calibration should be performed prior to body weight measurement or whether it should be performed at specific dates\u002Fintervals).\u003C\u002Fp>\u003Cp>b. SOP\u002FPBS\u002FGEN\u002F047, Sample and Reference Material Preparation for Biological Evaluation of Medical Devices, does not include detailed procedures for extraction depending on the test article (e.g., test articles indicated for prolonged or long-term tissue contact may require different extraction conditions than those with limited contact). Additionally, the SOP does not provide detailed instructions for monitoring of changes in the color of the test extract. Sample preparation is one of the crucial steps in biocompatibility testing of medical devices. Conditions of medical device extraction, such as extraction temperature, duration of extraction, and vehicle use can significantly impact the outcomes of a biocompatibility study.\u003C\u002Fp>\u003Cp>c. SOP\u002FPBS\u002FPAT\u002F012, Euthanasia of Laboratory Animals\u002FBirds, does not contain sufficiently detailed procedures for administration of carbon dioxide (CO2) for inhalation euthanasia for rodents to fulfill the objective of rapid unconsciousness with minimal distress to the animals. For example, the SOP does not contain information about the settings of the flowmeter for the delivery of the CO2 gas or include specific procedures for using CO2 inhalation in rodents.\u003C\u002Fp>\u003Cp>Failure of a testing facility to have adequate SOPs raises questions about the reliability and accuracy of the data and does not ensure the quality and integrity of data generated in a study. Inadequate SOPs yield inadequate protocols that introduce ambiguity and uncertainty as to how study requirements are to be followed, as well as inconsistent execution of studies and unreliable study results. Inadequate SOPs could result in study data with a high level of variability that challenges the ability to effectively interpret the study results associated with a device. This in turn adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials.\u003C\u002Fp>\u003Cp>Your written responses are inadequate. The responses provided revised SOPs, forms, and staff training records, but they do not: (1) detail how your testing facility will ensure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; and (2) address any planned preventive actions, such as frequency (e.g., quarterly, annual) of audits to check for compliance or future training for new staff and\u002For new procedures. Additionally, while your responses propose corrections for the specific observations noted, you have not indicated whether any systematic reviews of your procedures will be conducted to identify and correct any systemic issues, including ensuring that there are existing SOPs that cover all relevant functions, as well as ensuring that all SOPs are sufficiently detailed to allow personnel to correctly perform these functions. Thus, your written responses do not provide assurance that similar violations would not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure of the testing facility management to assure that personnel clearly understand the functions they are to perform [21 CFR 58.31(f)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>An example of the testing facility management’s failure to adhere to this requirement includes, but is not limited to, the following:\u003C\u002Fp>\u003Cp>a. For Guinea Pig Maximization Test (GPMT) study 24838, the study personnel failed to identify and record adverse tissue responses to the injected adjuvant and clinical observations (e.g., difficulty breathing). SOP\u002FPBS\u002FTOX\u002F008 indicates that after intradermal induction, skin reactions such as edema, erythema, and necrosis, along with other clinical signs will be recorded. However, the records that were reviewed did not indicate that clinical signs were recorded. In addition, there is no procedure that describes what clinical signs should be assessed to determine the health of the animal or how the technician would recognize skin reactions and distinguish between similar responses (e.g., between a “discrete” and “moderate” skin reaction). Furthermore, it was observed that study personnel training does not include species-specific in-life observations and when veterinarian oversight should be requested.\u003C\u002Fp>\u003Cp>Failure of testing facility management to assure that all personnel clearly understand the functions they are to perform and are adequately qualified and trained creates a high level of variability that does not ensure the validity and quality of the data. Personnel that do not clearly understand the functions they are to perform cannot consistently perform tasks according to the SOPs. This can have a negative impact on a study and calls into question the quality and integrity of studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>Your written responses are inadequate. Your responses included revised SOPs, training records, and creating a new division for Ethology &amp; Animal Welfare to focus on clinical sign observation, ethology, animal welfare training, and enrichment, in addition to appointing a technical consultant to assist with personnel training. However, it is not clear what oversight for the new head of Ethology and Animal Welfare will entail or what technical expertise will be provided by the technical consultant. Furthermore, your responses do not address planned preventive actions, such as frequency (e.g., quarterly, annual) of audits to check for compliance or future training for new staff and\u002For new procedures. Additionally, while your responses propose corrections for the specific observations noted, you have not indicated whether any systematic reviews of your training program will be conducted to identify and correct any gaps in personnel training. Furthermore, while you have provided training records containing quizzes that test personnel’s recollection of the training received, you have not described how personnel’s ability to perform the tasks in question will be assessed to ensure that the training achieves its intended goal. Thus, your written responses do not provide assurance that similar violations would not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure of the Quality Assurance Unit (QAU) to determine that no deviations from approved protocols or SOPs were made without proper authorization and documentation [21 CFR 58.35(b)(5)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QAU is responsible for determining that no deviations from approved protocols or SOPs were made without proper authorization and documentation. An example of the QAU’s failures to adhere to this requirement includes, but is not limited to, the following:\u003C\u002Fp>\u003Cp>a. For study 231918, the study plan stated that the rabbits should have a supraglottic airway device inserted; however, the surgical records showed that an endotracheal tube was used for delivery of inhalant anesthesia. There is no record to indicate that this deviation was identified by the QAU, and there is no documentation to indicate that this deviation was made with proper authorization.\u003C\u002Fp>\u003Cp>A reliable QAU is integral to the successful understanding and completion of any GLP study. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report is accurate and valid. Failure to perform QAU functions can have a negative impact on a study and calls into question the quality and integrity of studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>Your written responses are inadequate. Your written responses include generating a record of an SOP deviation, performing a root cause analysis, and opening a corrective and preventative actions plan. However, your responses do not detail planned preventive actions, such as frequency (e.g., quarterly, annual) of audits to check for compliance of the QAU or future training for new staff and\u002For new procedures. Additionally, while your responses propose corrections for the specific observations noted, you have not indicated whether any systematic reviews of your QAU will be conducted to identify and correct any systemic issues.\u003C\u002Fp>\u003Cp>In addition to the device studies described above, FDA investigators also observed that your facility performs studies intended to support the approval of new animal drugs. The overall conditions and practices at your facility, as exemplified above, may impact the validity and integrity of the data obtained to support new animal drug applications. For example, in study 19278, your records indicate you centrifuged the majority of blood samples before they were actually collected. In your response, you indicated you were unable to reconstruct what happened. This calls into question the quality and integrity of data generated from the nonclinical laboratory studies conducted at your testing facility. You should ensure that you consider animal drug studies as part of your corrective and preventive actions.\u003C\u002Fp>\u003Cp>FDA investigators also observed that the exterior of the testing facility had significant accumulations of dirt, animal droppings, and potential pest harborage. Upon inspection of Block F, the HVAC equipment on the outside of the building was found to be surrounded by a large amount of dirt and debris that could attract and provide harborage for various pests and could potentially be caught up in the HVAC equipment, possibly causing failure. Such conditions may impact nonclinical studies conducted at your facility.\u003C\u002Fp>\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your facility. It is your responsibility as a nonclinical laboratory to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the additional corrective and preventive actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the testing facility. Any submitted corrective action plan should include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. In addition, please provide a complete list of all nonclinical laboratory studies of FDAregulated devices for the last five years, including the name of the study, the test article, the name of the study director and sponsor, and the current status of the study. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you. In addition, FDA could initiate disqualification proceedings against you in accordance with 21 CFR 58.202. If you believe that you have complied with the Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your response should reference “CTS# EC250128\u002FE001” and be sent via email to: Irfan.Khan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>A copy of this letter has been sent to FDA’s OBMI Foreign Inspection Cadre via email at FDAInternationalBIMO@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Amrin Chowdhury by phone at (240) 402-8318 or email at Amrin.Chowdhury@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ouided Rouabhi, MS\u003Cbr>Acting Director\u003Cbr>DCEA1: Division of Clinical Policy and Quality\u003Cbr>Office of Clinical Evidence &amp; Analysis\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nS. Ramamoorthy, Ph.D.\n\nRecipient Title\n\nChief Executive Officer (CEO)\n\nPalamur Biosciences Private Limited\n\nBoothpur Mandal\n\nMahabubnagar 509382\n\nTelangana\n\nIndia\n\nram.murthy@palamurbio.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nDecember 11, 2025\nDear Dr. Ramamoorthy:\nThis Warning Letter is to inform you of objectionable conditions observed during the United States Food and Drug Administration (FDA) inspection conducted at Palamur Biosciences Private Limited (PBS) from January 20, 2025, to January 27, 2025, by investigators from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI) Foreign Inspection Cadre. This inspection was conducted to determine whether activities and procedures related to your participation in Good Laboratory Practice (GLP) nonclinical studies complied with applicable federal regulations. Specifically, FDA investigators focused on the list of studies below including, but not limited to, implantation, acute systemic toxicity, material mediated pyrogenicity (MMP), and guinea pig maximization tests conducted at your facility.\nThe list of studies below is not an all-inclusive list of studies impacted by the inspection or by the violations cited in this letter.\nStudy number\nTest\n\n231918\nImplantation Study\n\n24636\nImplantation Study\n\n231192\nAcute Systemic Toxicity\n\n231165\nAcute Systemic Toxicity\n\n231809\nAcute Systemic Toxicity\n\n231868\nAcute Systemic Toxicity\n\n24085\nAcute Systemic Toxicity\n\n24110\nAcute Systemic Toxicity\n\n24005\nMMP\n\n24084\nMMP\n\n24378\nMMP\n\n231866\nGuinea Pig Maximization Test\n\n231586\nGuinea Pig Maximization Test\n\n231191\nIntracutaneous Reactivity\n\n231196\nIn Vitro Cytotoxicity\n\nThese tests are used in nonclinical studies for the development of devices as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThe inspection was conducted under a program designed to ensure that data and information contained in requests for Investigational Device Exemption, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\nOur review of the inspection report prepared by the OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies, which concerns, among other things, requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). Compliance with Part 58 is intended to assure the quality and integrity of the safety data filed in a premarket submission. At the close of the inspection, the FDA investigators presented an inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you.\nWe received the initial response from your firm dated February 17, 2025, concerning our investigators’ observations noted on the Form FDA-483. We have since received follow-up responses to the initial response from your firm on the following dates:\nApril 13, 2025\nMay 12, 2025\nJuly 8, 2025\nAugust 12, 2025\nSeptember 16, 2025\nThis letter discusses your written responses to the noted investigators’ observations and requests prompt corrective action to address violations of 21 CFR Part 58. These violations include, but are not limited to, the following:\n1. Failure of the study director to assure that all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified [21 CFR 58.33(b)].\nThe study director has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation and reporting of results, and represents the single point of study control. The study director’s responsibilities include ensuring that all experimental data are accurately recorded and verified. Examples of the study director’s failures to adhere to this requirement include, but are not limited to, the following:\na. For study 231918, the Animal\u002FBird Requisition and Issuance Record shows that the rabbits were 7-8 months old, but the breeding records do not include birth dates. Additionally, the animals were only given identification (R1 through R12) when they were enrolled in and throughout the study, and this identification cannot be traced back to the Animal Issue Record maintained by the Animal Breeding and Husbandry (ABH) department. The Animal Issue Record lists species\u002Fstrain, sex, age range and body weight range for a group of rabbits issued for a particular study. However, there are no medical records associated with the individual rabbits and no way of verifying the accurate age of each animal. Because animal age can impact the analysis and interpretability of test results, it is important that the age of each animal in a study is accurately recorded and can be verified.\nb. The raw study data for the acute systemic toxicity studies (231192, 231165, 231809, 231868, 24085, and 24110) and MMP studies (24005, 24084, and 24378) did not have the rate of intravenous administration of the bolus in each animal recorded. Additionally, the start and end time of intravenous injection are not recorded. Study plans for all acute systemic toxicity and MMP studies require that intravenous injections be administered consistent with the guidelines outlined in the International Organization for Standardization (ISO) 10993, Biological Evaluation of Medical Devices, and\u002For the United States Pharmacopeia (USP) Chapter 151, Biological Tests – Pyrogen Test, as applicable. The rates of intravenous injections were not recorded; therefore, it cannot be verified whether these tests were conducted according to the testing guidelines.\nc. For study 24636, there were no records of physical examinations of Guinea Pigs 1 through 12 upon receipt of the animals from the vendor, upon release from quarantine, or before the surgical procedure. The health of the animals was not comprehensively examined and recorded at the start of the study and anesthesia status was not assessed before the surgical procedure. Therefore, it cannot be confirmed whether the animals were healthy or showing any abnormal clinical signs. Clinical observations are important to record for the reliability of the subsequent analysis of the responses of the animal to the test article, as well as for evaluating whether the animal needs any treatment or intervention.\nAs the principal point of study control, the study director did not ensure that all experimental data were accurately recorded and verified, which in turn yields questionable study results. Based on this failure, the FDA has concerns about the quality and integrity of data generated from the nonclinical laboratory studies conducted at your testing facility. Complete and accurate study data are necessary to allow FDA to fully assess the overall safety and risk of a device with an associated premarket submission. The unreliable data raises concerns about the quality and integrity of associated premarket submissions, which may put public health and safety at risk.\nYour written responses are inadequate. The written responses provided revised standard operating procedures (SOPs), forms, and staff training records, but they do not include any planned preventive actions such as frequency (e.g., quarterly, annual) of audits to check for compliance or future training for new staff and\u002For new procedures. Additionally, while you provided a copy of the form, PRM\u002FPBS\u002FTOX\u002F014, “Animal\u002FBird Requisition and Issuance Record” as evidence of the health status of the animals, the form lacks detailed documentation of physical examinations conducted by qualified personnel (e.g. veterinarian). Furthermore, while your responses propose corrections for the specific observations noted, you have not indicated whether any systematic reviews of your procedures will be conducted to identify and correct any systemic issues. Your explanation, when taken into consideration with the violations described above, which occurred in multiple studies, suggests systemic failures in study director oversight of nonclinical laboratory studies and brings into question the quality and integrity of safety data collected at your testing facility. Thus, your responses do not provide assurance that similar violations would not occur again.\n2. Failure of the testing facility to have standard operating procedures in writing setting forth nonclinical laboratory study methods that management is satisfied are adequate to ensure the quality and integrity of the data generated in the course of a study. [21 CFR 58.81(a)].\nSOPs should be adequate to ensure the quality and integrity of data generated in a study. However, not all SOPs appear to be adequate. Examples of your failures to adhere to this requirement include, but are not limited to, the following:\na. SOP\u002FPBS\u002FTOX\u002F001, Recording of Body Weight and Procedure for Feed and Water Consumption, does not include procedures for calibration of the balance used for weighing animals. Section 5.1 of the SOP states that, “[t]he balance will be set and calibrated as specific to the balance in use.” However, there is no specific information as to who is responsible for calibration (e.g., study personnel assigned to each study) or when calibration should be performed (e.g., whether the calibration should be performed prior to body weight measurement or whether it should be performed at specific dates\u002Fintervals).\nb. SOP\u002FPBS\u002FGEN\u002F047, Sample and Reference Material Preparation for Biological Evaluation of Medical Devices, does not include detailed procedures for extraction depending on the test article (e.g., test articles indicated for prolonged or long-term tissue contact may require different extraction conditions than those with limited contact). Additionally, the SOP does not provide detailed instructions for monitoring of changes in the color of the test extract. Sample preparation is one of the crucial steps in biocompatibility testing of medical devices. Conditions of medical device extraction, such as extraction temperature, duration of extraction, and vehicle use can significantly impact the outcomes of a biocompatibility study.\nc. SOP\u002FPBS\u002FPAT\u002F012, Euthanasia of Laboratory Animals\u002FBirds, does not contain sufficiently detailed procedures for administration of carbon dioxide (CO2) for inhalation euthanasia for rodents to fulfill the objective of rapid unconsciousness with minimal distress to the animals. For example, the SOP does not contain information about the settings of the flowmeter for the delivery of the CO2 gas or include specific procedures for using CO2 inhalation in rodents.\nFailure of a testing facility to have adequate SOPs raises questions about the reliability and accuracy of the data and does not ensure the quality and integrity of data generated in a study. Inadequate SOPs yield inadequate protocols that introduce ambiguity and uncertainty as to how study requirements are to be followed, as well as inconsistent execution of studies and unreliable study results. Inadequate SOPs could result in study data with a high level of variability that challenges the ability to effectively interpret the study results associated with a device. This in turn adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials.\nYour written responses are inadequate. The responses provided revised SOPs, forms, and staff training records, but they do not: (1) detail how your testing facility will ensure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; and (2) address any planned preventive actions, such as frequency (e.g., quarterly, annual) of audits to check for compliance or future training for new staff and\u002For new procedures. Additionally, while your responses propose corrections for the specific observations noted, you have not indicated whether any systematic reviews of your procedures will be conducted to identify and correct any systemic issues, including ensuring that there are existing SOPs that cover all relevant functions, as well as ensuring that all SOPs are sufficiently detailed to allow personnel to correctly perform these functions. Thus, your written responses do not provide assurance that similar violations would not occur again.\n3. Failure of the testing facility management to assure that personnel clearly understand the functions they are to perform [21 CFR 58.31(f)].\nAn example of the testing facility management’s failure to adhere to this requirement includes, but is not limited to, the following:\na. For Guinea Pig Maximization Test (GPMT) study 24838, the study personnel failed to identify and record adverse tissue responses to the injected adjuvant and clinical observations (e.g., difficulty breathing). SOP\u002FPBS\u002FTOX\u002F008 indicates that after intradermal induction, skin reactions such as edema, erythema, and necrosis, along with other clinical signs will be recorded. However, the records that were reviewed did not indicate that clinical signs were recorded. In addition, there is no procedure that describes what clinical signs should be assessed to determine the health of the animal or how the technician would recognize skin reactions and distinguish between similar responses (e.g., between a “discrete” and “moderate” skin reaction). Furthermore, it was observed that study personnel training does not include species-specific in-life observations and when veterinarian oversight should be requested.\nFailure of testing facility management to assure that all personnel clearly understand the functions they are to perform and are adequately qualified and trained creates a high level of variability that does not ensure the validity and quality of the data. Personnel that do not clearly understand the functions they are to perform cannot consistently perform tasks according to the SOPs. This can have a negative impact on a study and calls into question the quality and integrity of studies conducted at your testing facility.\nYour written responses are inadequate. Your responses included revised SOPs, training records, and creating a new division for Ethology & Animal Welfare to focus on clinical sign observation, ethology, animal welfare training, and enrichment, in addition to appointing a technical consultant to assist with personnel training. However, it is not clear what oversight for the new head of Ethology and Animal Welfare will entail or what technical expertise will be provided by the technical consultant. Furthermore, your responses do not address planned preventive actions, such as frequency (e.g., quarterly, annual) of audits to check for compliance or future training for new staff and\u002For new procedures. Additionally, while your responses propose corrections for the specific observations noted, you have not indicated whether any systematic reviews of your training program will be conducted to identify and correct any gaps in personnel training. Furthermore, while you have provided training records containing quizzes that test personnel’s recollection of the training received, you have not described how personnel’s ability to perform the tasks in question will be assessed to ensure that the training achieves its intended goal. Thus, your written responses do not provide assurance that similar violations would not occur again.\n4. Failure of the Quality Assurance Unit (QAU) to determine that no deviations from approved protocols or SOPs were made without proper authorization and documentation [21 CFR 58.35(b)(5)].\nThe QAU is responsible for determining that no deviations from approved protocols or SOPs were made without proper authorization and documentation. An example of the QAU’s failures to adhere to this requirement includes, but is not limited to, the following:\na. For study 231918, the study plan stated that the rabbits should have a supraglottic airway device inserted; however, the surgical records showed that an endotracheal tube was used for delivery of inhalant anesthesia. There is no record to indicate that this deviation was identified by the QAU, and there is no documentation to indicate that this deviation was made with proper authorization.\nA reliable QAU is integral to the successful understanding and completion of any GLP study. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report is accurate and valid. Failure to perform QAU functions can have a negative impact on a study and calls into question the quality and integrity of studies conducted at your testing facility.\nYour written responses are inadequate. Your written responses include generating a record of an SOP deviation, performing a root cause analysis, and opening a corrective and preventative actions plan. However, your responses do not detail planned preventive actions, such as frequency (e.g., quarterly, annual) of audits to check for compliance of the QAU or future training for new staff and\u002For new procedures. Additionally, while your responses propose corrections for the specific observations noted, you have not indicated whether any systematic reviews of your QAU will be conducted to identify and correct any systemic issues.\nIn addition to the device studies described above, FDA investigators also observed that your facility performs studies intended to support the approval of new animal drugs. The overall conditions and practices at your facility, as exemplified above, may impact the validity and integrity of the data obtained to support new animal drug applications. For example, in study 19278, your records indicate you centrifuged the majority of blood samples before they were actually collected. In your response, you indicated you were unable to reconstruct what happened. This calls into question the quality and integrity of data generated from the nonclinical laboratory studies conducted at your testing facility. You should ensure that you consider animal drug studies as part of your corrective and preventive actions.\nFDA investigators also observed that the exterior of the testing facility had significant accumulations of dirt, animal droppings, and potential pest harborage. Upon inspection of Block F, the HVAC equipment on the outside of the building was found to be surrounded by a large amount of dirt and debris that could attract and provide harborage for various pests and could potentially be caught up in the HVAC equipment, possibly causing failure. Such conditions may impact nonclinical studies conducted at your facility.\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your facility. It is your responsibility as a nonclinical laboratory to ensure compliance with the Act and applicable regulations.\nWithin 15 working days of receiving this letter, please provide documentation of the additional corrective and preventive actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the testing facility. Any submitted corrective action plan should include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. In addition, please provide a complete list of all nonclinical laboratory studies of FDAregulated devices for the last five years, including the name of the study, the test article, the name of the study director and sponsor, and the current status of the study. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you. In addition, FDA could initiate disqualification proceedings against you in accordance with 21 CFR 58.202. If you believe that you have complied with the Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\nYour response should reference “CTS# EC250128\u002FE001” and be sent via email to: Irfan.Khan@fda.hhs.gov.\nA copy of this letter has been sent to FDA’s OBMI Foreign Inspection Cadre via email at FDAInternationalBIMO@fda.hhs.gov. Please send a copy of your response to that office.\nIf you have any questions, please contact Amrin Chowdhury by phone at (240) 402-8318 or email at Amrin.Chowdhury@fda.hhs.gov.\nSincerely yours,\n\u002FS\u002F\nOuided Rouabhi, MS\nActing Director\nDCEA1: Division of Clinical Policy and Quality\nOffice of Clinical Evidence & Analysis\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Palamur Biosciences Private Limited","palamur-biosciences-private-limited-708579-12112025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpalamur-biosciences-private-limited-708579-12112025","2026-10-26T08:09:39.995495+00:00","2025-12-30","708579","S. Ramamoorthy, Ph.D.","2026-08-19T07:19:02.271+00:00","2025-12-11",{"id":282,"raw":283,"subject":151,"body_html":287,"body_text":288,"firm_name":289,"letter_id":290,"created_at":110,"fei_number":19,"letter_url":291,"updated_at":292,"action_type":22,"case_status":23,"posted_date":293,"marcs_cms_no":294,"product_type":295,"closeout_date":19,"issuing_office":83,"recipient_name":296,"body_fetched_at":297,"delivery_method":162,"recipient_title":19,"reference_number":19,"action_taken_date":298,"medical_device_id":19,"response_letter_date":19},1272,[284,285,286,83,151,13,13,13],"\u003Ctime datetime=\"2024-09-10T13:20:00Z\">09\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-30T04:00:00Z\">08\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Froot-bioscience-brands-llc-dba-naternal-673646-08302024\">Root Bioscience Brands, LLC dba Naternal\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Garrett Perdue\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Root Bioscience Brands, LLC dba Naternal\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Aviation Pkwy Ste 900\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morrisville\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27560\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@naternal.com\"> info@naternal.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 30, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 673646\u003C\u002Fp>\n\n\u003Cp>Dear Garrett Perdue:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.naternal.com in August 2024 and has observed that your website offers various products which you represent contain, in part, cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN). The claims on your website establish that your products, CBD Oils,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>FDA has also determined that your Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg)\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> products for animals offered for sale on your website www.naternal.com, are unapproved new animal drugs that are unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and are adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-healthfocus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, your CBD Oils, Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your website that provide evidence of the intended use of these products as drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002F17-full-spectrum-cbd-oil-benefits-for-all-ages:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“In another recent study, correlations between CBD and blood pressure were examined. Two groups were evaluated, one being test subjects who were given CBD and the other being a control group with a placebo. All subjects were exposed to stressors that would induce a higher blood pressure. The study concluded that a dose of CBD was helpful to reducing blood pressure.”\u003C\u002Fli>\n\t\u003Cli>“CBD may protect nerve cells from deteriorating, and a study from Frontiers in Pharmacology found that CBD can significantly decrease the negative effects of Alzheimer[’]s and also improve cognitive ability.”\u003C\u002Fli>\n\t\u003Cli>“CBD oil has been shown to have addiction-recovery effects particularly for cocaine, opioids, and psycho-stimulants.”\u003C\u002Fli>\n\t\u003Cli>“CBD oil has been shown to reduce the nature of PTSD attacks. A preliminary study has shown that the use of CBD oil, in conjunction with psychological therapy, has reduced the severity of the test subjects' attacks over the course of eight weeks.”\u003C\u002Fli>\n\t\u003Cli>“CBD has been studied for its possible uses for children, and while the science is still preliminary, there are some promising opportunities. One of the best is the use of CBD for children with autism. One study of 188 children with autism, ages 5 to 18, found that some symptoms, such as seizures, restlessness and rage attacks, were lessened.”\u003C\u002Fli>\n\t\u003Cli>“Further small studies have been done into calming ADHD and anxiety in children, and while the results thus far are anecdotal, they do show potential. A 2016 study backed up the suggestion that CBD can help with sleep and anxiety for children, and a 2013 study showed that CBD for anxiety can help with regulatory control.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-for-veterans:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“What Is CBD? . . . It’s a great option for those that want the medicinal benefits of cannabis without the high, and many veterans are turning to CBD to help them battle PTSD, stress, anxiety, insomnia, chronic pain, and inflammation.”\u003C\u002Fli>\n\t\u003Cli>“CBD has also shown promise in helping to fight anxiety, insomnia, and chronic pain; as well as helping with addiction recovery for those that have developed a substance abuse disorder while trying to cope with PTSD and other stressors. And since veterans are twice as likely to die from an opioid overdose than the general population, CBD can provide a real way forward as it is kinder to the mind and the body.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-benefits-of-cbd-for-football:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“While CBD can’t prevent concussions, much research has gone into discovering ways that CBD can help treat them. One major study from the University of Miami has found that, in animal trials, combination therapy improved the cognitive function of subjects.(Combination therapy involves taking CBD along with dexanabinol, a synthetic cannabinoid.) In Canada, a study is being conducted on former hockey players to see if the severity of post-concussion brain disorders can be treated with CBD.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-and-cbg-for-skincare:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“In the eyes, endocannabinoid receptors allow CBG to help treat glaucoma by reducing intraocular pressure, as well as acting as a powerful vasodilator to protect and soothe. Additionally, some experiments have shown that CBG is effective at decreasing inflammatory bowel disease, in addition to protecting neurons in animals with Huntington's disease.”\u003C\u002Fli>\n\t\u003Cli>“On the cancer front, CBG has been shown to block receptors that contribute to cancer cell growth, slowing colon cancer in mice and inhibiting tumors in colon carcinogenesis.”\u003C\u002Fli>\n\t\u003Cli>“As an antibacterial agent, CBG goes where other drugs can't, helping to fight Staphylococcus aureus (MRSA) strains. Cannabis topical formulations have also been used for decades to help fight skin infections, though an understanding of why it works is only recently coming into focus with the use of CBG for skincare.”\u003C\u002Fli>\n\t\u003Cli>“Other medicinal benefits of CBG include appetite stimulation, which is of particular interest to cancer patients and other muscle wasting diseases.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-endocannabinoid-system-part-2:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Early studies into CBG indicate that it interacts with specific bodily systems, making it a promising medicinal substance. Research shows that it could be a highly effective treatment for glaucoma because it lowers intraocular pressure. Studies have also found it to decrease inflammation related to inflammatory bowel disease effectively.”\u003C\u002Fli>\n\t\u003Cli>“One 2015 study on mice showed that CBG provided neuroprotection related to Huntington’s disease. Furthermore, CBG may inhibit the growth of certain cancer cells, such as those that cause colon cancer. It also has been shown to be an effective antibacterial agent, an appetite stimulant, and a potential treatment for bladder dysfunction disorders.”\u003C\u002Fli>\n\t\u003Cli>“A different study also provided evidence that CBN could have anti-inflammatory, antibiotic, and anti-convulsant effects.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-benefits-of-cbd-for-people-with-autism:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“We are starting to understand how CBD may be a game-changer for people with autism to help ease their anxiety, calm their stimming, and reduce any severe behaviors.”\u003C\u002Fli>\n\t\u003Cli>“Many parents of children with autism report a lessening of aggressive behaviors and physical violence after taking CBD because it helps the child deal with the strong emotions that may come on without warning.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your CBD Oils, Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>The Department of Health and Human Services (HHS) has determined that a public health emergency exists nationwide involving the opioid crisis.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You market your CBD products for the treatment or cure of opioid addiction. However, these products have not been determined by FDA to be safe and effective for these (or any other) uses. Further, the unproven treatments could cause patients to forego or delay FDA-approved treatments for opioid addiction or withdrawal. The marketing and sale of unapproved opioid addiction treatment products is a potentially significant threat to the public health. Therefore, FDA is taking measures to protect consumers from products that, without approval by FDA, claim to diagnose, mitigate, prevent, treat or cure opioid addiction.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Animal Drugs\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>During our review of your firm’s website www.naternal.com, FDA has determined that your firm offers for sale the unapproved new animal drugs Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg). Based on our review of your website these products for animals are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your website that provide evidence of the intended use of these products as animal drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fproducts\u002Fcbd-for-pets:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>January 24, 2023 customer review states, “I have been using this CBD for my pup who has seizures for some time, since starting CBD she has not had one. I like that there are no unnecessary ingredients, and she takes it with no problems.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o Naternal.com replied, “Thank you for the review, \u003Cstrong>(b)(6)\u003C\u002Fstrong> That is amazing news - we are so glad to hear that your pup's seizures stopped!!! – Naternal”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fproducts\u002Fcbd-for-pets-1200mg:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>January 25, 2023 customer review states, “Best place for CBD oil. Really helps my older dog's arthritis pain”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o Naternal.com replied, “Thank you, \u003Cstrong>(b)(6)\u003C\u002Fstrong>. We are grateful to provide great service and products that help to our community. Glad to hear that it's helping ease your dog's pain.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>October 3, 2022 customer review states, “The full spectrum pet CBD helps our old girl not only get around easier, but also has helped regulate her diabetes symptoms! I'm not saying this is a replacement for regular medical treatment but it has helped with her quality of life tremendously. Her steps and movements aren't so rigid when she has had her dose of CBD!”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o Naternal.com replied, “…We are so happy that our Pet 1200mg CBD Tincture is helping your sweet pup with her diabetes and her mobility! Give her an extra treat for us. Thank you very much for your support and positive feedback!”\u003C\u002Fp>\n\n\u003Cp>On your blog post titled “CBD Dosing For Pets” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-dosing-for-pets:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD has a wide range of uses-cases in relation to health and wellness reasons, including the potential to aid conditions like chronic pain, anxiety, insomnia and more... Many people with pets have begun looking into CBD oil use for pain and inflammation reasons because veterinarian-prescribed medications can be costly and come with a variety of unwanted side effects. Other people use CBD for their pets to help calm them on particularly stressful occasions, such as during travel or when fireworks are going off in the neighborhood.”\u003C\u002Fli>\n\t\u003Cli>“If you are someone who is interested in more natural alternatives to prescription medications for your pets, then CBD might be worth looking into further. One study was done by Dr. Joseph Wakshlag of Cornell University and published in the journal Frontiers in Veterinary Science. Titled ‘Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs,’ the study looked at the effects of a hemp-based cannabidiol product to treat pain from arthritis in dogs. More than 80% of the dogs in the study saw a significant decrease in pain and improved mobility.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your blog post titled “9 Reasons to Use CBD for Pets” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002F9-reasons-to-use-cbd-for-pets:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD can be used to help your pets stay healthy, active, and happy. It may be beneficial for aiding some diseases and conditions in animals, especially dogs and cats, but also horses and other family animals.”\u003C\u002Fli>\n\t\u003Cli>“We’ve all been around anxious pets - they may be nervous around other people or other animals, they may not like car rides or loud noises, and some even get nervous being left alone at home. The outputs of their induced anxiety is often hiding, barking and whining excessively, shaking and sometimes even destruction of furniture and other items around the house. People have found CBD to be helpful in aiding their pet’s anxiety for many of the use-cases listed above.”\u003C\u002Fli>\n\t\u003Cli>“Typically used for skin ailments or injuries, CBD topicals are a great option for pets and they are easy to use! With the presence of fatty acids in hemp extract, these products can be used to calm inflammation caused by skin irritation and can even promote new cell growth, allowing for quicker healing.”\u003C\u002Fli>\n\t\u003Cli>“If your pet has a chronic condition like arthritis, or other musculoskeletal problems, CBD may be a great option to talk to your veterinarian about. Known for its anti-inflammatory properties, daily incorporation of CBD may help provide some relief to pets that deal with chronic pain.”\u003C\u002Fli>\n\t\u003Cli>“It May Help Avoid Seizures”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your blog post titled “CBD Oil for Dogs - Your Full Guide” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-oil-for-dogs-your-full-guide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD may be an option for dogs that are recovering from surgery, battling certain ailments or illnesses, or are in need of comfort due to separation anxiety or other potential stressful events or situations they may need to deal with.”\u003C\u002Fli>\n\t\u003Cli>“Many dog owners have gained interest in the use of CBD for reasons including pain and inflammation, separation anxiety or situational anxiety, nausea, and general wellness needs for their aging loved ones. CBD isn't some magical cure, but it can help improve the quality of life for your dog, and the best part is that it's better than other pain pills and medications that may cause your pup to deal with a long list of unwanted side effects.”\u003C\u002Fli>\n\t\u003Cli>“One such study on the effects of CBD in dogs showed that four out of five dogs with osteoarthritis had an improvement in their pain and mobility after receiving a few mg of CBD per kg of body weight.”\u003C\u002Fli>\n\t\u003Cli>“Another study on CBD oil for dogs showed that epileptic dogs had significantly fewer seizures when given CBD as opposed to receiving seizure medication or a placebo. While dogs also had a reduction with placebo and other treatments, the effects weren't as pronounced as those who received CBD.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your blog post titled “Does CBD help with Lyme Disease?” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fdoes-cbd-help-with-lyme-disease:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“My dog \u003Cstrong>(b)(6)&nbsp;\u003C\u002Fstrong>was diagnosed with Lyme disease in January 2020. Yes, our pets can get Lyme disease too! She was very lethargic, mostly slept all day and would hardly eat. I looked into a more natural remedy for her to ease her discomfort days, and Naternal offers our furry pets CBD oil in Full Spectrum! You'll see your furry pet do a complete turnaround with their pain level! Similar to how it is for us.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg) are “new animal drugs” under section 201(v) of the FD&amp;C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-1. These products are not approved, conditionally approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nJill Furman, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance and Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This encompasses both broad spectrum and full spectrum CBD oils marketed on your website.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On your website www.naternal.com, your Naternal Hemp Extract Oil for Pets products are also referred to as Pet Full Spectrum CBD Oil 300 MG, CBD for Pets 600mg, and Pet Full Spectrum CBD Oil 1200 MG.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued October 26, 2017, and subsequently renewed), available at https:\u002F\u002Faspr.hhs.gov\u002Flegal\u002FPHE\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGarrett Perdue\n\nRecipient Title\n\nCEO\n\nRoot Bioscience Brands, LLC dba Naternal\n\n951 Aviation Pkwy Ste 900\n\nMorrisville, NC 27560\n\nUnited States\n\ninfo@naternal.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nAugust 30, 2024\n\nRE: 673646\n\nDear Garrett Perdue:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.naternal.com in August 2024 and has observed that your website offers various products which you represent contain, in part, cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN). The claims on your website establish that your products, CBD Oils,1 Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\n\nFDA has also determined that your Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg)2 products for animals offered for sale on your website www.naternal.com, are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and are adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-healthfocus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nUnapproved New Drugs\n\nBased on a review of your website, your CBD Oils, Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your website that provide evidence of the intended use of these products as drugs include, but are not limited to, the following:\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002F17-full-spectrum-cbd-oil-benefits-for-all-ages:\n\n“In another recent study, correlations between CBD and blood pressure were examined. Two groups were evaluated, one being test subjects who were given CBD and the other being a control group with a placebo. All subjects were exposed to stressors that would induce a higher blood pressure. The study concluded that a dose of CBD was helpful to reducing blood pressure.”\n\n“CBD may protect nerve cells from deteriorating, and a study from Frontiers in Pharmacology found that CBD can significantly decrease the negative effects of Alzheimer[’]s and also improve cognitive ability.”\n\n“CBD oil has been shown to have addiction-recovery effects particularly for cocaine, opioids, and psycho-stimulants.”\n\n“CBD oil has been shown to reduce the nature of PTSD attacks. A preliminary study has shown that the use of CBD oil, in conjunction with psychological therapy, has reduced the severity of the test subjects' attacks over the course of eight weeks.”\n\n“CBD has been studied for its possible uses for children, and while the science is still preliminary, there are some promising opportunities. One of the best is the use of CBD for children with autism. One study of 188 children with autism, ages 5 to 18, found that some symptoms, such as seizures, restlessness and rage attacks, were lessened.”\n\n“Further small studies have been done into calming ADHD and anxiety in children, and while the results thus far are anecdotal, they do show potential. A 2016 study backed up the suggestion that CBD can help with sleep and anxiety for children, and a 2013 study showed that CBD for anxiety can help with regulatory control.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-for-veterans:\n\n“What Is CBD? . . . It’s a great option for those that want the medicinal benefits of cannabis without the high, and many veterans are turning to CBD to help them battle PTSD, stress, anxiety, insomnia, chronic pain, and inflammation.”\n\n“CBD has also shown promise in helping to fight anxiety, insomnia, and chronic pain; as well as helping with addiction recovery for those that have developed a substance abuse disorder while trying to cope with PTSD and other stressors. And since veterans are twice as likely to die from an opioid overdose than the general population, CBD can provide a real way forward as it is kinder to the mind and the body.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-benefits-of-cbd-for-football:\n\n“While CBD can’t prevent concussions, much research has gone into discovering ways that CBD can help treat them. One major study from the University of Miami has found that, in animal trials, combination therapy improved the cognitive function of subjects.(Combination therapy involves taking CBD along with dexanabinol, a synthetic cannabinoid.) In Canada, a study is being conducted on former hockey players to see if the severity of post-concussion brain disorders can be treated with CBD.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-and-cbg-for-skincare:\n\n“In the eyes, endocannabinoid receptors allow CBG to help treat glaucoma by reducing intraocular pressure, as well as acting as a powerful vasodilator to protect and soothe. Additionally, some experiments have shown that CBG is effective at decreasing inflammatory bowel disease, in addition to protecting neurons in animals with Huntington's disease.”\n\n“On the cancer front, CBG has been shown to block receptors that contribute to cancer cell growth, slowing colon cancer in mice and inhibiting tumors in colon carcinogenesis.”\n\n“As an antibacterial agent, CBG goes where other drugs can't, helping to fight Staphylococcus aureus (MRSA) strains. Cannabis topical formulations have also been used for decades to help fight skin infections, though an understanding of why it works is only recently coming into focus with the use of CBG for skincare.”\n\n“Other medicinal benefits of CBG include appetite stimulation, which is of particular interest to cancer patients and other muscle wasting diseases.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-endocannabinoid-system-part-2:\n\n“Early studies into CBG indicate that it interacts with specific bodily systems, making it a promising medicinal substance. Research shows that it could be a highly effective treatment for glaucoma because it lowers intraocular pressure. Studies have also found it to decrease inflammation related to inflammatory bowel disease effectively.”\n\n“One 2015 study on mice showed that CBG provided neuroprotection related to Huntington’s disease. Furthermore, CBG may inhibit the growth of certain cancer cells, such as those that cause colon cancer. It also has been shown to be an effective antibacterial agent, an appetite stimulant, and a potential treatment for bladder dysfunction disorders.”\n\n“A different study also provided evidence that CBN could have anti-inflammatory, antibiotic, and anti-convulsant effects.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-benefits-of-cbd-for-people-with-autism:\n\n“We are starting to understand how CBD may be a game-changer for people with autism to help ease their anxiety, calm their stimming, and reduce any severe behaviors.”\n\n“Many parents of children with autism report a lessening of aggressive behaviors and physical violence after taking CBD because it helps the child deal with the strong emotions that may come on without warning.”\n\nYour CBD Oils, Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nThe Department of Health and Human Services (HHS) has determined that a public health emergency exists nationwide involving the opioid crisis.3 You market your CBD products for the treatment or cure of opioid addiction. However, these products have not been determined by FDA to be safe and effective for these (or any other) uses. Further, the unproven treatments could cause patients to forego or delay FDA-approved treatments for opioid addiction or withdrawal. The marketing and sale of unapproved opioid addiction treatment products is a potentially significant threat to the public health. Therefore, FDA is taking measures to protect consumers from products that, without approval by FDA, claim to diagnose, mitigate, prevent, treat or cure opioid addiction.\n\nUnapproved New Animal Drugs\n\nDuring our review of your firm’s website www.naternal.com, FDA has determined that your firm offers for sale the unapproved new animal drugs Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg). Based on our review of your website these products for animals are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&C Act.\n\nExamples of claims from your website that provide evidence of the intended use of these products as animal drugs include, but are not limited to, the following:\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fproducts\u002Fcbd-for-pets:\n\nJanuary 24, 2023 customer review states, “I have been using this CBD for my pup who has seizures for some time, since starting CBD she has not had one. I like that there are no unnecessary ingredients, and she takes it with no problems.”\n\no Naternal.com replied, “Thank you for the review, (b)(6) That is amazing news - we are so glad to hear that your pup's seizures stopped!!! – Naternal”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fproducts\u002Fcbd-for-pets-1200mg:\n\nJanuary 25, 2023 customer review states, “Best place for CBD oil. Really helps my older dog's arthritis pain”\n\no Naternal.com replied, “Thank you, (b)(6). We are grateful to provide great service and products that help to our community. Glad to hear that it's helping ease your dog's pain.”\n\nOctober 3, 2022 customer review states, “The full spectrum pet CBD helps our old girl not only get around easier, but also has helped regulate her diabetes symptoms! I'm not saying this is a replacement for regular medical treatment but it has helped with her quality of life tremendously. Her steps and movements aren't so rigid when she has had her dose of CBD!”\n\no Naternal.com replied, “…We are so happy that our Pet 1200mg CBD Tincture is helping your sweet pup with her diabetes and her mobility! Give her an extra treat for us. Thank you very much for your support and positive feedback!”\n\nOn your blog post titled “CBD Dosing For Pets” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-dosing-for-pets:\n\n“CBD has a wide range of uses-cases in relation to health and wellness reasons, including the potential to aid conditions like chronic pain, anxiety, insomnia and more... Many people with pets have begun looking into CBD oil use for pain and inflammation reasons because veterinarian-prescribed medications can be costly and come with a variety of unwanted side effects. Other people use CBD for their pets to help calm them on particularly stressful occasions, such as during travel or when fireworks are going off in the neighborhood.”\n\n“If you are someone who is interested in more natural alternatives to prescription medications for your pets, then CBD might be worth looking into further. One study was done by Dr. Joseph Wakshlag of Cornell University and published in the journal Frontiers in Veterinary Science. Titled ‘Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs,’ the study looked at the effects of a hemp-based cannabidiol product to treat pain from arthritis in dogs. More than 80% of the dogs in the study saw a significant decrease in pain and improved mobility.”\n\nOn your blog post titled “9 Reasons to Use CBD for Pets” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002F9-reasons-to-use-cbd-for-pets:\n\n“CBD can be used to help your pets stay healthy, active, and happy. It may be beneficial for aiding some diseases and conditions in animals, especially dogs and cats, but also horses and other family animals.”\n\n“We’ve all been around anxious pets - they may be nervous around other people or other animals, they may not like car rides or loud noises, and some even get nervous being left alone at home. The outputs of their induced anxiety is often hiding, barking and whining excessively, shaking and sometimes even destruction of furniture and other items around the house. People have found CBD to be helpful in aiding their pet’s anxiety for many of the use-cases listed above.”\n\n“Typically used for skin ailments or injuries, CBD topicals are a great option for pets and they are easy to use! With the presence of fatty acids in hemp extract, these products can be used to calm inflammation caused by skin irritation and can even promote new cell growth, allowing for quicker healing.”\n\n“If your pet has a chronic condition like arthritis, or other musculoskeletal problems, CBD may be a great option to talk to your veterinarian about. Known for its anti-inflammatory properties, daily incorporation of CBD may help provide some relief to pets that deal with chronic pain.”\n\n“It May Help Avoid Seizures”\n\nOn your blog post titled “CBD Oil for Dogs - Your Full Guide” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-oil-for-dogs-your-full-guide:\n\n“CBD may be an option for dogs that are recovering from surgery, battling certain ailments or illnesses, or are in need of comfort due to separation anxiety or other potential stressful events or situations they may need to deal with.”\n\n“Many dog owners have gained interest in the use of CBD for reasons including pain and inflammation, separation anxiety or situational anxiety, nausea, and general wellness needs for their aging loved ones. CBD isn't some magical cure, but it can help improve the quality of life for your dog, and the best part is that it's better than other pain pills and medications that may cause your pup to deal with a long list of unwanted side effects.”\n\n“One such study on the effects of CBD in dogs showed that four out of five dogs with osteoarthritis had an improvement in their pain and mobility after receiving a few mg of CBD per kg of body weight.”\n\n“Another study on CBD oil for dogs showed that epileptic dogs had significantly fewer seizures when given CBD as opposed to receiving seizure medication or a placebo. While dogs also had a reduction with placebo and other treatments, the effects weren't as pronounced as those who received CBD.”\n\nOn your blog post titled “Does CBD help with Lyme Disease?” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fdoes-cbd-help-with-lyme-disease:\n\n“My dog (b)(6) was diagnosed with Lyme disease in January 2020. Yes, our pets can get Lyme disease too! She was very lethargic, mostly slept all day and would hardly eat. I looked into a more natural remedy for her to ease her discomfort days, and Naternal offers our furry pets CBD oil in Full Spectrum! You'll see your furry pet do a complete turnaround with their pain level! Similar to how it is for us.”\n\nYour Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg) are “new animal drugs” under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-1. These products are not approved, conditionally approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance and Compliance\n\nCenter for Veterinary Medicine\n\nU.S. Food and Drug Administration\n\n____________________\n\n1 This encompasses both broad spectrum and full spectrum CBD oils marketed on your website.\n\n2 On your website www.naternal.com, your Naternal Hemp Extract Oil for Pets products are also referred to as Pet Full Spectrum CBD Oil 300 MG, CBD for Pets 600mg, and Pet Full Spectrum CBD Oil 1200 MG.\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued October 26, 2017, and subsequently renewed), available at https:\u002F\u002Faspr.hhs.gov\u002Flegal\u002FPHE\u002FPages\u002Fdefault.aspx.","Root Bioscience Brands, LLC dba Naternal","root-bioscience-brands-llc-dba-naternal-673646-08302024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Froot-bioscience-brands-llc-dba-naternal-673646-08302024","2026-10-26T08:09:51.034023+00:00","2024-09-10","673646","Animal & VeterinaryDrugs","Garrett Perdue","2026-08-19T23:49:49.071+00:00","2024-08-30",{"id":300,"raw":301,"subject":306,"body_html":307,"body_text":308,"firm_name":309,"letter_id":310,"created_at":44,"fei_number":19,"letter_url":311,"updated_at":312,"action_type":22,"case_status":23,"posted_date":313,"marcs_cms_no":19,"product_type":314,"closeout_date":19,"issuing_office":37,"recipient_name":315,"body_fetched_at":316,"delivery_method":162,"recipient_title":19,"reference_number":19,"action_taken_date":317,"medical_device_id":19,"response_letter_date":19},2294,[302,303,304,37,305,13,13,13],"\u003Ctime datetime=\"2022-12-13T14:20:00Z\">12\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-05T05:00:00Z\">12\u002F05\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthriftmaster-texas-llc-dba-thriftmaster-global-holdings-inc-and-tm-global-biosciences-llc-641057\">Thriftmaster Texas, LLC. d\u002Fb\u002Fa ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated Human Foods\u003Cbr \u002F>\r\n","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated Human Foods","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven Haynes\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Thriftmaster Texas, LLC. d\u002Fb\u002Fa ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2614 Andjon Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@thriftmasterholdings.com\"> admin@thriftmasterholdings.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 5, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: # 641057\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Steven Haynes:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at www.cedarcreekdistributors.com, www.thriftmasterholdings.com, and https:\u002F\u002Fapelindx.com in November 2022 and has determined that you take orders there for various products, which you represent as containing cannabidiol (CBD).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> We have also reviewed your social media websites at www.instagram.com\u002Fthriftmasterholdings and www.facebook.com\u002Fthriftmasterholdings, which are accessible from your website www.thriftmasterholdings.com, where consumers can purchase your products. The claims on your websites and social media accounts establish that your products, “ApelinDx metered dose inhaler,” “Maia CBD Tincture Inhaler,” “Maia CBD Oil,” “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” “Maia Gummies,” and “CBD Pill” (hereinafter referred to as “your CBD products”), are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1).\u003C\u002Fp>\n\n\u003Cp>FDA has also determined that your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” food products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products into interstate commerce under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll). Consumers may confuse these products with traditional foods; therefore, with these products there is a risk of unintended consumption of CBD.\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find specific information about how FDA regulates cannabis-derived products at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\">https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We also observed that your website, www.thriftmasterholdings.com, and social media websites make claims that your CBD products may be intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Furthermore, your “ApelinDx metered dose inhaler” and “Maia CBD Tincture Inhaler” products are intended to deliver CBD through oral inhalation. These products are particularly concerning to the agency because the ingredients and potential impurities in oral inhalation sprays may trigger laryngospasm and bronchospasm and may be toxic to the tissues in the upper or lower airways. Inhalation products that are intended to act locally in the respiratory system also may be absorbed and exert undesirable systemic effects, such as increased heart rate or elevated blood pressure.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your websites and social media websites, your CBD products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your websites and social media websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your “About Us” webpage https:\u002F\u002Fcedarcreekdistributors.com\u002Fabout-us\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD is FDA approved to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and Tuberous Sclerosis Complex.”\u003C\u002Fli>\n\t\u003Cli>“As of 2020, there are various clinical studies underway hoping to determine CBD’s long-thought potential to assist with a variety of physical and mental health ailments, including pain, mood disorders and respiratory problems.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “We’re in the News” hyperlink https:\u002F\u002Fthriftmasterholdings.com\u002Fwp-content\u002Fuploads\u002F2021\u002F07\u002FUSA-today-AD-compressed-7.15.21.pdf accessed through your website www.thriftmasterholdings.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD May Be Key to Reducing ARDS, the Leading Cause of COVID-19 Deaths”\u003C\u002Fli>\n\t\u003Cli>“Thriftmaster has been heavily involved in clinical studies, with a goal of proving CBD and CBC’s efficacy to improved conditions related to aliments such as . . . Alzheimer’s and Post Traumatic Stress Disorder.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “CBD Helps” hyperlink https:\u002F\u002Fwww.eurekalert.org\u002Fpub_releases\u002F2020-10\u002Fmcog-chr101620.php accessed through your website www.thriftmasterholdings.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD helps reduce lung damage from COVID by increasing levels of protective peptide”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Instagram social media website www.instagram.com\u002Fthriftmasterholdings:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>May 31, 2021 post – “Learn more about how ApelinDx™ supports ARDS and Alzheimer’s research (link in bio).”\u003C\u002Fli>\n\t\u003Cli>June 14, 2021 post – “TM Global Bioscience, LLC, a medically-focused division of ThriftMaster Global Holdings, announced that the patent-pending broad-spectrum CBD formulation in its ApelinDx™ metered dose inhaler may increase survival rates of COVID-19 patients.”\u003C\u002Fli>\n\t\u003Cli>June 21, 2021 post – “See our product being used in ‘a new research collaboration between the Dental College of Georgia and the Medical College of Georgia is investigating the affect [sic] CBD can have on reducing plaque in the brain of Alzheimer’s patients.’”\u003C\u002Fli>\n\t\u003Cli>June 30, 2021 post – “We are heading towards finding answers about the potential CBD has to make a change in the medical world . . . #apelindx #metereddoseinhaler #mdi #alzheimers #alzheimersawareness #dementia #dementiaawareness #cbd #cbdinhaler”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook social media website www.facebook.com\u002Fthriftmasterholdings:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>February 1, 2021 post – “Early studies suggest that CBD may be a useful tool in the fight against COVID-19.”\u003C\u002Fli>\n\t\u003Cli>February 4, 2021 post – “[A] study out of the Innovare Journal of Medical Sciences produced promising results regarding #cannibidiols [sic] potential to assist with cognitive illnesses, including #anxiety and #depression.”\u003C\u002Fli>\n\t\u003Cli>March 25, 2021 post – “‘Researchers discovered in this trial that in mice who have been genetically altered to show symptoms of Alzheimer’s, #CBD normalized levels and functions; improving brain cognition’.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your website https:\u002F\u002Fapelindx.com hyperlinks to a news report discussing the use of CBD to delay the progression of Alzheimer’s disease. The news report shows an image of a product that states “ApelinDx” on the label and appears to be a metered dose inhaler.\u003C\u002Fp>\n\n\u003Cp>Your CBD products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your CBD products are misbranded within the meaning of section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) Your CBD products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use because no FDA-approved applications are in effect for these products. The introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>301(ll) and Adulterated Human Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products are foods to which CBD has been added.\u003C\u002Fp>\n\n\u003Cp>However, you should be aware that it is a prohibited act under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>You should also be aware that, as defined in section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>* * *\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your websites www.thriftmasterholdings.com and https:\u002F\u002Fapelindx.com redirect consumers to your website www.cedarcreekdistributors.com to purchase your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See \u003Cstrong>GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome\u003C\u002Fstrong>). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSteven Haynes\n\nThriftmaster Texas, LLC. d\u002Fb\u002Fa ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC\n\n2614 Andjon Dr.\n\nDallas, TX 75220\n\nUnited States\n\nadmin@thriftmasterholdings.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nCenter for Food Safety and Applied Nutrition\n\nWARNING LETTER\n\nDecember 5, 2022\n\nRE: # 641057\n\nDear Steven Haynes:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at www.cedarcreekdistributors.com, www.thriftmasterholdings.com, and https:\u002F\u002Fapelindx.com in November 2022 and has determined that you take orders there for various products, which you represent as containing cannabidiol (CBD).1 We have also reviewed your social media websites at www.instagram.com\u002Fthriftmasterholdings and www.facebook.com\u002Fthriftmasterholdings, which are accessible from your website www.thriftmasterholdings.com, where consumers can purchase your products. The claims on your websites and social media accounts establish that your products, “ApelinDx metered dose inhaler,” “Maia CBD Tincture Inhaler,” “Maia CBD Oil,” “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” “Maia Gummies,” and “CBD Pill” (hereinafter referred to as “your CBD products”), are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1).\n\nFDA has also determined that your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” food products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products into interstate commerce under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll). Consumers may confuse these products with traditional foods; therefore, with these products there is a risk of unintended consumption of CBD.\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nWe also observed that your website, www.thriftmasterholdings.com, and social media websites make claims that your CBD products may be intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.2 As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Furthermore, your “ApelinDx metered dose inhaler” and “Maia CBD Tincture Inhaler” products are intended to deliver CBD through oral inhalation. These products are particularly concerning to the agency because the ingredients and potential impurities in oral inhalation sprays may trigger laryngospasm and bronchospasm and may be toxic to the tissues in the upper or lower airways. Inhalation products that are intended to act locally in the respiratory system also may be absorbed and exert undesirable systemic effects, such as increased heart rate or elevated blood pressure.\n\nUnapproved New Drugs\n\nBased on a review of your websites and social media websites, your CBD products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your websites and social media websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nOn your “About Us” webpage https:\u002F\u002Fcedarcreekdistributors.com\u002Fabout-us\u002F:\n\n“CBD is FDA approved to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and Tuberous Sclerosis Complex.”\n\n“As of 2020, there are various clinical studies underway hoping to determine CBD’s long-thought potential to assist with a variety of physical and mental health ailments, including pain, mood disorders and respiratory problems.”\n\nOn your “We’re in the News” hyperlink https:\u002F\u002Fthriftmasterholdings.com\u002Fwp-content\u002Fuploads\u002F2021\u002F07\u002FUSA-today-AD-compressed-7.15.21.pdf accessed through your website www.thriftmasterholdings.com:\n\n“CBD May Be Key to Reducing ARDS, the Leading Cause of COVID-19 Deaths”\n\n“Thriftmaster has been heavily involved in clinical studies, with a goal of proving CBD and CBC’s efficacy to improved conditions related to aliments such as . . . Alzheimer’s and Post Traumatic Stress Disorder.”\n\nOn your “CBD Helps” hyperlink https:\u002F\u002Fwww.eurekalert.org\u002Fpub_releases\u002F2020-10\u002Fmcog-chr101620.php accessed through your website www.thriftmasterholdings.com:\n\n“CBD helps reduce lung damage from COVID by increasing levels of protective peptide”\n\nOn your Instagram social media website www.instagram.com\u002Fthriftmasterholdings:\n\nMay 31, 2021 post – “Learn more about how ApelinDx™ supports ARDS and Alzheimer’s research (link in bio).”\n\nJune 14, 2021 post – “TM Global Bioscience, LLC, a medically-focused division of ThriftMaster Global Holdings, announced that the patent-pending broad-spectrum CBD formulation in its ApelinDx™ metered dose inhaler may increase survival rates of COVID-19 patients.”\n\nJune 21, 2021 post – “See our product being used in ‘a new research collaboration between the Dental College of Georgia and the Medical College of Georgia is investigating the affect [sic] CBD can have on reducing plaque in the brain of Alzheimer’s patients.’”\n\nJune 30, 2021 post – “We are heading towards finding answers about the potential CBD has to make a change in the medical world . . . #apelindx #metereddoseinhaler #mdi #alzheimers #alzheimersawareness #dementia #dementiaawareness #cbd #cbdinhaler”\n\nOn your Facebook social media website www.facebook.com\u002Fthriftmasterholdings:\n\nFebruary 1, 2021 post – “Early studies suggest that CBD may be a useful tool in the fight against COVID-19.”\n\nFebruary 4, 2021 post – “[A] study out of the Innovare Journal of Medical Sciences produced promising results regarding #cannibidiols [sic] potential to assist with cognitive illnesses, including #anxiety and #depression.”\n\nMarch 25, 2021 post – “‘Researchers discovered in this trial that in mice who have been genetically altered to show symptoms of Alzheimer’s, #CBD normalized levels and functions; improving brain cognition’.”\n\nAdditionally, your website https:\u002F\u002Fapelindx.com hyperlinks to a news report discussing the use of CBD to delay the progression of Alzheimer’s disease. The news report shows an image of a product that states “ApelinDx” on the label and appears to be a metered dose inhaler.\n\nYour CBD products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nMisbranded Drugs\n\nYour CBD products are misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) Your CBD products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use because no FDA-approved applications are in effect for these products. The introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\n301(ll) and Adulterated Human Foods\n\nAccording to your product labeling, your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products are foods to which CBD has been added.\n\nHowever, you should be aware that it is a prohibited act under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.3 There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\n\nYou should also be aware that, as defined in section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.4\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation that authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\n* * *\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n____________________\n\n1 Your websites www.thriftmasterholdings.com and https:\u002F\u002Fapelindx.com redirect consumers to your website www.cedarcreekdistributors.com to purchase your products.\n\n2 On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n3 CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.\n\n4 Under section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.","Thriftmaster Texas, LLC. d\u002Fb\u002Fa ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC","thriftmaster-texas-llc-dba-thriftmaster-global-holdings-inc-and-tm-global-biosciences-llc-641057","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthriftmaster-texas-llc-dba-thriftmaster-global-holdings-inc-and-tm-global-biosciences-llc-641057","2026-10-26T08:10:11.866518+00:00","2022-12-13","DrugsFood & Beverages","Steven Haynes","2026-08-20T01:22:50.74+00:00","2022-12-05",15,{"510k":320,"classification":321,"enforcement":322,"event":323,"event_backfill":324,"pma":325,"warning_letter":326},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]